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Introduction
The global impact of HIV
Currently, 35 million people are living with human immunodeficiency virus (HIV) worldwide 
and the HIV population is still growing. Globally, the majority (70%) of the HIV population 
lives in sub-Saharan Africa. Western and central Europe and North America accounts for 
approximately 2.3 million HIV-infected patients.
Although the rate of new HIV infections is continuing to decline in most parts of the 
world, the number of new HIV infections is still very high with more than 2 million new HIV 
infections in 2013. 
 Mother-to-child HIV transmission (MTCT) is the most common route of HIV- infection 
among infants and children. An estimated 1.4 million pregnant women infected with HIV 
give birth annually worldwide. Each day, approximately 1000 infants acquire HIV due to 
MTCT during pregnancy, delivery or breastfeeding.1 Providing access to antiretroviral 
treatment for pregnant women living with HIV has averted more than 900 000 new HIV 
infections among children since 2009.2 Its implementation together with other effective 
interventions has led to dramatic declines in the number of perinatally HIV-infected children 
from 15-40% to <2%.3
Nowadays, fewer people are dying of acquired immunodeficiency syndrome (AIDS)-related 
illnesses. In the past three years alone, the number of AIDS-related deaths have fallen by 
approximately one-fifth which represents the largest decline in the past decade. This is a 
direct result of the progress that has been made on the global access to antiretroviral 
treatment. Despite this success AIDS remains one of the top causes of infectious disease-re-
lated mortality worldwide, responsible for nearly 1.5 million AIDS-related deaths in 2013.2
Antiretroviral treatment
During the past 30 years there has been a remarkable progress in the treatment of HIV 
infection. The development of combination antiretroviral therapy against HIV is considered 
one of the great success stories of modern medicine. In the beginning of the pandemic 
when AIDS was first recognized in 1981, and linked to HIV in 1983, all that could be offered 
to patients suffering from the complications of AIDS was palliative care and treatment of 
opportunistic infections. 
The first antiretroviral drug that was used for its activity against HIV was zidovudine, 
a nucleoside reverse transcriptase inhibitor (NRTI). Zidovudine obtained accelerated 
approval in 1987 by the US Food and Drug Administration (FDA) but failed to give a 
sustained virological suppression when used as a single drug (monotherapy) as HIV 
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Raltegravir was the first approved HIV-1 integrase inhibitor by the FDA and EMA and is to 
be administered orally in a dosage 400 mg twice daily.11,12 Initially, raltegravir was licensed in 
combination with other antiretroviral agents for treatment-experienced patients ≥ 18 years 
with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The good safety 
profile and its potent and rapid antiretroviral activity has quickly extended the use of 
raltegravir from salvage therapy to first-line treatment. In 2009, the FDA and EMA changed 
raltegravir’s approval to include antiretroviral treatment-naive HIV-1-infected patients.8,9,13 
Role of raltegravir in HIV management
Immediately after the introduction of raltegravir with its new mechanism of action, it 
played an important role in HIV management. It presented an effective therapeutic option 
for pretreated HIV-infected patients with multidrug-resistant virus and limited treatment 
options.14,15 Despite its expanded approval in treatment-naive patients, the role of 
raltegravir as first-line agent in HIV management was not so clear in clinical practice. In the 
December 2009 update of the Guidelines for the Use of Antiretroviral Agents in 
HIV-1-Infected Adults and Adolescents from the Department of Health and Human 
Services raltegravir was recommended together with tenofovir/emtricitabine as one of 
the four preferred regimens in treatment-naive patients.16 Nonetheless, clinicians in the 
Netherlands considered raltegravir less appealing for initial therapy because of its twice 
daily dosage regimen. In previous years much effort had been put into simplifying the 
HIV treatment to improve adherence. With the introduction of the first once-a-day 
three-drug-combination tablet consisting of efavirenz, tenofovir and emtricitabine (Atripla) in 
2006, the twice daily dosage of raltegravir can be seen as a disadvantage.8 The QDMRK 
study, a phase III study which compared the efficacy, safety, and pharmacokinetics of 
800 mg raltegravir once a day versus 400 mg twice a day in treatment-naive HIV-infected 
patients, was in progress at that time and the results were highly anticipated.17,18
Apart from the new mechanism of action and the potent virological efficacy of raltegravir, 
one of its benefits is a good safety profile. At that time long-term data with clinical 
experience using raltegravir were not yet available. Although, this was just a matter of 
time as phase II and III studies were ongoing and preliminary data were reassuring. 
Furthermore, raltegravir was seen as an antiretroviral drug that could potentially be of 
great value in special patient populations, such as in children, and in pregnant women to 
prevent MTCT. Additional studies were needed to confirm this. 
quickly developed resistance to zidovudine.4 A number of new nucleosides were introduced 
and the use of dual NRTI therapy was well established and seemed promising at first. 
However, suppression of the HIV viral load remained suboptimal with NRTI dual therapy. 
During the next decade the initial optimism on HIV treatment disappeared as the AIDS 
pandemic continued to grow and many lives were lost to AIDS. Eventually HIV treatment 
evolved rapidly with the introduction of the first protease inhibitors (PIs) and nonnucleoside 
reverse transcriptase inhibitor (NNRTIs) in the mid-1990s. These new antiretroviral drugs 
in combination with the NRTIs made it possible to use the much more effective triple 
therapy. Combination antiretroviral therapy (cART) consisting of at least three antiretroviral 
agents from two different drug classes was found to be essential for effective and 
sustained virological suppression of HIV.4,5 The AIDS death rate in the United States fell by 
more than two-thirds within two years after the licensing of the first PI.4,6 HIV infection has 
turned from a fatal disease into a chronic illness. For approximately one decade the 
standard of care for HIV infection included two NRTIs in combination with a PI or an NNRTI 
as third agent. 
Progress in HIV treatment was made in simplifying the complex multidrug regimens and 
reducing side effects, which significantly improved adherence and reduced treatment 
failure. Although HIV treatment had made a huge step forward, some HIV-infected 
individuals who have had extensive prior antiretroviral therapy failed to sustain maximal 
viral suppression with the available combinations of antiretroviral agents due to the 
development of resistant virus. Also drug toxicity and tolerability limited the continued 
use of several antiretroviral agents in patients. Moreover the transmission of new HIV 
infections with multidrug resistant virus against the existing drug classes highlighted 
the urgent need for novel antiretroviral drugs, preferably against new HIV targets.7 
A multifaceted approach to antiretroviral therapy, using combinations of inhibitors that 
target different steps of the viral life cycle, was, and still is, considered the best potential for 
long-term control of HIV infection. It wasn’t until the end of 2007 that the FDA and the 
European Medicines Agency (EMA) granted accelerated approval for raltegravir, the first of 
a new class of antiretroviral agents called HIV-1 integrase strand transfer inhibitors (INSTI), 
commonly referred to as integrase inhibitors.8,9 
Raltegravir, the first of a new class
Infection with HIV-1 requires a few essential steps in the viral replication. One of these 
steps is integration of viral DNA into the host cell genome by the HIV-1 specific enzyme 
called integrase. Blocking the strand transfer activity for this enzyme limits viral replication 
and thereby the infection of new cells. Raltegravir selectively inhibits integrase and 
represented a new therapeutic target for the treatment of HIV infection.10 
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used with great caution with commonly used antiretroviral agents due to pharmacokinetic 
interactions. 35
 Besides conventional medication for comorbidities, approximately 60% of HIV-infected 
patients use complementary and alternative medicines to treat HIV-related symptoms 
and side effects of antiretroviral therapy. But even herbal medicines may cause clinically 
significant interactions with antiretroviral agents with potential drug failure as a result.36-39
These are a few examples of common medical conditions within the HIV-infected population 
and the subsequent use of various therapeutic drug classes besides cART. Polypharmacy and 
managing these potential drug-drug interactions is considered the next therapeutic 
challenge in HIV.40 
The use of clinical pharmacology
Clinical pharmacology is the science that studies the effect of drugs in humans with a 
focus on the translation and application of basic pharmacological principles into clinical 
practice. Two major principles in clinical pharmacology that are involved in the relationship 
between dose, drug exposure, and response in patients, are the pharmacokinetics and 
pharmacodynamics of a drug. Pharmacokinetics can be defined as what the body does to 
the drug and is comprised of the absorption, distribution, metabolism, and elimination 
profile. Pharmacodynamics is what the drug does to the body and can be divided into 
efficacy or therapeutic response, and toxicity. Clinical pharmacology plays a critical role in 
the treatment of HIV infection and can connect the gap between the medical science of 
antiretroviral drugs and their use in daily clinical practice. 
Although many antiretroviral drugs are now available, a limited number of combinations have 
been proven to be effective in individual patients. An understanding of the interindividual 
variation in response, both efficacy and toxicity, of antiretroviral drugs has evolved over 
time leading to individualization of antiretroviral therapy based on the pharmacological 
characteristics of antiretroviral agents. The need for individualized approaches to cART 
has been further increased due to the presence of comorbidities in especially the older 
HIV population. Most HIV-infected patients take at least three antiretroviral agents, but 
may also take a variety of medication for concomitant illnesses whether or not related 
to HIV. With the use of multiple antiretroviral agents, it is critical to understand the pharmaco-
kinetics of these agents to avoid or manage drug-drug interactions.41 Many antiretroviral 
agents, in particular PIs and NNRTIs, are not only substrates but also inhibitors or inducers of 
cytochrome P450 or other hepatic enzymes and drug transporters. Probably the best 
known example of a perpetrator of pharmacokinetic drug-drug interactions within the 
HIV treatment, is the use of ritonavir. Ritonavir is a potent inhibitor of the CYP3A4 enzyme, 
HIV and drug-drug interactions
The introduction of effective antiretroviral therapy has increased the life expectancy of 
HIV-infected individuals.19 In high-income countries, approximately 33% of all adults living 
with HIV were aged 50 years and over in 2012.20 In 2015, more than 50% of all HIV-infected 
individuals living in the USA will be 50 years of age or older.19,21 Additionally, it is believed 
that HIV infection, and quite possibly its treatment, may be contributing to the acceleration 
of the aging process by several years when compared to uninfected individuals.22 The older 
HIV population is increasingly experiencing common medical conditions associated with 
aging, such as hypertension, dyslipidemia, cognitive impairment, diabetes, osteoporosis, and 
malignancies. Some of these conditions are more prevalent in HIV-infected individuals 
compared to uninfected individuals from the same age. As a consequence an increasing 
number of patients on antiretroviral treatment need medication for various comorbidities 
which significantly enhances the potential for drug-drug interactions.23
For example, HIV-infected patients, especially patients ≥ 50 years of age, are at increased 
risk of cardiovascular disease (CVD).21,24 Dyslipidemia, which is highly prevalent among 
HIV-infected patients, contributes to this increased risk. Statins lower plasma low-density 
lipoprotein (LDL) cholesterol levels and are frequently being used as lipid-lowering 
therapy in HIV-infected patients.25,26 However, the concomitant use of statins and 
antiretroviral agents, in particular PIs and NNRTIs, may lead to clinically relevant pharmaco-
kinetic drug-drug interactions with potentially severe statin-induced toxicity as a result.27-29
The introduction of cART has reduced the risk of AIDS-defining malignancies and 
dramatically prolonged survival. But as a result the HIV population is increasingly more at 
risk for development of non-AIDS-defining malignancies that typically occur at older ages. 
Although the type of cancer that HIV-infected patients are diagnosed with is changing, 
the need for treatment with chemotherapy in combination with cART is increasingly 
common. Concomitant use of cART with chemotherapy is complicated due to drug-drug 
interactions and overlapping toxic effects.30,31
Depression is the most common mental health disorder among HIV-patients with a 
lifetime prevalence that is approximately 2-fold higher than among HIV-uninfected 
individuals.32,33 Depression is associated with an increased risk of treatment failure and viral 
resistance of antiretroviral agents due to adherence problems.34 Therefore treating 
depression with antidepressant therapy is important to improve health outcomes in those 
living with HIV.
Of the 35 million people living with HIV worldwide, approximately 4 - 5 million are 
coinfected with hepatitis C (HCV).2 Several antivirals to treat HCV should be avoided or 
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 characterization of raltegravir transport by drug transporters indicates that raltegravir is 
subject to P-glycoprotein (P-gp)-mediated efflux.58,59 Raltegravir does not appear to influence 
UGT enzymes. Unlike other antiretroviral drug classes, such as PIs and NNRTIs, raltegravir is 
not a substrate of CYP450 enzymes and does not inhibit or induce CYP450 enzymes.53
Approximately 7-14% of a raltegravir dose is excreted unchanged in the urine. No clinically 
important effects were observed on the pharmacokinetic profile of raltegravir in patients 
with moderate hepatic insufficiency (Child Pugh score 7-8) or severe renal insufficiency 
(creatinine clearance <30 mL/min/1.73 m2).60 The pharmacokinetics of raltegravir displays 
considerable inter- and intraindividual variability.61,62
Initial pharmacokinetic/pharmacodynamic analyses based on phase II and III clinical studies 
did not suggest a particular threshold for a raltegravir plasma concentration associated 
with reduced efficacy. In 2012 the pharmacokinetic data of the QDMRK study (800 mg 
once daily versus 400 mg twice daily) showed that the trough level (C
12h
) is considered the 
most important parameter to evaluate with respect to raltegravir’s virological efficacy, 
with a suggested threshold of 0.020 mg/L.17 
Raltegravir: drug-drug interactions
Managing potential drug-drug interactions in HIV-infected patients may be challenging 
for clinicians and pharmacists, especially when multiple interacting agents are used. 
A potential strategy is to choose an antiretroviral regimen with little propensity to interact with 
concomitant medication. Based on the available theoretical data and drug-interaction 
studies, raltegravir is not known to inhibit or induce CYP450 enzymes or UGT enzymes. 
Although the metabolic profile of raltegravir or its transport via drug transporters might 
not be fully clarified, raltegravir could be considered a preferred antiretroviral agent if 
potential pharmacokinetic interactions are a concern. However, theoretical data is not 
always sufficient to predict pharmacokinetic interactions as unexpected drug-drug 
interactions with raltegravir have been observed in previous studies.63,64
Some guidelines and articles on the management of cancer in HIV-infected patients 
recommend to use raltegravir as an alternative for NNRTIs and PIs to avoid potential phar-
macokinetic drug-drug interactions via the CYP450 pathway.30,31,65,66 Nonetheless, little is 
known on the pharmacokinetics of raltegravir in this setting, including the potential 
influence of severe chemotherapy-induced intestinal toxicity on the absorption and total 
exposure to raltegravir.
which is an important liver enzyme responsible for the hepatic metabolism of many 
therapeutic agents. Although ritonavir is being used for its positive effect as booster for 
the PIs to improve their pharmacokinetic properties, its negative impact on the occurrence 
of adverse drug-drug interactions is generally known. Polypharmacy could be a reason 
for clinicians to start with or switch to an alternative antiretroviral regimen with little 
propensity to interact with concomitant medication. 
Pharmacokinetic drug-drug interactions as well as intra- and interpatient pharmacokinetic 
variability are some of the main causes for suboptimal drug exposure and is an important 
reason for treatment failure in HIV-infected patients. Therapeutic drug monitoring (TDM) 
is managing the therapeutic regimen of an individual patient by measuring drug concentrations, 
usually in blood. In HIV infection, TDM has been used to optimize and individualize cART 
response.42-46 Especially certain patient groups who are at increased risk for pharmacokinetic 
variability resulting in potential low or elevated plasma concentrations could benefit from 
TDM. These special patient populations include pediatric and pregnant patients, patients 
with renal and hepatic impairment, and patients with complex drug-drug interactions.42,44,47-49 
Pregnancy is associated with considerable physiological changes which may influence the 
pharma cokinetic profile of antiretroviral agents and lead to decreased drug exposure. 50,51 
To monitor the effect of pharmacokinetic drug-drug interactions, drug measurements of 
an antiretroviral drug before and after introduction of an interacting agent can establish 
 patient-specific targets and guide subsequent dose adjustments.52
In conclusion, it is widely acknowledged that better understanding of the clinical pharma - 
cology, including the pharmacokinetics of antiretroviral drugs is essential for their safe 
and effective use in HIV-infected patients. 
Clinical pharmacology of raltegravir 
Raltegravir (Isentress®) became available at the end of 2007 as film-coated tablets 
containing 400 mg raltegravir (as potassium). The recommended dose of raltegravir in 
adult HIV-infected patients is 400 mg orally twice daily with or without food.53,54
 Raltegravir absorption is rapid, with a time to reach maximum plasma concentration 
of 1 to 3 hours, depending on the food intake. Raltegravir solubility, and oral absorption, 
improves at higher gastrointestinal pH values. The apparent terminal half-life of raltegravir is 
approximately 9 hours and steady-state plasma concentrations are generally reached in 
approximately 2-3 days.55,56
Raltegravir is primarily metabolized by glucuronidation via UDP-glucuronosyltransfer ase 
(UGT)1A1 in the liver, with minor contributions from UGT1A3 and UGT1A9.57 In vitro 
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Part 2: Pharmacokinetics in special patient populations
The second part of this thesis focuses on the pharmacokinetics of raltegravir and the 
application of TDM in special patient populations.
 The use of cART in pregnant HIV-infected women is important in the prevention of 
MTCT. Raltegravir could play an important role when a rapid decline in maternal plasma 
HIV RNA is needed to prevent MTCT during delivery or as an alternative antiretroviral drug 
in complex treatment-experienced HIV-infected pregnant women. We studied the effect 
of pregnancy on the pharmacokinetics of raltegravir and its safety, and efficacy in 
HIV-infected pregnant women (Chapter 6).
TDM could be of value in HIV-infected patients at risk for complex pharmacokinetic 
drug-drug interactions, such as HIV-infected patients who need to use chemotherapeutic 
agents.30,31 In Chapter 7 we describe a short case series of three HIV-infected patients with 
advanced stage non-Hodgkin lymphoma and use of chemotherapy in whom TDM of 
raltegravir was performed as part of our regular patient care. We used a limited plasma 
sampling method to estimate the exposure to raltegravir.
Raltegravir was the first INSTI approved by the FDA (December 2011) and EMA (December 
2012) for treatment of HIV infection in the pediatric population.11,12 Two age-appropriate 
formulations suitable for infants and young children were introduced: chewable tablets and 
granules which are administered as oral suspension. In Chapter 8 we discuss our 
experience with TDM and dose optimalization of raltegravir chewable tablets in a 4 
year-old HIV-infected patient, as well as provide a review of the available literature and 
information on the pharmacokinetics of raltegravir in children.
Aim of the thesis
The overall aim of this thesis was to study the clinical pharmacology of the HIV-1 integrase 
inhibitor raltegravir to optimize its safe and effective use in HIV-infected patients in clinical 
practice. Part 1 of the thesis focuses on pharmacokinetic drug-drug interactions between 
raltegravir and other frequently used concomitant therapeutic agents or alternative 
medication for coexisting medical conditions. Part 2 of the thesis presents the pharmaco-
kinetics and TDM of raltegravir in special patient populations. 
Part 1: Drug-drug interactions
To recommend the safe use of raltegravir with other frequently used or otherwise important 
concomitant medication, four pharmacokinetic drug-drug interaction studies were conducted 
in healthy volunteers. 
 Chapter 2 describes the two-way pharmacokinetic drug-drug interaction between 
raltegravir and atorvastatin. In addition to this, we investigated the tolerability of the 
treatment combination and whether raltegravir influenced the short-term lipid-lowering effect 
of atorvastatin. Raltegravir and atorvastatin share a similar metabolic pathways via UGT 
and P-gp which might interfere with both their pharmacokinetic profiles. 
Chapter 3 evaluates the two-way pharmacokinetic drug-drug interaction and tolerability 
of concomitant administration of citalopram, a selective serotonin reuptake inhibitor 
(SSRI) for the treatment of depression, and raltegravir in healthy volunteers. 
Boceprevir was in 2011 introduced as a newly developed NS3 serine protease inhibitor for the 
treatment of chronic HCV genotype 1 infection.67 Boceprevir should be avoided or used 
with great caution with commonly used antiretroviral agents due to pharmacokinetic 
interactions via the CYP450 pathway.68,69 In order to recommend raltegravir as a preferred 
agent for combined HIV/HCV treatment with boceprevir, we designed a pharmacokinetic 
drug-drug interaction study between raltegravir and boceprevir as presented in Chapter 4. 
A popular herbal product used worldwide by HIV-infected patients is Ginkgo biloba 
extract, which is used for its claimed beneficial effects on concentration, memory, 
depressive disorders, and dementia.70 There is in vitro and animal evidence that Ginkgo 
biloba modulates UGT enzymes.71-74 Therefore we performed the herb-drug pharmaco-
kinetic interaction study between Ginkgo biloba and raltegravir (Chapter 5).
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Abstract 
Background
Dyslipidemia is highly prevalent among patients with HIV infection and contributes 
to an increased risk of cardiovascular disease. We investigated the influence of a frequently 
used statin, atorvastatin, on the pharmacokinetics of the HIV integrase inhibitor raltegravir 
and vice versa.
Methods
Open-label, crossover 3-period phase I trial in 24 healthy volunteers. Subjects took 
raltegravir 400 mg two times a day for 7 days, atorvastatin 20 mg once a day for 
7 days, and the combination of atorvastatin 20 mg once a day + raltegravir 400 mg two 
times a day for 7 days with 2-week washout periods in between. Intensive steady-state 
12- and 24-hour pharmacokinetic blood sampling was performed. Geometric mean ratios 
of the test treatment (combination raltegravir + atorvastatin) versus the reference 
treatment (raltegravir or atorvastatin alone) and 90% confidence intervals were calculated 
for the area under the plasma concentration-time curve (AUC). Fasting lipid profiles were 
obtained to assess short-term lipid-lowering effect of atorvastatin with or without 
concomitant raltegravir use.
Results
Twenty-four healthy volunteers (11 males) were enrolled. All but 1 subject completed the trial 
and no serious adverse events were reported. Geometric mean ratios (90% confidence 
interval) were 1.01 (0.68-1.51) for raltegravir AUC
0-12h 
and 1.00 (0.90-1.11) for atorvastatin AUC
0-24h. 
The AUC
0-24h 
metabolite-to-parent ratio for atorvastatin lactone, ortho-hydroxy and para-hydroxy 
atorvastatin did not change during concomitant raltegravir use. The effect of atorvastatin on 
low-density lipoprotein cholesterol was not significantly different when combined with 
raltegravir versus atorvastatin alone (p=0.638).
Conclusions
Atorvastatin 20 mg has no clinically relevant effect on the pharmacokinetics of raltegravir 
and vice versa. The combination was well tolerated and can be administered without dose 
adjustments. 
Introduction
The introduction of effective antiretroviral therapy has increased the life expectancy of 
HIV-infected individuals. By 2015, it is projected that more than 50% of all HIV-infected 
individuals living in the USA will be 50 years of age or older.1 HIV-infected patients, 
especially patients older than or equal to 50 years of age, are at increased risk of 
comorbidities such as cardiovascular disease (CVD).1,2 Dyslipidemia is highly prevalent 
among patients with HIV infection and contributes to the increased cardiovascular risk in 
this patient population. Although data on prevention of CVD in HIV-infected patients are 
limited, available evidence suggests to use intervention strategies in the HIV-infected 
population similar to those for the general population. International guidelines on the 
treatment of HIV infection include recommendations on the use of statins for the 
treatment of HIV-associated dyslipidemia and prevention of artherosclerotic disease.3-5 
Statins lower plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are widely used as 
lipid-lowering therapy in HIV-infected patients.6-8 A retrospective cohort study of 700 
patients with HIV showed that atorvastatin and rosuvastatin were preferable to pravastatin 
because of greater declines in total cholesterol.9 Currently, atorvastatin is one of the most 
commonly prescribed statins for HIV-infected patients. In addition, statins exhibit anti- 
inflammatory effects and are currently of interest for their potential immune-modulatory 
properties in HIV-infected patients.10-12
A complicating factor in the concomitant use of antiretroviral agents and lipid-lowering drugs 
is the occurrence of drug-drug interactions, specifically between statins and HIV protease 
inhibitors or non-nucleoside reverse transcriptase inhibitors.13-17 Raltegravir, an HIV integrase 
inhibitor, does not influence cytochrome P450 (CYP) enzymes and has in general little 
propensity to interact with other medication. In contrast to protease inhibitors and 
efavirenz, raltegravir has a beneficial lipid profile. Switching from ritonavir-boosted 
protease inhibitors to raltegravir does not only improve plasma lipids but also led to 
significant changes in several cardiovascular biomarkers associated with inflammation, 
insulin resistance, and hypercoagulability.18 Therefore, raltegravir could be one of the 
preferred antiretroviral agents in HIV-infected patients with dyslipidemia and statin use, 
especially in older patients with comorbidities and the subsequent use of concomitant 
medications. 
The concomitant use of raltegravir and atorvastatin has not been investigated yet in a 
pharmacokinetic study, although there is, at least theoretically, a risk for a drug-drug 
interaction. Raltegravir is primarily metabolized by glucuronidation via UDP-glucuronosyl-
transferase (UGT) 1A1 in the liver, with minor contributions from UGT1A3 and UGT1A9.19 
It is not known to influence CYP enzymes, UGT enzymes or organic  anion-transporting 
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good age-appropriate health condition as established by physical examination, medical 
history, electrocardiography and biochemical, hematologic, and urinalysis testing within 4 
weeks before day 1. Main exclusion criteria were a positive HIV, hepatitis B and C test result 
and use of any medication except for acetaminophen from 2 weeks preceding dosing. 
Study drug and dosing
The approved dose of raltegravir (Isentress; Merck Sharp & Dohme Ltd, Hoddesdon, United 
Kingdom) is 400 mg twice daily.20,25 The clinical dosage of atorvastatin (Lipitor; Pfizer, New 
York, NY) ranges from 10 to 80 mg once daily orally.26 In this study, atorvastatin 20 mg 
tablets were taken once daily in the morning during atorvastatin treatment periods. A 
treatment duration of 7 days for all treatment periods was chosen to reach steady-state 
plasma concentrations of the study drugs and to allow sufficient time to observe any 
competition for a particular metabolic pathway with concomitant use. On the days of 
pharmacokinetic sampling, both raltegravir and atorvastatin were taken on an empty 
stomach. A standardized breakfast, consisting of 1 glass of milk and 2 slices of buttered 
wheat bread with 48+ cheese and cervelat, was served at 2 hours after dosing. Intake of 
medication at the clinical trial unit was supervised and recorded by the study personnel. 
Tablets were counted to assess adherence. In addition, drug intake of atorvastatin at home 
was monitored by use of microelectronic monitoring system (MEMS) caps (Aardex Ltd, 
Zug, Switzerland), which records the opening of the medication bottle. Subjects were 
asked to write down the exact times of medication intake in a booklet. Because the 
raltegravir medication bottles were incompatible with MEMS caps, we were unable to 
monitor the raltegravir intake electronically.
Study procedures
Pharmacokinetic assessment was performed at steady-state conditions at day 7 of each 
treatment period. Blood samples for pharmacokinetic analysis were collected into lithi-
um-heparinized tubes from predose until 12 hours after intake of the study drug with an 
additional sample at 24 hours after intake of atorvastatin. Blood samples for analysis of 
atorvastatin and the metabolites atorvastatin lactone, ortho-hydroxy atorvastatin, and 
para-hydroxy atorvastatin were immediately put on ice and centrifuged within 30 minutes 
at 1,900 x g at 4°C. Plasma was transferred to polypropylene tubes and kept on ice for a 
maximum of 3 hours until storage at -80°C awaiting further bioanalysis. Blood samples for 
analysis of raltegravir were centrifuged for 5 minutes at 1,900 x g at 20°C. Plasma was 
transferred to polypropylene tubes and stored at -40°C until further bioanalysis. 
Safety assessment consisted of monitoring adverse events and laboratory evaluations 
(biochemistry and hematology). Adverse events were graded according to the Division of 
AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (version 1.0, 
December 2004) and causality assessment with the study drugs was performed. 
polypeptide (OATP)-1B1.20,21 Raltegravir is subject to minor P-glycoprotein (P-gp)-mediated 
efflux.22 Atorvastatin and its metabolites are to various extent substrates for CYP3A4, 
UGT1A1, UGT1A3, and P-gp. The active uptake transporter OATP1B1 facilitates the uptake of 
atorvastatin into the hepatocytes, which is the site of action for statins.23,24 When administered 
in high dose, atorvastatin increases the bioavailability of digoxin, most probably by inhibition 
of P-gp. There is no evidence that atorvastatin influences the metabolism of UGT 
substrates.23 Because raltegravir and atorvastatin share similar metabolic pathways 
through UGT and P-gp, a pharmacokinetic interaction cannot be excluded. 
The primary objective of this study was to assess the effect of steady-state raltegravir 400 
mg twice daily on the pharmacokinetics of steady-state atorvastatin 20 mg once daily and 
vice versa in healthy volunteers. Secondary objectives included the safety and tolerability 
of the treatment combination and the lipid-lowering effect of short-term atorvastatin use 
in the presence and absence of raltegravir.
Methods
Design
This open-label 3-period randomized crossover phase I trial in 24 healthy volunteers was 
conducted from May to July 2013 at the Radboud University Medical Center, Nijmegen, 
the Netherlands. The study was designed to determine the effect of steady-state raltegravir 
on the pharmacokinetics of steady-state atorvastatin and vice versa by intrasubject 
comparison.
 
Healthy volunteers were equally randomized to one of the following treatment sequences: 
ABC; ACB; BCA; BAC; CAB; or CBA. The treatments regimens were (A), raltegravir 400 mg 
twice daily for 7 days; (B), atorvastatin 20 mg once daily for 7 days; and (C), raltegravir 400 
mg twice daily and atorvastatin 20 mg once daily for 7 days. Every treatment period was 
followed by a washout period of 14 days. Blood samples for pharmacokinetic assessment 
were collected at day 7 of each treatment period during a 12-hour period for raltegravir 
and a 24-hour period for atorvastatin after observed intake of the study medication. The 
trial was approved by the Investigational Review Board of the Radboud University Medical 
Center, Nijmegen, The Netherlands. The trial was conducted in accordance with Good 
Clinical Practice and the Declaration of Helsinki and registered at ClinicalTrials.gov 
(NCT01779687). All participants signed informed consent before screening evaluations. 
Study population
Healthy male and female participants between the age of 18 and 55 and with a body mass 
index of 18-30 kg/m2 were eligible for enrolment. Included participants had to be in a 
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Statistical analysis
The data obtained in this study were analyzed according to an equivalence approach that 
is recommended for pharmacokinetic interaction studies by the Food and Drug 
Administration and European Medicines Agency (EMA) guidelines.30-32 For atorvastatin 
and its metabolites AUC GMRs with 90% CI within the range of 0.80-1.25 are considered to 
indicate no significant interaction between atorvastatin and raltegravir. For raltegravir, 
AUC GMRs with 90% CI within the range of 0.74-1.35 are considered to indicate no 
significant interaction if the GMR lies within the conventional acceptance range of 
0.80-1.25. According to the “Guideline on the Investigation of Bioequivalence” (EMA), the 
wider equivalence range could be considered for highly variable drugs (intrasubject 
coefficient of variation >30%), such as raltegravir, if this range in pharmacokinetic 
parameters is not considered clinically relevant. Sample size calculation (beta = 0.2, alpha 
= 0.1) was based on an assumed intrasubject SD of 0.5 for raltegravir AUC, an equivalence 
range of 0.74-1.35, and the hypothesis that there is no difference in AUC for the reference 
and test treatment. The required number of participants was 20, and to account for 
dropouts a total number of 24 participants were included. Statistical analyses were carried 
out using IBM SPSS Statistics software version 20. To compare the mean change (95% CI) 
in fasting serum lipid profile (day 7 - 1) between 2 treatments a paired t-test was performed. 
Results
Baseline characteristics
Twenty-four healthy volunteers (13 females, 11 males) were enrolled. Subjects were white 
(n=23) or mixed-race (n=1). One subject withdrew consent and did not complete the 
reference treatment period with raltegravir alone because of reasons not related to the 
study. Median (range) age and body mass index were 31 (18-55) years and 20.9 (18.3-28.9) 
kg/m2, respectively. The subjects were in good general health, according to medical 
history, physical examination, vital signs, and laboratory data. Adherence to the study 
treatment was good. One subject took an extra tablet atorvastatin 20 mg in the evening 
on days 1 and 4 during the treatment period of atorvastatin with raltegravir. These 
deviations did not lead to exclusion of the subject from pharmacokinetic analysis. All other 
subjects took all doses of atorvastatin and raltegravir according to tablet count, booklet, 
MEMS caps recordings and blood concentrations. 
Pharmacokinetics
The plasma concentration versus time curves and the steady-state pharmacokinetic parameters 
of raltegravir alone and with concomitant use of atorvastatin 20 mg once daily are shown 
in Figure 1A and Table 1. Mean exposure to raltegravir, which is expressed as AUC
0-12h
, was 
similar for raltegravir coadministered with atorvastatin relative to raltegravir alone: the 
Participants were to refrain from sports and strenuous exercise during the treatment 
periods to avoid potential exercise induced myalgia and creatine kinase (CK) elevations. 
The lipid-lowering effect of atorvastatin was evaluated by measuring serum lipid profiles 
after 12 hours overnight fasting on days 1 and 7 of each treatment period. A lipid profile 
in serum consisted of total cholesterol, triglycerides, high-density lipoprotein (HDL) 
cholesterol, non-HDL cholesterol and LDL cholesterol (calculated by means of the 
Friedewald equation).27
Bioanalytical methods
Atorvastatin, atorvastatin lactone, orthy-hydroxy atorvastatin, and para-hydroxy atorvastatin 
in plasma were quantified using a validated liquid chromatography-tandem mass 
spectrometry bioanalytical method with a linear calibration range of 0.0500 – 20.0 ng/mL 
for all analytes at Analytical Biochemical Laboratory BV (Assen, The Netherlands). 
Concentrations of raltegravir in plasma were analyzed using a validated reversed-phase 
high-pressure liquid chromatography with fluorescence detection. The linear calibration 
range in plasma was 0.014-10.0 mg/L. The raltegravir assay was performed at the laboratory 
of the Pharmacy of the Radboud University Medical Center (Nijmegen, The Netherlands) 
and externally validated through the International Interlaboratory Quality Control Program 
for Measurement of Antiretroviral Drugs in Plasma and by the Clinical Pharmacology 
Quality Assurance and Quality Control program.28,29
Pharmacokinetic analysis
Pharmacokinetic parameters were determined using a noncompartmental model in 
WinNonlin/Phoenix version 6.3 (Pharsight Corporation, St. Louis, MO). Based on the 
individual plasma concentration-time data, the following pharmacokinetic parameters of 
raltegravir, atorvastatin, atorvastatin lactone, orthy-hydroxy atorvastatin, and para-hydroxy 
atorvastatin were determined: the area under the plasma concentration-time curve from 
0 to 12 hours (raltegravir) or 24 hours (atorvastatin) after intake using the trapezoidal rule 
(AUC
0-tau
), the trough concentration (C
12h
/C
24h
) defined as the sample taken at 12 and 
24 hours, respectively after intake, the maximum plasma concentration of the drug (C
max
), 
the time to reach C
max
 (t
max
) and the apparent elimination half-life (t
1/2
). Pharmacokinetic 
parameters are reported as geometric means with 95% confidence intervals (CIs). 
Geometric mean ratios (GMRs) of the pharmacokinetic parameters of the test treatment 
(combination raltegravir + atorvastatin) versus the reference treatment (raltegravir or 
atorvastatin alone) and 90% CIs were calculated after log-transformation of within-subject 
ratios using a mixed-effects bioequivalence module in WinNonlin/Phoenix. Atorvastatin 
metabolite-to-parent ratios (mean ± SD) of AUC
0-24h 
were calculated for both treatments.
34 35
Chapter 2 Atorvastatin and raltegravir drug interaction
Safety and tolerability
The study medication was generally well tolerated. No serious adverse events were 
reported and there were no discontinuations due to adverse events. Twenty-two subjects 
reported a total of 121 adverse events. Twenty-five adverse events (21%) reported by a 
total of 14 subjects were considered possible (n=20) or probable (n=5) related to the study 
medication. All possible and probable drug-related adverse events were mild (toxicity 
grade 1 or 2), resolved without sequela, and were not related to a specific treatment 
period. The reported adverse events were myalgia (n=6, 4 subjects), abdominal pain/
bloated feeling (n=4), fatigue (n=3, 2 subjects), CK elevation grade 2 (n=3), headache (n=2), 
nausea (n=2) and diarrhoea, dry mouth, pruritis, general malaise and transaminase 
elevation (all reported once). Nonsymptomatic CK elevation classified as grade 2 (2.1-4.0 
times the upper limit of normal) was reported once during atorvastatin treatment and 
twice during treatment with atorvastatin and raltegravir. Myalgia without CK elevation 
was reported 3 times during raltegravir treatment or its washout period, twice during 
atorvastatin treatment, and once when raltegravir was combined with atorvastatin. 
GMR with 90% CI of AUC
0-12h
 was 1.01 (0.68-1.51). Raltegravir pharmacokinetics was highly 
variable which is best seen in the large 90% CI around the GMRs in Table 1 and graphically 
in Figure 1B. Figure 1B shows considerable variation in the amount and direction of the 
individual changes in AUC
0-12h
 of raltegravir alone compared with the combination with 
atorvastatin. The GMR of the main pharmacokinetic parameter raltegravir AUC
0-12h
 fell within 
the range of 0.80-1.25, and the 90% CI partly overlaps the range of 0.74-1.35 that reflects 
the variability.
Figure 2 shows the plasma concentration versus time curves of atorvastatin (A) and the 
metabolites atorvastatin lactone (B), ortho-hydroxy atorvastatin (C), and para-hydroxy 
atorvastatin (D) when atorvastatin 20 mg once daily was administered alone or with 
raltegravir 400 mg twice daily. The steady-state pharmacokinetic parameters of atorvastatin 
and its metabolites and the GMRs are described in Table 2. Relative to administration 
of atorvastatin alone, the coadministration of raltegravir did not have an effect on the 
pharmacokinetic parameters of atorvastatin, atorvastatin lactone, ortho- hydroxy, and 
para-hydroxy atorvastatin. The GMRs of the exposure (AUC
0-24h
) to atorvastatin and the 
major metabolites were close to 1.0 and the 90% CI fell entirely within the range of 0.80-1.25. 
At steady state mean (±SD) metabolite-to-parent ratios of AUC
0-24h 
for treatment with 
atorvastatin alone versus treatment with raltegravir were 0.80 (±0.27) versus 0.77 (±0.30) 
for atorvastatin lactone, 1.24 (±0.38) versus 1.19 (±0.37) for ortho-hydroxy atorvastatin and 
0.17 (±0.06) in both treatments for para-hydroxy atorvastatin. Figure 3 shows the 
individual atorvastatin metabolite- to-parent ratios of AUC
0-24h
. 
Figure 1 Geometric mean (+ upper 95% CI) raltegravir plasma concentration-time 
profiles (A) and individual AUC
0-12h
 (B) at steady state when raltegravir 400 mg twice daily 
was administrated alone or with atorvastatin 20 mg once daily.
Table 1   Comparison of steady-state pharmacokinetic parameters of raltegravir  
400 mg twice daily alone and with coadministration of atorvastatin 20 mg 
once daily in healthy volunteers. 
Pharmacokinetic 
parameter
Raltegravir alone
n=23
Raltegravir  
+ atorvastatin
n=24
Raltegravir  
+ atorvastatin: 
raltegravir alone
Geometric 
mean
95% CI Geometric 
mean
95% CI GMR 90% CI
AUC
0-12h
 (mg·h/L) 4.13 (2.91-5.87) 4.23 (2.92-6.14) 1.01 (0.68-1.51)
C
max
 (mg/L) 1.29 (0.83-1.99) 1.48 (0.96-2.28) 1.14 (0.70-1.86)
t
max
a (h) 1.55 (0.55-3.00) 1.50 (0.63-2.00)
C
12h
 (mg/L) 0.052 (0.035-0.077) 0.049 (0.039-0.062) 0.96 (0.69-1.32)
t
1/2
b
 
(h) 3.28 (2.64-4.09) 3.35 (2.86-3.93) 0.97 (0.77-1.21)
a For t
max
, median + interquartile range is reported.
b t
1/2
 could not be determined in 4 and 6 subjects for respectively raltegravir alone and raltegravir+ atorvastatin.
AUC
0-12h
, area under the plasma concentration-time curve up to 12 hours after intake; CI, confidence interval; 
C
max
, maximum plasma concentration; C
12h
, plasma concentration 12 hours after intake; GMR, Geometric Mean Ratio; 
t
1/2
, apparent elimination half-life; t
max
, time to reach C
max
.
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Lipid-lowering effects
Table 3 summarizes the mean (95% CI) change (day 7 - 1) in serum lipid profile observed 
after short-term treatment with atorvastatin 20 mg once daily alone or together with 
raltegravir. Raltegravir did not significantly influence the short-term lipid-lowering effects 
of atorvastatin on total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and 
non-HDL cholesterol (p > 0.05). In our healthy study population a distinct lipid-lowering 
effect was observed after only 6 doses of atorvastatin 20 mg once daily: mean (95% CI) 
change in LDL cholesterol (mmol/L) was -0.14 (-0.26 to -0.02) for raltegravir alone compared 
with -1.17 (-1.38 to -0.97) for atorvastatin alone and -1.22 (-1.40 to -1.03) for atorvastatin with 
raltegravir (p < 0.001). 
Figure 2 Geometric mean (+ upper 95% CI) plasma concentration-time profiles of 
atorvastatin (A) and the metabolites atorvastatin lactone (B), ortho-hydroxy atorvastatin 
(C), and para-hydroxy atorvastatin (D) at steady state when atorvastatin 20 mg once daily 
was administered alone or with raltegravir 400 mg twice daily.
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Table 2   Comparison of steady-state pharmacokinetic parameters of atorvastatin, 
 atorvastatin lactone, ortho-hydroxy atorvastatin, para-hydroxy atorvastatin after 
 administration of atorvastatin 20 mg once daily alone and coadministration  
with raltegravir 400 mg twice daily in healthy volunteers. 
Analyte and 
 pharmacokinetic 
parameter
Atorvastatin alone
n=24
Atorvastatin  
+ Raltegravir
n=23 
Atorvastatin  
+ Raltegravir : 
 Atorvastatin alone
Geometric 
mean
95% CI Geometric 
mean
95% CI GMR 90% CI
Atorvastatin
AUC
0-24h
 (ng·h/mL) 43.7 (36.3-52.6) 44.6 (35.9-55.6) 1.00 (0.90-1.11)
C
max
 (ng/mL) 9.28 (7.32-11.8) 9.95 (7.68-12.9) 1.05 (0.84-1.30)
t
max
a (h) 0.52 (0.50-1.0) 0.50 (0.50-1.0)
C
24h
 (ng/mL) 0.382 (0.305-0.479) 0.391 (0.304-0.501) 0.99 (0.86-1.15)
t
1/2 
(h) 6.92 (6.24-7.67) 6.97 (6.15-7.90) 1.00 (0.91-1.10)
Atorvastatin lactone
AUC
0-24h
 (ng·h/mL) 33.3 (27.2-40.8) 32.4 (25.6-40.8) 0.96 (0.87-1.06)
C
max
 (ng/mL) 3.00 (2.43-3.70) 2.96 (2.31-3.79) 0.97 (0.86-1.09)
t
max
a (h) 2.0 (1.5-6.0) 2.0 (1.0-3.0)
C
24h
 (ng/mL) 0.388 (0.307-0.491) 0.369 (0.286-0.477) 0.93 (0.81-1.07)
t
1/2 
(h) 7.17 (6.64-7.73) 7.29 (6.65-7.99) 1.01 (0.94-1.07)
Ortho-hydroxy atorvastatin
AUC
0-24h
 (ng·h/mL) 51.7 (44.7-59.9) 50.0 (42.9-58.3) 0.97 (0.90-1.04)
C
max
 (ng/mL) 6.21 (4.89-7.90) 6.21 (5.00-7.71) 1.00 (0.82-1.20)
t
max
a (h) 1.0 (0.52-2.0) 1.0 (1.0-1.5)
C
24h
 (ng/mL) 0.561 (0.489-0.636) 0.528 (0.469-0.594) 0.94 (0.84-1.05)
t
1/2 
(h) 7.44 (6.85-8.09) 7.37 (6.70-8.12) 0.99 (0.91-1.07)
Para-hydroxy atorvastatin
AUC
0-24h
 (ng·h/mL) 7.13 (5.71-8.91) 6.95 (5.38-8.97) 0.96 (0.88-1.06)
C
max
 (ng/mL) 0.470 (0.365-0.605) 0.442 (0.331-0.590) 0.94 (0.82-1.07)
t
max
a (h) 12 (2.3-12) 6.0 (1.5-12)
C
24h
 (ng/mL) 0.175 (0.142-0.217) 0.179 (0.137-0.234) 1.00 (0.87-1.14)
a For t
max
, median + interquartile range is reported.
AUC
0-24h
, area under the plasma concentration-time curve up to 24 hours after intake; CI, confidence interval; C
max
, 
maximum plasma concentration; C
24h
, plasma concentration 24 hours after intake; GMR, Geometric Mean Ratio; t
1/2
, 
apparent elimination half-life; t
max
, time to reach C
max
.
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Discussion
In HIV-infected patients the use of lipid-lowering therapy with statins is complicated by 
drug-drug interactions with antiretroviral agents, specifically with HIV protease inhibitors 
or non-nucleoside reverse transcriptase inhibitors.13-17 The purpose of this study was to 
evaluate the 2-way pharmacokinetic drug-drug interaction and tolerability of concomitant 
administration of atorvastatin 20 mg once daily and the HIV integrase inhibitor raltegravir 
400 mg twice daily in healthy volunteers. Our findings suggest that atorvastatin 20 mg has 
no clinically relevant effect on the pharmacokinetics of raltegravir. Raltegravir does not 
influence the pharmacokinetics of atorvastatin and its metabolites and did not seem to 
influence the short-term lipid-lowering effect of atorvastatin. These results are relevant 
for the increasing number of HIV-infected patients who are at risk for CVD and have 
dyslipidemia that requires therapy with potent statins such as atorvastatin. 
The metabolism of atorvastatin is complex with CYP3A4 being the major enzyme 
responsible for the formation of the 2 active metabolites: ortho-hydroxy atorvastatin acid 
and para-hydroxy atorvastatin acid. About 70% of the circulating inhibitory activity for 
HMG-CoA reductase is attributable to these active metabolites. The majority of clinically 
relevant drug-drug interactions with atorvastatin involve inhibition or induction of 
CYP3A4. Raltegravir is not an inducer or inhibitor of CYP450 and could be an alternative for 
other antiretroviral agents, such as protease inhibitors, if drug-drug interactions are a 
concern. Atorvastatin acid (the parent drug), para- and ortho-hydroxy atorvastatin are in 
equilibrium with their inactive lactone forms.33 UGT1A1 and UGT1A3 are involved in the 
acid to lactone conversion, whereas esterases mediate the hydrolysis of atorvastatin 
lactone to the open acid form of atorvastatin.24,34 Because raltegravir is primarily 
metabolized by UGT1A1 and to a lesser extent UGT1A3 we considered it relevant to 
analyze the 2 active hydroxyl metabolites and the lactone form of atorvastatin acid. The 
mean exposure (AUC
0-24h
) to atorvastatin, atorvastatin lactone, ortho-hydroxy or 
para-hydroxy atorvastatin was not influenced by concomitant raltegravir use. Metabo-
lite-to-parent ratios remained unaffected, and no competition for this particular UGT 
metabolic pathway with concomitant use was observed. The mean exposure to raltegravir 
(AUC
0-12h
) was similar for treatment with raltegravir alone compared with raltegravir 
combined with atorvastatin and resulted in a GMR of 1.01. The pharmacokinetics of 
raltegravir is highly variable which was observed in our study as well.35,36 The 90% CIs 
partly overlap the predefined range of 0.74-1.35 for no clinically relevant interactions. 
A limitation of our study is that the included participants were predominantly white 
individuals. Therefore, our study population does not reflect the demographics of the 
HIV-infected population around the world and its genetic variability. A more important 
limitation of our study could be that we used atorvastatin 20 mg while the maximum 
Figure 3  Individual and mean (± SD) metabolite-to-parent ratios of AUC
0-24h
 (ng·h/mL) 
of atorvastatin with the metabolites atorvastatin lactone, ortho-hydroxy atorvastatin, 
and para-hydroxy atorvastatin when atorvastatin 20 mg once daily was administered 
alone or with raltegravir 400 mg twice daily.
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Table 3   Mean change (95% CI) in plasma lipid profile of short-term treatment  
with atorvastatin 20 mg once daily with and without coadministration of 
raltegravir.
Lipid parameter 
(mmol/L)
Atorvastatin alone Atorvastatin  
+ Raltegravir
p
Cholesterol -1.31 (-1.55 to -1.08) -1.37 (-1.56 to -1.18) 0.629
HDL cholesterol -0.09 (-0.13 to -0.06) -0.05 (-0.10 to -0.01) 0.199
LDL cholesterol -1.17 (-1.38 to -0.97) -1.22 (-1.40 to -1.03) 0.638
Triglycerides -0.22 (-0.37 to -0.08) -0.22 (-0.41 to -0.34) 0.997
Non-HDL cholesterol -1.31 (-1.56 to -1.07) -1.32 (-1.49 to -1.14) 0.977
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In conclusion, our findings suggest that atorvastatin 20 mg has no clinically relevant effect on 
the pharmacokinetics of raltegravir. Raltegravir does not influence the pharmacokinetics 
of atorvastatin and has no effect on its short-term lipid-lowering effect. The combination 
can be administered with no dose adjustments. Coadministration of raltegravir and 
atorvastatin 20 mg was safe and well tolerated in our study in healthy HIV-negative 
subjects. 
registered daily dose of atorvastatin is 80 mg. Only the highest dose (80 mg) of atorvastatin, 
which is not often used in clinical practice, increases the bioavailability of digoxin (AUC 
increased by 15%), most probably by inhibition of P-gp. Raltegravir is only a weak substrate 
of P-gp and does not have a small therapeutic window like digoxin, making it less likely 
that inhibition of P-gp has a clinically significant effect on the pharmacokinetics of 
raltegravir. Another limitation could be that the lipid-lowering effect was evaluated after a 
relatively short duration of atorvastatin use. However, in our study, atorvastatin 20 mg 
once daily during 1 week significantly decreased LDL cholesterol, as well as total cholesterol 
and non-HDL cholesterol compared with no treatment with atorvastatin, suggesting we 
allowed sufficient time to evaluate the lipid-lowering effects. 
The treatment combination of atorvastatin and raltegravir was well tolerated. A total of 
6 mild cases of myalgia were reported by 4 subjects, and 3 subjects had mild-to-moderate 
CK elevation with no symptoms. These adverse events were not related to a specific 
treatment period and did not occur more frequent during concomitant atorvastatin and 
raltegravir use. Although uncommon, cases of myopathy and rhabdomyolysis have been 
reported with raltegravir use.16,37,38 Raltegravir-based therapy has been reported to be 
associated with a higher prevalence of symptomatic skeletal muscle toxicity, which 
seemed to not be concentration- or time-dependent, and not associated with elevated 
CK.39 However, significant CK elevations were seen with raltegravir use, but in these 
patients symptoms were uncommon, not severe, and occurred in patients with identifiable 
risk factors.40 Although a causal relationship with raltegravir has not been clearly 
established, raltegravir should be used with caution in patients who have had myopathy 
or rhabdomyolysis in the past or have any predisposing issues including other medicinal 
products associated with these conditions. All statins carry the potential risk of myopathy 
and in rare cases progression to fatal rhabdomyolysis. High atorvastatin doses as well as 
certain pharmacokinetic drug-drug interactions, particularly those leading to higher 
concentrations in the peripheral blood and muscle cells, increase the risk of muscle 
toxicity. Atorvastatin-treated patients experiencing myopathy were found to have higher 
plasma concentrations of the hydroxymetabolites and cyclic lactones.41 Because exposure 
to atorvastatin and metabolite-to-parent ratios in this study were not influenced by 
concomitant raltegravir use, an increase in statin-induced muscle toxicity due to a phar-
macokinetic interaction with raltegravir is not likely to occur. Although our study did not 
show any safety issues, the short-term design without the use of high-dose atorvastatin 
and its healthy study population preclude a different monitoring approach for muscle 
toxicity than currently advised in the product labeling of both drugs.
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Abstract
Background
Depression is the most common mental health disorder among HIV-infected patients. 
When treating HIV-infected patients with a selective serotonin reuptake inhibitor (SSRI), 
potential drug-drug interactions with antiretroviral agents have to be taken into account. 
We investigated the two-way pharmacokinetic drug-drug interaction and tolerability of 
concomitant administration of the SSRI citalopram and the HIV-1 integrase inhibitor 
raltegravir in healthy volunteers. 
Methods
An open-label, crossover, two-period trial was conducted in 24 healthy volunteers. 
Subjects received the following treatments: citalopram 20 mg once daily for 2 weeks 
followed by the combination with raltegravir 400 mg twice daily for 5 days and after a 
washout period raltegravir 400mg twice daily for 5 days. Intensive steady-state pharmaco -
kinetic blood sampling was performed. Geometric mean ratios (GMRs) of the combination 
versus the reference treatment and 90% CIs were calculated for the area under the plasma 
concentration-time curve (AUC). CYP2C19 genotyping was performed because it influences 
N-demethylation of citalopram to desmethylcitalopram.
Results
A total of 22 healthy volunteers completed the trial. GMRs (90% CI) were 1.00 (0.98, 1.03) for 
citalopram AUC
0-24h, 
0.99 (0.88, 1.12) for desmethylcitalopram AUC
0-24h
 and 0.77 (0.50, 1.19) 
for raltegravir AUC
0-12h
. Raltegravir plasma concentration 12 h after intake (C
12h
) did not 
change with concomitant use of citalopram. Within each CYP2C19 phenotype subgroup 
the citalopram metabolite-to-parent ratio, which is a measure for metabolic enzyme 
activity, was not influenced by concomitant raltegravir use.
Conclusions
Raltegravir does not influence the pharmacokinetics of citalopram and desmethylcitalopram. 
Citalopram did not change the pharmacokinetics of raltegravir in a clinically meaningful 
way. The combination was well tolerated and can be administered without dose 
adjustments. 
Introduction 
Depression is the most common mental health disorder among HIV-infected patients. 
The lifetime prevalence of depression in patients infected with HIV is approximately twofold 
higher than among HIV-uninfected individuals.1-4 Depression is a risk factor for poor 
adherence to antiretroviral therapy and is associated with an increased risk of treatment 
failure, disease progression and mortality.5-7 Recognizing and treating depression is important 
in order to improve quality of life and health outcomes in those living with HIV.2,8,9
Antidepressant therapy is effective in most HIV-infected patients with major depression 
and treatment options are similar to HIV-negative patients. Selective serotonin reuptake 
inhibitors (SSRIs) and tricyclic antidepressants are equally effective, but SSRIs have 
demonstrated more favourable side effect profiles and are generally better tolerated.10,11 
Compliant SSRI use is associated with improved adherence to antiretroviral agents, leading 
to improved HIV viral control and increased CD4+ T-cell counts.12 Citalopram is a widely 
used SSRI in the general population and has a relatively favorable drug interaction profile 
compared to other SSRIs.11 This suggests that citalopram may be a good choice for the 
treatment of depression in HIV-infected patients who are at risk for experiencing drug-drug 
interactions.13
Biotransformation of citalopram is mainly hepatic by cytochrome P450 enzymes (CYP) 
2C19, CYP3A4 into the main metabolite desmethylcitalopram, which is further metabolized 
by CYP2D6 to didesmethylcitalopram.13-18 At steady state, plasma concentrations of 
desmethylcitalopram and didesmethylcitalopram are approximately 30-50% and 5-10% 
that of the parent compound, respectively. The metabolites do not likely contribute 
significantly to the clinical effects of citalopram, since they are present in lower 
concentrations and have been shown in vitro to be much weaker inhibitors of serotonine 
reuptake than citalopram.19 The genotype of CYP2C19 plays an important role in the 
extent of N-demethylation of citalopram to desmethylcitalopram in vivo.20,21 Citalopram is 
a weak CYP2D6 inhibitor and has weak or no effect on CYP1A2, CYP2C19 and CYP3A4. 
Desmethylcitalopram is a slightly more potent inhibitor of CYP2D6 and may mediate a 
mild interaction with other drugs metabolized by CYP2D6.13,14 An in vitro study revealed 
that citalopram is a weak inhibitor of P-glycoprotein (P-gp).22,23
Raltegravir is the first registered HIV-1 integrase strand transfer inhibitor (INSTI) and 
guidelines recommend its use with tenofovir and emtricitabine in treatment-naïve 
HIV-infected patients.24 Raltegravir is generally well tolerated and has minimal potential to 
interact with concomitant medication because it does not influence CYP or UDP-glucu-
ronosyltransferase (UGT) enzymes.25 Raltegravir is subject to minor P-gp-mediated efflux 
and is primarily metabolized by UGT1A1. Depression was added to the product labelling 
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as a precaution for use after identification of several post-marketing cases. In four patients 
with ongoing depression and use of antidepressants an association between starting 
raltegravir and exacerbation of depression was described.26 The mechanism by which 
raltegravir may have contributed to the observed psychiatric decompensation remains 
unknown. According to the authors, a potential cause could be one or more as yet 
unidentified drug-drug interactions with raltegravir and the antidepressant agents used. 
In one of the cases citalopram was used.
With the combined use of citalopram and raltegravir, no major pharmacokinetic interaction 
via UGT and CYP enzymes is theoretically expected. A minor interaction may occur 
through inhibition of P-gp-mediated transport of raltegravir by citalopram. However 
theoretical data is not always sufficient to predict pharmacokinetic interactions as 
unexpected drug-drug interactions with raltegravir have been observed in previous 
studies.27,28
The objective of this study was to assess the two-way pharmacokinetic interaction 
between raltegravir and citalopram in healthy volunteers, and to evaluate the safety and 
tolerability of the treatment combination.
Method
Study design
This open-label, two-period, randomized, crossover, phase I trial in 24 healthy volunteers 
was conducted from February to April 2014 at the Radboud university medical center, 
Nijmegen, The Netherlands. The study was designed to determine the effect of raltegravir 
400 mg twice daily on the pharmacokinetics of citalopram 20 mg once daily and vice 
versa by intrasubject comparison. 
The healthy volunteers were randomized into two groups of 12 subjects. The treatment 
regimen for group 1 was citalopram 10 mg once daily for three days followed by dose 
escalation to 20 mg once daily for two weeks (reference citalopram). Citalopram was 
continued with raltegravir 400 mg twice daily for 5 days (test combination). Citalopram 
was tapered off and after a washout period raltegravir 400 mg twice daily was given for 5 
days (reference raltegravir). Group 2 started with the raltegravir reference treatment and 
after a washout period continued with the same citalopram reference treatment and 
combination treatment as group 1. Pharmacokinetic assessment was performed on three 
occasions on the last day of each treatment period. The trial was approved by the Investi-
gational Review Board of the Radboud university medical center, Nijmegen, The 
Netherlands. The trial was conducted in accordance with Good Clinical Practice and the 
Declaration of Helsinki, and registered at ClinicalTrials.gov (NCT01978782). All participants 
signed informed consent prior to screening evaluations. 
Study population
Healthy male and female participants between the age of 18 and 55 and with a body mass 
index (BMI) of 18 to 30 kg/m2 were eligible for enrolment. Included participants had to be 
in a good, age-appropriate health condition as established by physical examination, 
medical history, electrocardiography and biochemical, hematologic, and urinalysis testing 
within 4 weeks prior to day 1. Main exclusion criteria were a positive HIV, hepatitis B and C 
test result, presence of long QT syndrome or prolonged QT time and use of any medication 
except for acetaminophen from 2 weeks preceding dosing. 
Study drug and dosing
The approved dosage of raltegravir (Isentress, Merck Sharp & Dohme Ltd, Hoddesdon, UK) 
is 400 mg twice daily.25,29 The clinical dosage of citalopram for depression in patients from 
18-65 years old is 20 mg once daily orally which can be increased to a maximum of 40 mg 
once daily depending on the effect. We studied the effect of 20 mg citalopram once daily 
and included dose escalation at start, as well as tapering off before discontinuation of 
citalopram to minimize the risk of adverse events (AEs). A treatment duration of two weeks 
for citalopram and 5 days for raltegravir was chosen to allow sufficient time to reach 
steady-state plasma concentrations on the day of pharmacokinetic assessment. On the 
days of pharmacokinetic sampling, both raltegravir and citalopram were taken on an 
empty stomach. A standard breakfast (480 kCal; 26 g fat) was served at 2 h after dosing. 
Intake of medication at the clinical research centre was supervised and recorded by the 
research nurses. Tablets were counted to assess adherence. In addition, drug intake of 
citalopram at home was monitored by use of microelectronic monitoring system (MEMS) 
caps (Aardex Ltd, Zug, Switzerland), which records the opening of the medication bottle. 
Subjects were asked to write down the exact times of medication intake in a booklet. 
Study procedures
Intensive pharmacokinetic sampling was performed at plasma steady-state conditions. 
Additional trough samples were collected during treatment to monitor adherence and to 
ensure that steady-state plasma concentrations had been reached on the day of pharma-
cokinetic assessment. Blood samples were collected into lithium-heparinized tubes 
during a 12-h period for raltegravir and a 24-h period for citalopram after observed intake 
of the study medication. Blood samples were centrifuged for 5 minutes at 1900 x g at 20°C. 
Plasma was transferred to polypropylene tubes and stored at -40°C until further bioanalysis. 
All participants who received study drugs were included in the safety data set. Safety 
assessment consisted of monitoring AEs and laboratory evaluations (biochemistry and 
hematology). Cardiovascular safety assessment, consisting of blood pressure measurement 
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and electrocardiogram (ECG) recording, was performed predose and 3 h after the first 
intake of 10 mg and 20 mg citalopram, and repeated at steady state. ECG recordings were 
evaluated by the medical investigator for potential prolongation of QT intervals. Adverse 
events were graded according to the Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events (version 1.0, December 2004) and causality assessment 
with the study drugs was performed. Genotyping of CYP2C19 for the presence of the 
alleles *2 (681G>A), *3 (636G>A), and *17 (806C>T) was performed by the Department of 
Clinical Chemistry at Erasmus Medical Center (Rotterdam, The Netherlands) as previously 
described.30,31 The CYP2C19 genotypes were classified into four phenotypes: poor 
metabolizer (PM) carrying two loss-of-function alleles (*2/*2, *2/*3, *3/*3); intermediate 
metabolizer (IM) carrying one loss-of-function allele (*1/*2, *1/*3, *2/*17); extensive 
metabolizer (EM) carrying normal function alleles (*1/*1, *1/*17), and ultra rapid metabolizer 
(UM) for alleles (*17/*17).
Bioanalytical methods
The citalopram and desmethylcitalopram assay was performed at the laboratory of the 
Pharmacy of Maastricht University Medical Centre (Maastricht, The Netherlands) by use of 
a validated reversed-phase ultra performance liquid chromatography method with 
fluorescence detection. The linear calibration range in plasma was 1.0 to 200 µg/L. 
Concentrations of raltegravir in plasma were analyzed using a validated reversed-phase 
high-pressure liquid chromatography with fluorescence detection as previously 
described.32 The linear calibration range in plasma was 0.014-10.0 mg/L. The raltegravir 
assay was performed at the laboratory of the Pharmacy of the Radboud university medical 
center (Nijmegen, The Netherlands) and externally validated through the International 
 Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in 
Plasma, as well as by the Clinical Pharmacology Quality Assurance and Quality Control 
Program (CPQA).33,34
Pharmacokinetic analysis
Pharmacokinetic parameters were determined using a noncompartmental model in 
WinNonlin/Phoenix version 6.3 (Pharsight Corporation, St. Louis, MO, USA). Based on the 
individual plasma concentration-time data, the following pharmacokinetic parameters of 
raltegravir, citalopram and desmethylcitalopram were determined: the area under the 
plasma concentration-time curve from 0 to 12 h (raltegravir) or 24 h (citalopram and 
desmethylcitalopram) after intake using the trapezoidal rule (AUC
0-tau
), the trough 
concentration defined as the plasma concentration of raltegravir 12 hours after intake 
(C
12h
) or the plasma concentration of citalopram/desmethylcitalopram 24 hours after 
intake (C
24h
), the maximum plasma concentration of the drug (C
max
), the time to reach C
max
 
(t
max
), the apparent elimination half-life (t
1/2
), the apparent oral clearance (CL/F), and the 
apparent volume of distribution (V/F). Pharmacokinetic parameters are reported as 
geometric means with 95% CIs. Geometric mean ratios (GMRs) of the pharmacokinetic 
parameters of the test treatment (combination raltegravir + citalopram) versus the 
reference treatment (raltegravir or citalopram alone) and 90% CIs were calculated using 
a mixed-effects bioequivalence module in WinNonlin/Phoenix. Citalopram metabolite- 
to-parent ratios expressed as mean ± standard deviation (SD) of AUC
0-24h 
were calculated 
when citalopram was administered alone versus concomitant raltegravir use for all 
subjects and CYP2C19 phenotype subgroups. 
Statistical analysis
The data obtained in this study were analyzed according to an equivalence approach that 
is recommended for pharmacokinetic interaction studies by FDA and EMA guidelines.35-37 
For citalopram and desmethylcitalopram AUC GMRs with 90% CIs within the range of 0.80 
to 1.25 are considered to indicate no significant interaction with raltegravir. For raltegravir 
AUC GMR with 90% CIs within the range of 0.74 to 1.35 are considered to indicate no 
significant interaction if the GMR lies within the conventional acceptance range of 0.80 to 
1.25. According to the ‘Guideline on the Investigation of Bioequivalence’ (EMA) the wider 
equivalence range could be considered for highly variable drugs (intrasubject coefficient 
of variation >30%), such as raltegravir, if this range in pharmacokinetic parameters is not 
considered clinically relevant. Sample size calculation (beta=0.2, alpha=0.1) was based on 
an equivalence range of 0.74-1.35 assuming no difference in AUC of raltegravir with or 
without citalopram and an intrasubject standard deviation of 0.5 for raltegravir AUC. The 
required number of participants was 20 and to account for dropouts a total number of 24 
participants were included. 
Results
Baseline characteristics
In total, 24 healthy volunteers (11 females, 13 males) were enrolled and 22 subjects 
completed the study. One subject decided to withdraw consent because of mild (grade 1) 
AEs after intake of a single dose of 10 mg citalopram. One subject withdrew consent after 
completing the reference treatment with raltegravir due to personal reasons. Subjects 
were Caucasian (n=22) or mixed-race (n=2). Median (range) age and BMI were 47 (18-53) 
years and 24.8 (20.9-29.3) kg/m2, respectively. Twenty-two subjects had evaluable 
citalopram curves. According to CYP2C19 genotyping these 22 subjects were classified 
into the following phenotypes: CYP2C19 PM (n=1), CYP2C19 IM (n=7), and CYP2C19 EM 
(n=14). Adherence to the study treatment was good according to tablet count, booklet 
and MEMS caps recordings. There were no deviations in drug intake in 21 subjects. Two 
subjects missed 1-2 doses and one subjects took one extra dose of study medication. 
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Pharmacokinetics
Raltegravir plasma concentration versus time curves and steady-state pharmacokinetic 
parameters of raltegravir 400 mg twice daily alone and coadministered with citalopram 20 mg 
once daily are shown in Figure 1 and Table 1. Coadministration of citalopram decreased 
raltegravir geometric mean peak plasma concentration (C
max
) and exposure (AUC
0-12h
) to 
raltegravir by 36% and 23%, respectively, compared to administration of raltegravir alone. 
The median time to reach C
max
 of raltegravir was 2.0 hours irrespective of citalopram 
treatment. The GMR of the raltegravir AUC
0-12h
 fell below the predefined interval of 
0.80-1.25 according to the equivalence approach and the 90% CI was large and overlapped 
the lower bound of the predefined interval of 0.74-1.35 for highly variable drugs. GMR of 
C
max 
as well as the lower bound of the 90% CI fell below the lower level of the 0.74-1.35 
interval. The geometric mean C
12h
 and apparent elimination half-life (t
1/2
) were similar after 
concomitant use of citalopram and raltegravir compared to raltegravir alone with GMRs 
close to 1.0. 
Raltegravir pharmacokinetics exhibit a high degree of inter- and intrasubject variability, 
which apart from the large CIs in Table 1 is best seen graphically in Figure 2. Figure 2 
shows the individual subject changes in AUC
0-12h
 (Figure 2A) and C
max
 (Figure 2B) of 
treatment with raltegravir alone versus coadministration with citalopram. Despite an 
average decrease in the AUC and C
max
 of raltegravir when coadministered with citalopram, 
an increase in AUC and C
max
 was observed in, respectively, 45% (n=10) and 36% (n=8) of 
the subjects with paired pharmacokinetic curves (n=22). 
Figure 1 Geometric mean (+ upper 95% CI) raltegravir plasma concentration-time 
profiles at steady state when raltegravir 400 mg twice daily was administrated alone or 
with citalopram 20 mg once daily.
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Table 1   Comparison of steady-state pharmacokinetic parameters of raltegravir  
400 mg twice daily alone and with coadministration of citalopram 20 mg 
once daily in healthy volunteers.
Pharma cokinetic 
parameter
Raltegravir alone
(n=23)
Raltegravir  
+ citalopram
(n=22)
Raltegravir  
+ citalopram: 
 raltegravir alone
Geometric 
mean
95% CI Geometric 
mean
95% CI GMR 90% CI
AUC
0-12h
 (mg·h/L) 6.82 (4.64-10.0) 5.27 (3.43-8.10) 0.77 (0.50-1.19)
C
max
 (mg/L) 2.45 (1.60-3.76) 1.58 (0.93-2.68) 0.64 (0.38-1.09)
t
max
 a (h) 2.0 (1.0-3.0) 2.0 (1.5-3.0)
C
12h
 (mg/L) 0.054 (0.037-0.080) 0.056 (0.043-0.073) 1.03 (0.71-1.50)
t
1/2
 b
 
(h) 2.65 (2.28-3.09) 2.89 (2.43-3.44) 1.09 (0.94-1.28)
CL/F (L/h 58.6 (39.9-86.2) 75.9 (49.4-117) 1.29 (0.84-1.99)
V/F b (L) 191 (120-305) 246 (142-428) 1.21 (0.77-1.89)
a For t
max
, median + interquartile range is reported. 
b t
1/2
 and V/F could not be determined in 3 and 4 subjects for raltegravir alone and raltegravir + citalopram, respectively.
Abbreviations: AUC
0-12h
, area under the plasma concentration-time curve up to 12 h after intake; CI, confidence 
interval; C
max
, maximum plasma concentration; C
12h
, plasma concentration 12 h after intake; CL/F, apparent oral 
clearance; GMR, geometric mean ratio; t
1/2
, apparent elimination half-life; t
max
, time to reach C
max
; V/F, apparent volume 
of distribution.
Figure 2  Individual AUC
0-12h
 (A) and C
max
 (B) of raltegravir at steady state when raltegravir 
400 mg twice daily was administrated alone (RAL) or with citalopram 20 mg once daily 
(RAL + CITAL).
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Figure 3 shows the plasma concentration-time curves of citalopram and desmethylcitalopram 
when citalopram 20 mg once daily was administered alone or with raltegravir 400 mg 
twice daily. The steady-state pharmacokinetic parameters of citalopram and desmethyl-
citalopram and the GMRs are described in Table 2. Coadministration of raltegravir did not 
have an effect on the pharmacokinetic parameters of citalopram and desmethylcitalopram. 
The GMRs of the exposure (AUC
0-24h
) to both citalopram and desmethylcitalopram, were 
close to 1.0 and the 90% CI fell entirely within the range of 0.80 to 1.25. The same applies 
to the other calculated parameters in Table 2. 
At steady state mean (±SD) metabolite-to-parent ratios of AUC
0-24h 
(n=22) did not change 
with concomitant raltegravir use and was 0.34 (±0.91) for citalopram alone versus 0.34 
(±0.94) for the combination. Mean (±SD) AUC
0-24h
 metabolite-to-parent ratios were 0.22 
versus 0.21 for CYP2C19 PM (n=1), 0.25 (±0.054) versus 0.25 (±0.060) for CYP2C19 IM (n=7), 
and 0.39 (±0.065) versus 0.39 (±0.066) for CYP2C19 EM (n=14) for the reference versus 
the test treatment. The subgroups CYP2C19 IM and PM have a reduced mean desmethyl-
citalopram-to-citalopram AUC
0-24h 
ratio compared to CYP2C19 EM. Within each phenotype 
subgroup the metabolite-to-parent ratio was not influenced by raltegravir use. 
Safety and tolerability
The study medication was well tolerated and no serious AEs or grade 3/4 events were 
reported. A total of 18 of the 24 subjects who received study medication reported 66 AEs 
that were considered to be possibly (94%) or probably (6%) related to the study medication. 
The treatment-related AEs were mild in severity and categorized as toxicity grade 1 (86%) 
and grade 2 (14%). Most frequently reported AEs (≥ 5% incidence and > 2 subjects) were 
headache (n=19, 8 subjects), drowsiness (n=7, 7 subjects), increased sweating of hands 
(n=6, 3 subjects), dizziness (n=3, 3 subjects) and nausea (n=3, 3 subjects). The majority of 
the AEs (n=47) started during the citalopram 10 mg lead-in phase and the 2-week 
reference treatment with citalopram 20 mg. Seven AEs were reported during the 5 days 
of combination treatment and 8 AEs started during the 5 days of raltegravir reference 
treatment. Four AEs were reported when citalopram was tapered off or during the 
Table 2   Comparison of steady-state pharmacokinetic parameters of citalopram and 
desmethylcitalopram after administration of citalopram 20 mg once daily 
alone and with coadministration of raltegravir 400 mg twice daily in healthy 
volunteers.
Analyte and  
pharmacokinetic 
parameter
Citralopram alone
(n=22)
Citalopram  
+ raltegravir
(n=22) 
Citalopram  
+ raltegravir : 
 citalopram alone
Geometric 
mean
95% CI Geometric 
mean
95% CI GMR 90% CI
Citalopram
AUC
0-24h
 (µg·h/L) 1140 (996-1304) 1144 (998-1311) 1.00 (0.98-1.03)
C
max
 (µg/L) 59.0 (52.2-66.6) 57.8 (50.7-65.8) 0.98 (0.95-1.01)
t
max
a (h) 4.0 (3.0-4.0) 3.1 (3.0-4.0)
C
24h
 (µg/L) 37.4 (32.3-43.2) 38.6 (33.6-44.4) 1.03 (1.00-1.07)
t
1/2 
(h) 28.1 (25.8-30.5) 31.6 (29.2-34.2) 1.13 (1.04-1.22)
CL/F (L/h) 17.6 (15.3-20.1) 17.5 (15.3-20.0) 1.00 (0.97-1.02)
V/F (L) 711 (615-822) 798 (687-926) 1.12 (1.03-1.22)
Desmethylcitalopram
AUC
0-24h
 (µg·h/L) 372 (333-415) 370 (333-411) 0.99 (0.88-1.12)
C
max
 (µg/L) 17.4 (15.6-19.3) 16.8 (15.1-18.7) 0.97 (0.86-1.09)
t
max
a (h) 10 (6.0-10) 10 (10-10)
C
24h
 (µg/L) 13.9 (12.4-15.6) 14.5 (13.0-16.1) 1.04 (0.92-1.18)
CL/F (L/h) 53.8 (48.2-60.0) 54.1 (48.6-60.1) 1.01 (0.89-1.14)
a For t
max
, median + interquartile range is reported. 
Abbreviations: AUC
0-24h
, area under the plasma concentration-time curve up to 24 hours after intake; CI, confidence 
interval; C
max
, maximum plasma concentration; C
24h
, plasma concentration 24 hours after intake; CL/F, apparent oral 
clearance; GMR, geometric mean ratio; t
1/2
, apparent elimination half-life; t
max
, time to reach C
max
; V/F, apparent volume 
of distribution.
Figure 3  Geometric mean (+95% CI) plasma concentration-time profiles of citalopram 
and the metabolite desmethylcitalopram at steady state when citalopram 20 mg once 
daily was administered alone or with raltegravir 400 mg twice daily.
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washout period just after discontinuing the study medication. There were no clinically 
relevant changes in safety laboratory measurements and cardiovascular safety assessment 
(vital signs and ECG). 
Discussion
Raltegravir concomitant use had no effect on the pharmacokinetics of citalopram and 
its main metabolite desmethylcitalopram. Relative to treatment with raltegravir alone, 
 coadministration of citalopram resulted in an average decrease in exposure to raltegravir 
by 23%, which is not considered to be of clinical importance. These results are relevant 
and reassuring for HIV-infected patients with a depressive disorder who require treatment 
with an SSRI, such as citalopram.
The average decrease of raltegravir AUC
0-12h
 (23%) when combined with citalopram, is 
largely due to a mean reduction in C
max
 of 36%. Lower peak plasma levels can be a result 
of a decrease in oral bioavailability. Efflux mechanisms such as P-gp play an important role 
in oral drug absorption. Inducers of P-gp could decrease the oral bioavailability and 
reduce C
max
 values of P-gp substrates. In vitro characterization of raltegravir transport by 
drug transporters indicates that raltegravir is a weak P-gp substrate.38 However, this does 
not explain the mean reduction in C
max
 of raltegravir when combined with citalopram, as 
in vitro research showed that citalopram is a weak P-gp inhibitor.22,23
Although in our study a mean decrease in C
max
 was observed, approximately one third of 
the subjects showed an increase in raltegravir C
max
 with citalopram use. The difference in 
C
max
 and AUC
0-12h 
of raltegravir in the presence or absence of citalopram is more likely due 
to the high variability in raltegravir pharmacokinetics instead of an effect caused by 
citalopram. The extensive intra- and interindividual variability in the pharmacokinetics of 
raltegravir seen in our study is described by others also and consistent with the known 
pharmacokinetic profile of raltegravir.39-41 A major contributor to the variability in raltegravir 
pharmacokinetics is pH dependent absorption and dissolution of raltegravir in the gastro-
intestinal tract.42 
An important consideration when interpreting the results is whether the changes in phar-
macokinetic parameters are clinically relevant. The magnitude of the observed effect on 
the AUC of raltegravir (23%) is not regarded to be of clinical importance. Similar effects on 
the pharmacokinetics of raltegravir are described with drug-interacting agents in the 
product information leaflet without special recommendations to adjust the dosage of 
raltegravir.25 Although no clear relationship between pharmacokinetic parameters and 
the efficacy of raltegravir has been established for the registered twice-daily dose regimen, 
the C
trough
 level is considered the most important parameter to evaluate with respect to 
virological efficacy.43 The geometric mean plasma concentration taken 12 h after intake of 
the last dose (C
12h
) in our study was similar after concomitant use of citalopram and 
raltegravir compared to raltegravir alone and well above the suggested threshold of 0.020 
mg/L from the QDMRK study.43 The pharmacokinetic parameters of raltegravir observed 
in our study are comparable to data in HIV-infected patients reported by Markowitz et al.44
The results of this study showed that raltegravir has no influence on the pharmacokinetics 
of citalopram and its main metabolite desmethylcitalopram. It confirms that raltegravir 
has no influence on CYP2C19, CYP3A4 or CYP2D6, which are involved in citalopram bio-
transformation and does not support a role of a drug-drug interaction in the described 
post-marketing cases with exacerbation of depression after initiating raltegravir.26
Pharmacogenetic factors can cause intersubject variability in plasma levels of citalopram 
and its metabolites. It is known that the metabolism of citalopram is affected by CYP2C19 
polymorphism.20,21 The citalopram metabolite-to-parent ratio of AUC
0-24h
, which is the 
most specific measure for enzyme activity, was reduced in CYP2C19 IMs and PMs 
compared to CYP2C19 EMs. Because our drug-drug interaction study is based on 
intrasubject comparison and no influence on CYP-enzymes was expected by raltegravir, 
any genetic differences in citalopram metabolism between subjects are expected to be of 
minor importance when interpreting the results. This is reflected by our findings that the 
GMR of the pharmacokinetic parameters of citalopram and desmethylcitalopram was 
close to 1.0. Furthermore citalopram metabolite-to-parent ratios of AUC
0-24h 
were not 
influenced by concomitant raltegravir use.
The use of citalopram and raltegravir was well tolerated and no serious AEs were reported 
during the conduct of this study. The reported AEs related to the study medication were 
mild, transient and mostly attributed to citalopram use. This was to be expected as 
citalopram is associated with certain AEs, such as somnolence and dizziness, in especially 
the first two weeks of treatment. 
There are a few limitations to our study. Our study population was predominantly 
Caucasian which does not represent the ethnic variability in the global HIV population. 
Another limitation could be that the combination treatment was started directly after the 
reference treatment with citalopram. We confirmed that steady-state conditions had 
been reached on the day of the first pharmacokinetic curve before raltegravir was added 
by comparing predose plasma concentrations of citalopram and desmethylcitalopram 
with C
trough
 levels taken two days in advance.
In summary, we evaluated the two-way pharmacokinetic drug-drug interaction and 
tolerability of concomitant administration of citalopram 20 mg once daily and raltegravir 
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400 mg twice daily in healthy volunteers. Raltegravir does not influence the pharmaco-
kinetics of citalopram and its main metabolite desmethylcitalopram. Coadministration of 
citalopram resulted in an average decrease in exposure to raltegravir by 23% which is not 
considered to be of clinical importance. The combination of raltegravir and citalopram 
was well tolerated and can be administered without dose adjustments.
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Abstract
Background
Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are 
likely to use both HIV and HCV treatment. Drug-drug interactions have been demonstrated 
between boceprevir, an HCV protease inhibitor, and frequently prescribed antiretroviral 
drugs, such as efavirenz and boosted HIV protease inhibitors. Concomitant administration 
of boceprevir with these drugs should be avoided. This study was designed to investigate 
the absence of a drug-drug interaction between boceprevir and raltegravir, an HIV 
integrase inhibitor.
Methods
This was an open-label, randomized, 2-period, crossover phase 1 trial in 24 healthy 
volunteers. All subjects were randomly assigned to receive boceprevir 800 mg every 8 
hours for 9 days plus a single dose of raltegravir 400 mg on day 10 followed by a washout 
period and a single dose of raltegravir 400 mg on day 38, or the same medication in 
reverse order. Blood samples for pharmacokinetics were collected and pharmacokinetic 
parameters were calculated.
Results
The geometric mean (GM) of raltegravir area under the concentration-time curve (AUC)
0-12h
 
and maximum plasma concentration (C
max
) for raltegravir + boceprevir versus raltegravir 
alone were 4.27 (95% confidence interval [CI], 3.22-5.66) versus 4.04 (95% CI, 3.09-5.28) 
mg·h/L and 1.06 (95% CI, 0.76-1.49) versus 0.93 (95% CI, 0.70-1.23) mg/L, respectively. GM 
ratio estimates of raltegravir AUC
0-12h
 and C
max
 for raltegravir + boceprevir versus raltegravir 
alone were 1.04 (90% CI, 0.88-1.22) and 1.11 (90% CI, 0.91-1.36), respectively. The GM of 
boceprevir AUC
0-8h
, C
max
, and C
8h
 were 5.45 (95% CI, 5.11-5.81) mg·h/L, 1.88 (95% CI, 1.72-2.06) 
mg/L, and 0.09 (95% CI, 0.07-0.11) mg/L, respectively. These data are comparable to those 
from historical controls.
Conclusions
Due to the absence of a clinically significant drug interaction, raltegravir can be recommended 
for combined HIV/HCV treatment including boceprevir.
Introduction
The prevalence of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) 
coinfection ranges from ±10% to 70% in Europe and North America.1 Since the introduction 
of combination antiretroviral therapy (cART), the life expectancy of HIV-infected patients 
has improved dramatically. Since then, liver-related deaths have become the most 
frequent cause of non-AIDS-related deaths, to which HCV coinfection makes a substantial 
contribution.2
The NS3 serine protease inhibitors boceprevir and telaprevir have been approved since 
2011 for use in patients with chronic HCV genotype 1 infection. When added to the 
standard of care, sustained virological response (SVR) rates improve by 25%-31% shown in 
HCV monoinfected patients.3,4 In total SVR rates around 68-75% are seen.
According to US guidelines, first-line cART for HIV-infected patients should consist of the 
2 nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir and emtricitabine, in 
combination with the nonnucleoside reverse transcriptase inhibitor efavirenz, the ritonavir- 
boosted HIV protease inhibitors atazanavir or darunavir, or the integrase inhibitor 
raltegravir.5
As HIV/HCV-coinfected patients are likely to use both HIV and HCV treatment, including 
the HCV protease inhibitors, simultaneously, it is important to know if drug-drug 
interactions occur. At this moment it is not recommended to coadminister boceprevir 
with darunavir/ritonavir, lopinavir/ritonavir, or efavirenz because decreased concentrations 
of boceprevir, as well as decreased concentrations of the boosted HIV protease inhibitors, 
have been found.6,7 Because the combination with atazanavir/ritonavir did not substantially 
influence boceprevir concentrations, although atazanavir levels were lower, coadministra-
tion of these drugs can be considered on a case-by-case basis.7 The only remaining 
first-line antiretroviral agent that can be added to an NRTI backbone is raltegravir. 
Raltegravir is a substrate of UDP-glucuronosyltransferase (UGT) and does not influence 
cytochrome P450 (CYP) enzymes; boceprevir is a substrate of aldo-keto reductase and 
CYP3A and inhibits CYP3A. Hence, no significant interaction between boceprevir and 
raltegravir is expected, but pharmacokinetic drug-drug interaction studies are lacking.
This pharmacokinetic study in healthy volunteers was performed to confirm that a 
clinically significant drug-drug interaction between raltegravir and boceprevir is absent.
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Materials and methods
Study design
This open-label, 2-period, randomized, crossover phase 1 trial was conducted from August 
to November 2011 at the Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands. The study was designed to determine the effect of steady-state boceprevir 
on the pharmacokinetics of a single dose of raltegravir by intrasubject comparison. The 
secondary objective was to examine the effect of a single dose of raltegravir on the phar-
macokinetics of steady-state boceprevir (by comparison with historical controls) and to 
study the safety of a single-dose raltegravir coadministered with steady-state boceprevir.
Healthy volunteers were equally randomized to 2 treatment groups. Group A received a 
single dose of 400 mg of raltegravir on day 10. After a washout period of 2 weeks, the 
participants took 800 mg of boceprevir every 8 hours with food for 9 days (days 29-37). On 
day 38 they received a single dose of 400 mg of raltegravir and 2 doses of 800 mg of 
boceprevir (1 together with raltegravir and 1 dose 8 hours later). Group B received the 
same regimens but in reversed order. On days 10 and 38, a 12-hour pharmacokinetic curve 
was recorded.
Procedures
The trial was approved by the Investigational Review Board of the Radboud University 
Nijmegen Medical Centre. The trial was conducted in accordance with Good Clinical 
Practice and the Declaration of Helsinki. All participants signed informed consent prior to 
screening evaluations.
Study population
Healthy male and female subjects aged 18-55 years and with a body mass index (BMI) of 
18-30 kg/m2 (extremes included) were eligible for enrolment. Included participants had to 
be in a good, age-appropriate health condition as established by physical examination, 
medical history, electrocardiography, and biochemical, hematologic, and urinalysis testing 
within 4 weeks prior to day 1. Main exclusion criteria were a history of sensitivity or 
idiosyncrasy to medicinal products or excipients; a positive HIV, hepatitis B or C test result; 
or the use of any medications (for 2 weeks preceding dosing) except for acetaminophen.
Study drug and dosing
The approved dose of boceprevir (Victrelis, Merck Sharp & Dohme) is 800 mg every 8 
hours with food.6 In this study, subjects took 4 capsules of 200 mg of boceprevir at 
approximately 08:00 hours, 16:00 hours, and 0:00 hours with a meal or a snack. A treatment 
duration of 10 days was chosen to reach steady state and to assess potential effects on 
metabolizing enzymes or drug transporters. Raltegravir (Isentress, Merck Sharp & Dohme) 
was administered as a single dose of 400 mg on day 10 and day 38 together with a 
standardized breakfast consisting of 2 slices of wheat bread (1 slice with cheese and 1 with 
sliced sausage) and 1 glass of milk.
Intake of medication at the clinical trial unit was supervised and recorded by the study 
personnel. Drug intake of boceprevir at home was monitored by use of microelectronic 
monitoring system (MEMS) caps (Aardex, Zug, Switzerland), which records the opening of 
the medication bottle. In addition, the weight of the bottles containing the boceprevir 
capsules was recorded on each visit day during boceprevir treatment to assess adherence. 
Subjects were asked to write down the exact times of medication intake in a booklet.
Pharmacokinetic sampling and safety assessments
Blood samples for assessment of pharmacokinetic parameters of raltegravir were collected 
during a 12-hour period after intake of a single dose of 400 mg of raltegravir on days 10 
and 38. Blood samples were collected into heparinized tubes and centrifuged for 10 
minutes at 1900 x g at 20°C. Plasma was transferred to polypropylene tubes and stored at 
-40°C until further bioanalysis.
 Blood samples for assessment of pharmacokinetic parameters of boceprevir were 
collected during an 8-hour period after intake of 800 mg of boceprevir on day 10 or 38. In 
addition, blood samples were taken predose on days 1, 3, 6, and 8 (group B) and on days 
28, 31, 34, and 36 (group A). Blood samples for boceprevir were collected into prechilled 
potassium-ethylenediaminetetraacetic acid-containing tubes and centrifuged for 15 
minutes at 1500 x g at 4°C within 30 minutes after blood collection. Plasma (1.5 mL) was 
transferred to prechilled cryovials containing 75 μL of 85% phosphoric acid, mixed by a 
vortex mixer and stored at ≤−20°C within 1 hour of sample collection.
Bioanalytic methods
Concentrations of raltegravir in plasma were analyzed by use of a validated reversed-phase 
high-pressure liquid chromatography (HPLC) method with fluorescence detection.8 The 
linear calibration ranges in plasma were from 0.014 mg/L to 10.0 mg/L. The raltegravir 
assay was performed at the laboratory of the Pharmacy of the Radboud University 
Nijmegen Medical Centre and was externally validated through the International Interlab-
oratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma, as well 
as by the Proficiency Testing Program of the ACTG/IMPAACT group.9,10
Boceprevir (SCH503034) is an approximately equal mixture of 2 diastereomers; SCH534128, 
the active diastereomer and SCH534129, which is inactive. The predominant metabolic 
pathway produces inactive stereoisomers, together called SCH629144.11 Concentrations of 
boceprevir were determined as the sum of concentrations of the 2 diastereomers 
SCH534128 and SCH534129. Concentrations of SCH629144 were obtained as the sum of 
concentrations of 4 analytes, namely, SCH783004, SCH783005, SCH783006, and SCH783007. 
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The overall lower limit of quantification (LLOQ) was 0.0048 mg/L for boceprevir and 0.0025 
mg/L for SCH629144. The calibration range for SCH534128 and SCH534129 and for the 4 
metabolites were from the LLOQ to 5.20 mg/L, 4.80 mg/L, and 2.50 mg/L, respectively. 
Concentrations of both diastereomers and its metabolites in collected plasma samples 
were determined using HPLC-tandem mass spectrometry at PPD Global Central Labs 
(Middleton, Wisconsin).
Pharmacokinetic analysis
Based on the individual plasma concentration-time data, the following pharmacokinetic 
parameters of raltegravir were determined: the area under the concentration-time curve 
from 0 to 12 hours after intake (AUC
0-12h
), maximum plasma concentration (C
max
), time of 
C
max
 (t
max
), the bioavailability adjusted volume of distribution (V/F), apparent oral clearance 
(CL/F), and the apparent elimination half-life (t
1/2
). For boceprevir (both diastereomers and 
metabolites) the same parameters were determined plus the concentration at 8 hours 
after intake (C
8h
); AUC was determined from 0 to 8 hours after intake (AUC
0-8h
). All pharma-
cokinetic parameters were calculated by noncompartmental methods using the linear 
log trapezoidal rule.
Statistical analysis
The data obtained in this study were analyzed according to an equivalence approach that 
is recommended for pharmacokinetic interaction studies.12,13 The main pharmacokinetic 
parameter to be evaluated in this respect was the exposure to raltegravir, as expressed in 
the AUC
0-12h
. The required sample size was calculated (power of 80%) assuming no 
difference in AUC
0-12h
 of raltegravir with or without boceprevir and an intrasubject 
coefficient of variation of 22.5% of raltegravir AUCs. The required number of participants 
was 20. Taking dropouts into account, in total 24 subjects were included in the study.
The geometric mean ratio estimates of all determined pharmacokinetic parameters of 
raltegravir with boceprevir versus raltegravir alone, except for t
max
, were calculated using 
the mixed model analysis, with the Kenward-Roger approach for the evaluation of the 
fixed effects. In addition, the nonparametric Wilcoxon signed-rank test was done for t
max
 
values between the 2 regimens. Geometric mean ratio estimates with 90% confidence 
interval (CI) entirely within the range of 0.80-1.25 were considered to indicate no significant 
interaction. Pharmacokinetic parameters of boceprevir (diastereomers and metabolites) 
were compared with historical data from healthy volunteers.
 Statistical analyses were carried out using SPSS software version 16.0 or higher (SPSS, 
Chicago, Illinois) and SAS 9.2. Descriptive statistics were calculated using Excel 2007 
software (Microsoft Corporation) or WinNonlin version 5.3 (Pharsight Corporation).
Results
Baseline characteristics
Twenty-four healthy volunteers (12 males) were included in the study. Subjects were of 
white (n = 22), black (n = 1), or mixed Asian/white (n = 1) ethnicity. The mean age and BMI 
were 38 years (range, 20-55 years) and 23 kg/m2 (18-27 kg/m2).
 Twenty-two subjects (10 males) completed the trial. One subject had to discontinue 
due to nonadherence to the study protocol and another subject because of elevated 
alanine aminotransferase. Both dropouts completed the raltegravir alone treatment and 
remained included in the demographics, safety, and pharmacokinetic analyses.
Compliance
The compliance to boceprevir treatment was good. All but 1 subject (21/22) took all doses of 
boceprevir and raltegravir according to pill count, diary, and MEMS caps recordings. Only 
1 subject missed 1 dose of boceprevir. Seven subjects (1-3 times per subject) took the 
dose of boceprevir outside a 2-hour time frame (07:00-09:00 hours/15:00-17:00 hours/ 
23:00-01:00 hours).
Pharmacokinetics
Pharmacokinetic parameters were calculated on all available data from the 24 subjects 
included in the trial. The plasma concentration versus time curves of raltegravir alone and 
of raltegravir with boceprevir are shown in Figure 1. The pharmacokinetic parameters of 
raltegravir with and without boceprevir are shown in Table 1. For raltegravir coadministered 
with boceprevir relative to raltegravir alone, the geometric mean ratio estimates of AUC
0-12h
 
Figure 1  Geometric mean plasma concentrations of raltegravir following a single dose 
of 400 mg raltegravir in the presence and absence of steady-state boceprevir.
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and C
max
 were 1.04 (90% CI, 0.88-1.22) and 1.11 (90% CI, 0.91-1.36). The geometric mean ratio 
estimates with 90% CI of the main pharmacokinetic parameter raltegravir AUC
0-12h
 fell 
entirely within the range of 0.80 to 1.25, which indicates no significant interaction with 
boceprevir. It is suggested that boceprevir does not influence the other pharmacokinetic 
parameters of raltegravir.
The plasma concentrations versus time curves of boceprevir, the active diastereomer 
SCH534128, and the inactive diastereomer SCH534129 after multiple doses of boceprevir 
are shown in Figure 2. The pharmacokinetic parameters of boceprevir, the diastereomers, 
and the metabolites together as SCH629144 are given in Table 2. The AUC
0-8h
 of boceprevir 
in this study was 5.45 mg·h/L and in historical controls the AUC
0-8h
 of boceprevir was 
5.41 mg·h/L.6 No differences in exposure to boceprevir or the individual diastereomers 
were observed compared with historical controls.
Adverse events and safety assessments
No serious adverse events were reported. In total, 90 adverse events were reported by 
22 subjects after intake of study medication. The most frequently reported adverse 
experiences that were possibly, probably, or definitely drug-related are shown in Table 3. 
Two adverse events (creatine kinase elevation and myalgia) were reported as grade 4 of 
intensity. All other adverse events were grade 1 or 2 of intensity. No additional side effects 
were seen when raltegravir was added to steady-state boceprevir.
Table 1   Comparison of single-dose pharmacokinetic parameters of raltegravir with or 
without coadministration of multiple doses of boceprevir in healthy volunteers
  n RAL + BOC
GM (95% CI)
n RAL
GM (95% CI)
na Geometric Mean 
Ratio Estimate 
(90% CI)
AUC
0-12h
 (mg·h/L) 22 4.27 (3.22-5.66) 24 4.04 (3.09-5.28) 22 1.04 (0.88-1.22)
C
max
 (mg/L) 22 1.06 (0.76-1.49) 24 0.93 (0.70-1.23) 22 1.11 (0.91-1.36)
t
max
b (h) 22 5.00 (1.00-12.00) 24 4.00 (1.00-12.03) 22
V/F (L) 19 261.2 (176.6-386.2) 19 335.3 (234.8-478.9) 17 0.75 (0.58-0.98)
CL/F (L/h) 19 82.5 (58.0-117.3) 19 81.4 (54.8-120.9) 17 0.99 (0.73-1.35)
t
1/2
 (h) 15 1.83 (1.42-2.34) 13 1.80 (1.31-2.47) 10 0.98 (0.74-1.30)
a The number of paired samples per parameter is given.
b For t
max
, median + range is reported; the result of the Wilcoxon signed-rank test was P = .312.
Abbreviations: AUC
0-12h
, area under the plasma concentration-time curve 0-12 hours after intake; BOC, boceprevir; 
CI, confidence interval; CL/F, apparent oral clearance; C
max
, maximum plasma concentration; RAL, raltegravir; 
t
1/2
, elimination half-life; t
max
, time to reach C
max
; V/F, volume of distribution.
Table 2   Pharmacokinetic parameters of multiple doses of boceprevir in  
healthy volunteers
boceprevir SCH534128 (active) SCH534128 
(inactive)
SCH629144 
(metabolites)
na GM (95% CI) GM (95% CI) GM (95% CI) GM (95% CI)
AUC
0-8h
 (mg·h/L) 22 5.45 (5.11-5.81) 3.74 (3.50-4.01) 1.69 (1.56-1.82) 22.69 (19.94-25.83)
C
max
 (mg/L) 22 1.88 (1.72-2.06) 1.23 (1.13-1.35) 0.65 (0.59-0.73) 5.19 (4.53-5.95)
t
max
b (h) 22 3.00 (1.50-5.00) 3.00 (1.50-5.00) 2.00 (1.50-5.00) 4.00 (2.00-5.00)
C
8h
 (mg/L) 22 0.09 (0.07-0.11) 0.07 (0.06-0.08) 0.02 (0.01-0.02) 1.30 (1.04-1.62)
V/F (L) 22 224.5 (201.6-250.0) 334.2 (298.7-373.9) 671.6 (587.7-767.4) 73.9 (64.1-85.2)
CL/F (L/h) 22 143.0 (133.9-152.7) 207.0 (193.1-221.9) 467.1 (431.9-505.2) 30.7 (26.7-35.1)
t
1/2
 (h) 20 1.10 (1.04-1.17) 1.14 (1.07-1.21) 1.01 (0.94-1.08) 1.65 (1.49-1.84)
a n = 13 for the SCH629144 t
1/2
.
b For t
max
, median (range) has been reported.
Abbreviations: AUC
0-8h
, area under the plasma concentration-time curve 0-8 hours after intake; C
8h
, concentration at 
8 hours after intake; CI, confidence interval; CL/F, apparent oral clearance; C
max
, maximum plasma concentration; 
GM, geometric mean; t
1/2
, elimination half-life; t
max
, time to reach Cmax; V/F, volume of distribution.
Figure 2  Geometric mean plasma concentrations of boceprevir, SCH534128, and SCH534129 
after multiple doses of boceprevir 800 mg and a single dose of raltegravir 400 mg.
0 2 4 6 8
0.0
0.5
1.0
1.5
2.0
SCH534128
SCH534129
Boceprevir
Time after dosing (h)
Co
nc
en
tr
at
io
n 
(m
g/
L)
72 73
Chapter 4 Boceprevir and raltegravir drug interaction
Discussion
No significant difference was observed for the most important pharmacokinetic parameter 
of raltegravir, AUC
0-12h
, between raltegravir alone and raltegravir in combination with 
boceprevir. Exposure to boceprevir in the presence of raltegravir was comparable to 
historical controls. Because boceprevir interacts with many other first-line antiretroviral 
drugs, it is relevant to know that boceprevir combined with raltegravir is a good treatment 
option for HIV/HCV-coinfected patients because of the absence of a clinically significant 
drug-drug interaction.
Boceprevir and telaprevir have shown some extensive drug-drug interactions with various 
drugs and drug classes. Several drug combinations with boceprevir or telaprevir should 
be avoided or should be used with great caution. These HCV protease inhibitors can be 
the perpetrator or victim of such interactions. Since there is an association between 
boceprevir and telaprevir exposure and HCV decline, a reduction in plasma concentrations 
might lead to a decreased efficacy of treatment or even to resistance.14-16 An explanation 
for the large number of drug-drug interactions with boceprevir and telaprevir, is that both 
HCV protease inhibitors are substrates and inhibitors of the CYP3A enzyme, which is 
responsible for the metabolism of numerous drugs.6,7,17,18 Besides that, they are also 
substrates and inhibitors of P-glycoprotein (P-gp), an efflux transporter that plays a 
significant role in the absorption and elimination of many drugs.6,7,17,18
At this moment, there are a number of studies performed on potential drug-drug 
interactions with the HCV protease inhibitors and antiretroviral drugs. Boceprevir did not 
influence the AUC of the NRTI tenofovir.19 The nonnucleoside reverse transcriptase 
inhibitor efavirenz is known to induce CYP3A enzymes and P-gp transporters and 
boceprevir AUC and trough concentrations were reduced by 19% and 44%, respectively, 
in combination with efavirenz; this combination should be avoided.19 When the HIV 
protease inhibitors boosted with ritonavir are coadministered with telaprevir or boceprevir, 
higher concentrations of the HCV protease inhibitors were theoretically expected (due to CYP3A 
inhibition by ritonavir), but controversially, concentrations were found to be lower. Trough 
concentrations of boceprevir were 18%, 35%, and 57% lower in combination with boosted 
atazanavir, darunavir, and lopinavir, respectively.20 In addition, decreased concentrations of 
the HIV protease inhibitors were found when taken with boceprevir.
Until now, the effect of boceprevir on raltegravir or vice versa was not known, but a 
drug-drug interaction was not expected based on the pharmacokinetic characteristics of 
both drugs. Boceprevir is metabolized by 2 distinctive pathways, mainly through ketone 
reduction by aldo-keto reductase (AKR1C2 and AKR1C3) and to a lesser extent by CYP3A4 
and CYP3A5.6,7 Because the biotransformation and clearance of boceprevir involves 2 
different enzymatic pathways, it is less likely to be subject to significant drug-drug 
interactions with concomitant medication affecting only 1 of these pathways. Boceprevir 
is a strong inhibitor of CYP3A4 and CYP3A5.6,7 Raltegravir is not a substrate of CYP and 
does not influence CYP-mediated metabolism of other agents.21,22 It is a P-gp substrate, 
and is metabolized by UGT but does not itself influence UGT-mediated metabolism of 
other agents.21-23
Because raltegravir is not a CYP3A substrate and thus will not be affected by the strong 
inhibition of CYP3A by boceprevir, and because raltegravir is metabolized by UGT but 
boceprevir is not known to influence UGT, a major drug-drug interaction is unlikely with 
this combination. A minor interaction may occur through inhibition of P-gp mediated 
transport of raltegravir by boceprevir.
 However, even when no drug interaction is expected theoretically, it may be 
recommended to collect sufficient clinical evidence to support this hypothesis because 
unexpected interactions with antiretroviral agents have been observed in the past. This is 
also true for raltegravir; for instance, there is a 17% decrease in atazanavir AUC
0-12h
 when 
combined with raltegravir, and combined use of tenofovir and raltegravir leads to 49% 
increase in raltegravir AUC.24,25
Table 3   Most frequently reported treatment drug-related adverse events in number  
of subjects reporting this adverse event 
Adverse 
event
Raltegravir
(n=24) (%)
Washout 
raltegravir 
(n=12) (%)
Boceprevir
(n=22) (%)
Boceprevir  
+ raltegravir
(n=22) (%)
Washout  
boceprevir 
+ raltegravir  
(n=10) (%)
Total
(n=24) (%)
Dysgeusia 17 (77) 17 (77)
Headache 2 (17) 4 (18) 3 (14) 8 (33)
Atypical 
lymphocytes
3 (14) 3 (14)
Nausea 3 (14) 3 (13)
Xerostomia 3 (14) 3 (13)
Elevated ALT 2 (9) 1 (10) 3 (13)
Myalgia 1 (8) 2 (9) 2 (8)
Sore throat 2 (9) 2 (8)
Dyspepsia 2 (9) 2 (8)
Elevated AST 1 (5) 1 (10) 2 (8)
Diarrhea 1 (5) 1 (5) 2 (8)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Since raltegravir has been demonstrated to be a drug with a low interaction profile and in 
general is the victim and not the perpetrator of drug-drug interactions, the primary 
objective of this study was to determine the effect of multiple doses of boceprevir on the 
pharmacokinetics of a single dose of raltegravir. Because influence of raltegravir on 
boceprevir was considered unlikely, and to reduce exposure of the drugs to healthy 
volunteers, we chose to perform a 1-way interaction study and therefore compared the 
pharmacokinetic data on boceprevir found in our study with data from historical controls. 
In light of other unexpected findings from drug-drug interaction studies with boceprevir 
that are known at this moment, a 2-way interaction study would be preferred in order to 
compare the boceprevir pharmacokinetics with and without raltegravir intraindividually.20 
Our study was conducted in healthy volunteers, limiting our interpretation in HIV/
HCV-coinfected patients. There are few data on the pharmacokinetics of a single dose of 
400 mg raltegravir in the target population. The pharmacokinetics of boceprevir are not 
different in HCV-positive or -negative patients, but in patients with cirrhosis higher plasma 
concentrations of boceprevir are found.6,7 It is, however, not likely that higher concentrations 
of boceprevir and/or raltegravir will affect the possibility of an interaction between these 
drugs.
Phase 2 clinical trials with boceprevir in HIV-coinfected patients is ongoing and interim 
results seem to be promising.26 Twelve weeks after therapy with boceprevir added to 
pegylated interferon-alfa and ribavirin, 60.7% of patients had an undetectable HCV load 
versus 26.5% of patients on standard of care only. In the study with boceprevir, patients 
were not allowed to use efavirenz and the number of patients on ritonavir-boosted HIV 
protease inhibitors or raltegravir was small. Unfortunately, drug concentration data have 
not yet been presented and, therefore, up till now, it remains unknown if reduced drug 
concentrations have contributed to HIV or HCV breakthroughs.
In conclusion, coadministration of multiple-dose boceprevir with raltegravir did not 
meaningfully affect single-dose raltegravir exposure. Steady-state boceprevir exposure 
after coadministration with a single dose of raltegravir was comparable to the exposure of 
boceprevir administered alone as reported for historical controls. Due to the absence of a 
clinically significant drug-drug interaction, raltegravir can be recommended for combined 
HIV/HCV treatment including boceprevir. In the groups of healthy volunteers participating 
in this study, coadministration of single-dose raltegravir to steady-state boceprevir was 
safe and well tolerated.
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Abstract
Medicinal herbs may cause clinically relevant drug interactions with antiretroviral agents. 
Ginkgo biloba extract is a popular herbal product among HIV-infected patients because 
of its positive effects on cognitive function. Raltegravir, an HIV integrase inhibitor, is 
increasingly being used as part of combined antiretroviral therapy. Clinical data on the 
potential inhibitory or inductive effect of Ginkgo biloba on the pharmacokinetics of 
raltegravir were lacking, and concomitant use was not recommended. We studied the 
effect of Ginkgo biloba extract on the pharmacokinetics of raltegravir in an open-label, 
randomized, two-period, crossover phase I trial in 18 healthy volunteers. Subjects were 
randomly assigned to a regimen of 120 mg of Ginkgo biloba twice daily for 15 days plus a 
single dose of raltegravir (400 mg) on day 15, a washout period, and 400 mg of raltegravir 
on day 36 or the test and reference treatments in reverse order. Pharmacokinetic sampling 
of raltegravir was performed up to 12 h after intake on an empty stomach. All subjects 
(9 male) completed the trial, and no serious adverse events were reported. Geometric 
mean ratios (90% confidence intervals) of the area under the plasma concentration-time 
curve from dosing to infinity (AUC
0-∞
)
 
and the maximum plasma concentration (C
max
)
 
of 
raltegravir with Ginkgo biloba versus raltegravir alone were 1.21 (0.93 to 1.58) and 1.44 (1.03 
to 2.02). Ginkgo biloba did not reduce raltegravir exposure. The potential increase in the 
C
max
 of raltegravir is probably of minor importance, given the large intersubject variability 
of raltegravir pharmacokinetics and its reported safety profile.
Introduction
Approximately 60% of HIV-infected patients use complementary and alternative 
medicines to treat HIV-related symptoms and side effects of conventional antiretroviral 
therapy. Herbal medicines can cause clinically significant interactions with antiretroviral 
agents with potential drug failure as a result.1,2 Among the most popular herbal products 
used worldwide is Ginkgo biloba extract, which is made from the leaves of the Ginkgo 
biloba tree. It is used for the treatment of peripheral vascular disease and is frequently 
taken for its claimed beneficial effects on concentration, memory, depressive disorders 
and dementia.3 Because cognitive impairment is one of the most feared complications 
among HIV-infected patients, the popularity of Ginkgo biloba within this patient group is 
easily explained.4 Although Ginkgo biloba extract has potential beneficial effects, 
self-medication with Ginkgo biloba may lead to undesirable drug interactions with regular 
medication. For example, a study in healthy subjects showed that plasma concentrations 
of midazolam (a CYP3A probe) were significantly reduced after Ginkgo biloba intake.5 
If this were also true with antiretroviral agents, it could place individual patients at risk for 
virological failure. 
In past years, a few articles have been published about the potential negative effects of 
Ginkgo biloba on the pharmacokinetics of antiretroviral agents. One case report described 
virological failure in an HIV-infected patient taking an efavirenz-based regimen due to 
concomitant use of Ginkgo biloba. Although the underlying mechanism remained 
unclear, terpene lactones in Ginkgo biloba may lower plasma efavirenz levels by the 
induction of CYP2B6, CYP3A4 and/or P-glycoprotein (P-gp).6 Unlike the inductive effects of 
Ginkgo biloba on the pharmacokinetics of midazolam, Ginkgo biloba extract did not 
change the exposure of lopinavir (a protease inhibitor and CYP3A substrate) when used 
with low-dose ritonavir. The use of low-dose ritonavir, a potent CYP3A inhibitor, may have 
offset the effect of Ginkgo biloba on the pharmacokinetics of lopinavir.5 
In vivo data of Ginkgo biloba with other antiretroviral drug classes, such as HIV integrase 
inhibitors, like raltegravir, are lacking. According to current guidelines, raltegravir in 
combination with tenofovir/emtricitabine is recommended as one of the preferred 
regimens for antiretroviral-naïve patients.7,8 Raltegravir targets the HIV-1 integrase enzyme 
and prevents the integration of viral DNA into the genome of the host cell. Raltegravir has 
shown sustained antiretroviral activity, is generally well tolerated and has little propensity 
to interact with other drugs. The primary route of metabolism is glucuronidation via 
UDP-glucuronosyltransferase 1A1 (UGT1A1) in the liver, with minor contributions from 
UGT1A3 and UGT1A9.9-11 In vitro studies suggest that raltegravir is a weak P-gp substrate.12 
There is in vitro and animal evidence that Ginkgo biloba modulates UGT enzymes. Ginkgo 
biloba extract and ginkgolides induce the expression of UGT1A1 in human primary 
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hepatocytes, although inhibitory effects on UGT enzymes of Ginkgo biloba extract, or 
one of its components, have been described, as well.13-16 Other investigations showed that 
long-term use of Ginkgo biloba inhibits P-gp-mediated drug transport, but contrary 
results have also been reported.3,17-20
Given the inconclusive data on the potential inhibitory or inductive effect of Ginkgo 
biloba extract on glucuronidation or P-gp-mediated transport, Ginkgo biloba may 
theoretically influence the exposure to raltegravir. Therefore, concomitant use is currently 
not recommended. The objectives of this study were to assess the effect of steady-state 
Ginkgo biloba on the pharmacokinetics of a single dose of raltegravir in healthy volunteers 
and to evaluate the safety and tolerability of the combination. 
Materials and methods
Study design
This open-label, randomized, two-period, crossover, single-centre, phase I trial was 
conducted from December 2010 to March 2011 at the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands). The study was designed to examine the 
effect of multiple doses of Ginkgo biloba on the pharmacokinetics of a single dose of 
raltegravir by intrasubject comparison. The secondary objective was to evaluate the safety 
of the combined use of raltegravir and Ginkgo biloba. 
Eighteen healthy volunteers (9 females and 9 males) were stratified according to gender in 
group A en B. In group A, participants received 120 mg of Ginkgo biloba twice daily for 14 
days, followed by a single dose on day 15, together with a single dose of 400 mg of 
raltegravir. After a washout period of 3 weeks, the participants received a single dose of 
400 mg of raltegravir on day 36. In group B, participants received the test and reference 
treatments in reverse order. They received a single dose of 400 mg of raltegravir on day 15, 
followed by a washout period of 1 week. On day 22 they started Ginkgo biloba treatment 
(120 mg twice daily for 14 days). On day 36, participants took a single dose of Ginkgo 
biloba together with a single dose of 400 mg of raltegravir. The trial was approved by the 
Investigational Review Board of the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. The trial was conducted in accordance with good clinical 
practice and the Declaration of Helsinki. The study was registered at http://www.
ClinicalTrials.gov (NCT01246804).
Study population
Healthy male and female participants between the age of 18 and 55 years and with a body 
mass index of 18 to 30 kg/m2 (extremes included) were eligible for enrolment. The 
included participants had to be in a good, age-appropriate health, as established by 
physical examination, medical history, electrocardiography, and biochemical, hematologic, 
and urinalysis testing within 4 weeks prior to day 1. The subjects had to be able and willing 
to sign an informed consent form prior to screening evaluations. The main exclusion 
criteria were a history of sensitivity or idiosyncrasy to medicinal products or excipients, a 
positive HIV or hepatitis B or C test result, or therapy with any drug (for 2 weeks preceding 
dosing), except for acetaminophen. Other exclusion criteria were participation in a drug 
trial or blood donation within 60 days prior to day 1 of the study. Pregnant and 
breastfeeding females were also excluded. 
Study drug and dosing
Ginkgo biloba extract is a complex mixture of chemical constituents, and the actual 
contents may vary depending on the part of the plant being processed, the season, or the 
manufacturing process.3 The industry standard for powdered extracts, as used in this 
study, is 24% flavonoids (quercetin, kaempferol, and isorhamnetin, among others) and 6% 
terpene lactones (ginkgolides and bilobalide) by weight. In this trial, the commercial 
product Tavonin (a tablet with 40 mg of Ginkgo biloba extract) was used because of its 
standardized composition of 9.6 mg of flavonoids and 2.4 mg of terpene lactone. Tavonin 
(Dr. Willmar Schwabe GmbH, Karlsruhe, Germany) is licensed in The Netherlands for the 
treatment of occlusive peripheral arterial disease. The Ginkgo biloba dose used in this trial 
(120 mg twice daily) is the recommended dosage for the prevention of cognitive decline 
and memory support.21,22 A treatment period of 14 days of Ginkgo biloba was chosen to 
reach steady state and asses potential effects on metabolizing enzymes or drug 
transporters. Raltegravir (Isentress; Merck Sharp & Dohme Limited, Hoddesdon, United 
Kingdom) was administered as a single dose of 400 mg on an empty stomach followed by 
a standardized breakfast 2 h after intake. The breakfast consisted of a glass of milk and two 
slices of wheat bread with cheese and cervelat. 
Pharmacokinetic sampling and safety assessments
Blood samples for assessment of the pharmacokinetic parameters of raltegravir were 
collected during a 12-hour period at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after 
intake of a single dose of 400 mg of raltegravir on days 15 and 36. Blood samples were 
collected into heparinized tubes and centrifuged for 10 minutes at 2930 x g at 20°C. Plasma 
was transferred to polypropylene tubes and stored at -40°C until further bioanalysis. Blood 
samples for serum biochemistry and hematology were taken on days 15 and 36, as well as 
before and during Ginkgo biloba treatment (days 1 and 8 of treatment). Subjects were 
asked about the presence of adverse events at each visit day. Screening for drugs of abuse 
in urine was performed on days 15 and 36; blood glucose and urinalysis were carried out 
on day 36. Pregnancy was checked by performing a human chorionic gonadotropin (hCG) 
blood test on all female subjects on days 15 and 36.
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Compliance
All intake of medication at the clinical trial unit was supervised and recorded by the study 
personnel. Intake of Ginkgo biloba tablets at home was monitored by use of micro-
electronic monitoring system (MEMS) caps (Aardex Ltd., Zug, Switzerland), which record 
the opening of the medication bottle. In addition, Ginkgo biloba tablets were counted 
on each visit day during Ginkgo biloba treatment to assess adherence. Subjects were 
asked to write down the exact times of intake in a booklet. 
Bioanalysis of raltegravir in plasma 
The concentrations of raltegravir in plasma were analyzed by use of a validated 
reversed-phase high-pressure liquid chromatography (HPLC) method with fluorescence 
detection. Sample preparation consisted of a liquid-liquid extraction by adding 500 µL of 
acetate buffer (pH 4.0; 0.2 M), 5 mL of hexane/dichloromethane (1:1 [vol/vol]), and 50 µL of 
internal standard (lormetazepam in methanol-water [1:1 {vol/vol}]) to 500 µL of plasma. 
The samples were mixed on a vortex mixer for 5 min, followed by centrifugation at 11500 
x g for 5 min. After freezing at -40°C for 5 min, the organic supernatant was decanted and 
evaporated at 37°C under a stream of nitrogen gas. The residue was reconstituted in 200 µL 
of eluent (acetonitrile-phosphate buffer, pH 4.8; 20 mM; 35:65 [vol/vol]). Forty microliters of 
the reconstituted solution was injected onto a SymmetryShield RP 18 column (3.5 µm; 
100 by 4.6 mm). The flow rate was set at 1.5 mL/min. Raltegravir was detected by the use 
of a fluorescence detector (λ
excitation
,
 
240 nm; λ
emission
,
 
412 nm). The lower limit of quantification 
was 0.014 mg/L. The linear calibration ranges in plasma were from 0.014 to 10 mg/L. The 
validation results displayed accuracies of the quality control samples of 100%, 102% and 
107% at plasma concentrations of 0.060, 0.400, and 4.00 mg/L. At the same concentrations, 
the precision values (within-day coefficients of variation [CV]) were 3.7%, 1.8%, and 0%, 
respectively. The raltegravir assay was performed at the laboratory of the Pharmacy of 
Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands) and was 
externally validated through the International Interlaboratory Quality Control Program for 
Measurement of Antiretroviral Drugs in Plasma.23 
Pharmacokinetic analysis
Pharmacokinetic parameters for raltegravir were calculated by noncompartmental 
methods using the WinNonlin software package (version 5.2; Pharsight, Mountain View, 
CA) and the linear log trapezoidal rule. Based on the individual plasma concentration-time 
data, the following pharmacokinetic parameters of raltegravir were determined: the area 
under the plasma concentration-time curve from dosing to infinity (AUC
0-∞
) (in mg·h/L), 
the area under the plasma concentration-time curve from 0 to 12 h after intake (AUC
0-12h
) 
(in mg·h/L), the maximum plasma concentration of the drug (C
max
)
 
(in mg/L), the time to 
reach C
max
 (t
max
) (in h), the apparent volume of distribution (V/F) (in L), the apparent oral 
clearance (CL/F) (in L/h) and the apparent elimination half-life (t
1/2
) (in h). 
Sample size and statistical analysis 
For the identification of a clinically relevant drug interaction, the bioequivalence approach 
was used, as described previously.24 The main pharmacokinetic parameter to be evaluated 
in this respect is the exposure to raltegravir, expressed as the AUC. Sample size calculation 
was performed using the method for two-period designs of Diletti et al.25 The required 
sample size was calculated (power of 80%) assuming no difference in the AUC of raltegravir 
with or without Ginkgo biloba and an estimated intrasubject coefficient of variation of the 
log-transformed AUC values for raltegravir of 20%. The required number of participants 
was 16. Taking dropouts into account, a total of 18 subjects were included. Geometric 
mean ratios (GMRs) with 90% confidence intervals (CI) were calculated for AUC
0-∞,
 AUC
0-12h
, 
C
max, 
and t
1/2
 after log transformation of within-subject ratios of raltegravir combined with 
Ginkgo biloba verus raltegravir alone. GMRs with 90% CI falling entirely within the range 
of 0.80 to 1.25 were considered to indicate no significant interaction. Statistical and 
descriptive analysis were carried out using SPSS for Windows, version 16.0.1 (SPSS, Chicago, 
IL), and Microsoft Office Excel 2007.
Results
Baseline characteristics 
A total of 18 subjects (9 male and 9 female, all Caucasian) were enrolled in the study and 
received treatment. The mean (range) age, body weight, and body mass index were 38 
(22 to 55) years, 72 (52 to 93) kg and 23 (19 to 28) kg/m2, respectively. The subjects were in 
good general health, according to medical histories, physical examinations, vital signs, 
and laboratory data. All included subjects completed the trial and were available for 
statistical evaluation.
Compliance 
The compliance of the Ginkgo biloba treatment of all 18 subjects was good, as indicated 
by their statements about the intake of the drug doses as noted in the booklets, the 
number of Ginkgo biloba tablets counted on each visit day, and the MEMS caps (data not 
shown). Only two subjects admitted to have missed one Ginkgo biloba dose.
Pharmacokinetics
The pharmacokinetic parameters and the plasma concentration versus time curves of 
raltegravir in the presence and absence of steady-state Ginkgo biloba are shown in Table 1 
and Figure 1. Ginkgo biloba increased the maximum plasma concentration (C
max
) and the 
area under the plasma concentration-time curve from dosing to infinity (AUC
0-∞
) of 
raltegravir. The apparent elimination half-life of raltegravir did not appear to be influenced 
by Ginkgo biloba. The median time to reach C
max
 of raltegravir was 2.0 h irrespective of 
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Ginkgo biloba treatment. For raltegravir coadministered with Ginkgo biloba relative to 
raltegravir alone, the GMRs (90% confidence intervals) was 1.21 (0.93- to 1.58) for AUC
0-∞
, 
1.44 (1.03 to 2.02) for C
max
, and 0.93 (0.73 to 1.17) for t
1/2 
(Table 1). Two subjects were excluded 
from the calculation of the GMRs of AUC
0-∞ 
and t
1/2
 because the t
1/2
 could not be determined 
in these subjects. Figure 2 shows the individual subject changes in the C
max
 and AUC
0-∞
 of 
raltegravir alone and coadministered with Ginkgo biloba. Although a small majority of the 
subjects showed an increase of C
max
 upon coadministration, considerable variation in the 
amount and direction of the effect was seen, as well as variation between individuals. This 
also applies to the observed individual changes in the AUC
0-∞
. The coefficient of variation 
of the AUC
0-∞
 values of raltegravir alone and raltegravir with Ginkgo biloba were 66% and 
51%, respectively. 
Adverse events and safety assessments
The study medication was generally well tolerated, and no serious adverse events were 
reported. There were no discontinuations due to adverse events, and all subjects 
completed the trial. Sixteen subjects reported a total of 32 adverse events. Five (16%) 
adverse events were considered possibly drug-related (all were classified as grade I). 
Diarrhea was reported by two subjects during Ginkgo biloba treatment and one subject 
reported a transient headache which was possibly related to raltegravir and/or Ginkgo 
biloba. One subject developed a grade I triglyceride elevation after administration of 
raltegravir which returned to normal within 7 days. One subject had a mild elevated 
gamma- glutamyltransferase (γ-GT), which remained elevated during the study. 
Table 1   Comparison of single-dose pharmacokinetic parameters of raltegravir with  
or without coadministration of multiple doses of Ginkgo biloba in healthy 
volunteers 
Pharmacokinetic 
parameter
Raltegravir alone Raltegravir  
+ Ginkgo biloba
Raltegravir  
+ Ginkgo biloba /  
Raltegravir alone
Geometric 
mean
95% CI Geometric 
mean
95% CI GMR 90% CI
AUC
0-∞
 (mg·h/L) 6.35b (4.39-9.18) 7.44 (5.10-10.9)  1.21b (0.93-1.58)
AUC
0-12h
 (mg·h/L) 5.93 (4.21-8.34) 7.33 (5.01-10.7) 1.24 (0.97-1.58)
C
max
 (mg/L) 2.08 (1.39-3.12) 3.01 (2.00-4.52) 1.44 (1.03-2.02)
t
max
a (h) 2.00 (1.13-3.00) 2.00 (1.50-2.00)
CL/F (L/h) 63.0b (43.6-91.1) 53.8 (36.8-78.5)
V/F (L) 288b (193-429) 220 (148-325)
t
1/2 
(h) 3.17b (2.61-3.86) 2.83 (2.42-3.32) 0.93b (0.73-1.17)
a For t
max
, median + interquartile range is reported. 
b Two subjects were excluded because the t
1/2
 could not be determined.
AUC
0-∞
, area under the plasma concentration-time curve from dosing to infinity; AUC
0-12h
, area under the plasma 
 concentration-time curve up to 12 h after intake; CI, confidence interval; CL/F, apparent oral clearance; C
max
, maximum 
plasma concentration; GMR, Geometric Mean Ratio; t
1/2
, apparent elimination half-life; t
max
, time to reach C
max
; V/F, 
volume of distribution.
Figure 1  Geometric mean plasma concentrations following a single dose of 400 mg of 
raltegravir in the presence and absence of steady-state Ginkgo biloba (semilog scale on 
the inset).
Figure 2  Individual changes in the maximum plasma concentration (A) and the area 
under the concentration-time curve (B) of raltegravir alone versus raltegravir coadministrated 
with Ginkgo biloba (GB). 
Two subjects were excluded from figure 2B because AUC
0-∞
 could not be determined.
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Discussion
Herb-drug interactions are an important consideration in HIV-infected patients because 
herbs are frequently used, often not reported, and a potential cause for drug failure. A 
popular herbal product among HIV-infected individuals is Gingko biloba extract, despite 
a lack of evidence for effectiveness or safety within this special patient group. Because 
human and preclinical data were inconclusive with regard to Ginkgo biloba’s potential to 
modulate UGT and P-gp activity, a drug-interaction study with raltegravir in healthy 
volunteers was carried out. 
Steady-state Ginkgo biloba increased the mean exposure to raltegravir (AUC
0-∞
) by 21% 
and the C
max
 by 44%. However, the large 90% confidence interval for the GMRs partly 
overlaps the predefined range of 0.80 to 1.25 in the bioequivalence approach and reflects 
the variability in the individual changes in the AUC
0-∞
 and C
max 
of raltegravir.24 Based on our 
findings, raltegravir exposure after a single dose was not clinically significantly reduced by 
concomitant use of Ginkgo biloba extract at steady state, making it less likely that Ginkgo 
biloba is an UGT inducer as suggested in in vitro research.13 The observed mean increase in 
the C
max
 by concomitant use of Ginkgo biloba is more likely to be caused by a change in 
oral bioavailability than by inhibition of the metabolism of raltegravir, because the 
apparent elimination half-life of raltegravir remained unaffected. The slight increase of 
raltegravir AUC
0-∞
 when combined with Ginkgo biloba, is largely due to the observed 
increase in the C
max
 (Figure 1). The difference in the C
max
 of raltegravir alone versus 
raltegravir with Ginkgo biloba within subjects could be (partly) due to the normal 
intrasubject variability in raltegravir pharmacokinetics instead of an effect caused by 
Ginkgo biloba. It is known that raltegravir pharmacokinetics exhibits considerable intra- 
en intersubject variability.26,27 A possible explanation for the increase in the C
max
 and bio-
availability of raltegravir when combined with Ginkgo biloba could be the inhibition of 
P-gp by Ginkgo biloba. In vitro characterization of raltegravir transport by drug transporters 
indicates that raltegravir is a weak P-gp substrate.12 P-gp is an active ATP-dependent efflux 
pump and is encoded by the ABCB1 gene. Efflux mechanisms, such as P-gp, are responsible 
for transporting a broad range of compounds out of the intestinal epithelial cells back into 
the intestinal lumen, and plays an important role in oral drug absorption. The effect of 
chronic use of Ginkgo biloba extract on the pharmacokinetics of the P-gp substrate 
talinolol was studied in healthy volunteers. The observed increase in the C
max
 by 33% and 
AUC by 21 % without any significant alterations in the t
max
 and t
1/2
 of talinolol supports our 
hypothesis.19,20 The variation in change of the oral bioavailability of raltegravir and 
subsequent C
max
 values could be a reflection of individual variation in the inhibitory 
potential of P-gp by Ginkgo biloba. The expression and transport activities of P-gp may 
differ between individuals due to genetic variation in the highly polymorphic ABCB1 
gene.28,29 Therefore, the extent of the inhibition of P-gp may vary accordingly. Although 
inhibition of P-gp-mediated efflux of raltegravir by Ginkgo biloba is an interesting 
hypothesis, one must be cautious in translating findings obtained from in vitro experiments 
directly to the clinical setting. Raltegravir transport by P-gp is not yet confirmed in human 
studies. There are currently no clinical data indicating that the pharmacokinetic profile of 
raltegravir may be affected by selective P-gp inducers or inhibitors. 
It is well known that the pharmacokinetics of raltegravir displays large intersubject 
variability, which was observed in our study, as well (CV in AUC
0-∞
, 66%).26,27 Contributing 
factors, in general, are differences in absorption due to food intake or pH effects, genetic 
polymorphisms associated with altered UGT1A1 activity, and potential drug interactions. 
In this study, raltegravir was administered in a fasted state to minimize intersubject 
variability. Nevertheless, differences in gastric pH and therefore absorption of raltegravir 
probably led to variability in pharmacokinetic parameters between subjects, and maybe 
within subjects, as well. Individuals with decreased UGT1A1 expression caused by 
UGT1A1*28 polymorphism (approximately 7 to 19% of the Caucasian population is 
homozygous for UGT1A1*28), are known to have moderately elevated plasma levels of 
raltegravir. However, this increase in plasma levels is not considered to be of clinical 
importance.30,31 Pharmacogenetic testing was not performed in our study, and UGT1A1*28 
polymorphism might have contributed to the intersubject variability, as well. In two 
subjects, the elimination half-life of raltegravir could not be determined because of 
secondary peaks in the plasma concentration-time curve. These secondary peaks are 
frequently observed in pharmacokinetic studies of raltegravir and can be attributed to 
either delayed absorption or enterohepatic circulation, which is not uncommon for UGT 
substrates.10,26 The pharmacokinetic parameters observed in this study were compared 
with data from Wenning et al., as these healthy subjects (all with UGT1A1*1/*1 genotype) 
were exposed to similar study conditions, i.e., a single intake of a 400-mg raltegravir tablet 
on an empty stomach.31 No major differences between our data and these historical 
controls could be observed.
The combined use of chronic Ginkgo biloba and a single dose of raltegravir was well 
tolerated. No serious events were reported during the trial. The reported adverse events 
related to the study medication were mild and transient. In clinical practice, raltegravir is 
well tolerated, with no dose-related toxicities indentified so far. Given that there have 
been no acute safety findings associated with peak raltegravir concentrations, the 
somewhat higher C
max
 values for raltegravir when coadministered with Ginkgo biloba 
compared with intake of raltegravir alone are not expected to lead to any meaningful 
clinically significant safety concerns.
Our study was undertaken in healthy volunteers, limiting our interpretation in HIV-infected 
individuals with concomitant medication and comorbidity. Because of the inconsistencies 
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and controversies in the literature regarding the exact action of Ginkgo biloba extract on 
metabolizing enzymes or drug transporters and the variation in effect seen in this study, 
it is not possible to draw any definite conclusions. However this study does provide data 
to support the idea that raltegravir can be used safely for the management of HIV infection 
when taken in combination with Ginkgo biloba. No decrease in AUC
0-∞
 of raltegravir was 
observed, and the increase in maximum plasma concentrations are not considered to be 
of clinical importance, due to the normal intersubject variability of raltegravir pharmaco-
kinetics and the good safety profile of raltegravir.
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Abstract
Background
The use of raltegravir in human immunodeficiency virus (HIV)–infected pregnant women is 
important in the prevention of mother-to-child HIV transmission, especially in circumstances 
when a rapid decline of HIV RNA load is warranted or when preferred antiretroviral agents 
cannot be used. Physiological changes during pregnancy can reduce antiretroviral drug 
exposure. We studied the effect of pregnancy on the pharmacokinetics of raltegravir 
and its safety and efficacy in HIV-infected pregnant women.
Methods
An open-label, multicenter, phase 4 study in HIV-infected pregnant women receiving 
raltegravir 400 mg twice daily was performed (Pharmacokinetics of Newly Developed 
Antiretroviral Agents in HIV-Infected Pregnant Women Network). Steady-state pharmaco-
kinetic profiles were obtained in the third trimester and postpartum along with cord and 
maternal delivery concentrations. Safety and virologic efficacy were evaluated.
Results
Twenty-two patients were included, of which 68% started raltegravir during pregnancy. 
Approaching delivery, 86% of the patients had an undetectable viral load (<50 copies/mL). 
None of the children were HIV-infected. Exposure to raltegravir was highly variable. 
Overall area under the plasma concentration-time curve (AUC) and plasma concentration 
at 12 hours after intake (C
12h
) in the third trimester were on average 29% and 36% lower, 
respectively, compared with postpartum: Geometric mean ratios (90% confidence 
interval) were 0.71 (0.53–0.96) for AUC
0-12h 
and 0.64 (0.34–1.22) for C
12h
. The median ratio of 
raltegravir cord to maternal blood was 1.21 (interquartile range, 1.02–2.17; n = 9).
Conclusions
Raltegravir was well tolerated during pregnancy. The pharmacokinetics of raltegravir 
showed extensive variability. The observed mean decrease in exposure to raltegravir 
during third trimester compared to postpartum is not considered to be of clinical 
importance. Raltegravir can be used in standard dosages in HIV-infected pregnant 
women.
Introduction
An estimated 1.4 million pregnant women infected with human immunodeficiency virus 
(HIV) give birth annually worldwide, of which the majority live in sub-Saharan Africa.1 
Mother-to-child HIV transmission (MTCT) is the most common route of HIV infection 
among infants and children. Each day, approximately 1000 infants acquire HIV due to 
MTCT during pregnancy, delivery or breastfeeding. 
Combination antiretroviral therapy (cART) is the standard of care for the prevention of 
perinatal transmission. The main goal of cART is maximal suppression of HIV replication. Its 
implementation together with other effective interventions has led to dramatic declines 
in the number of perinatally HIV-infected children from 15-40% to <2%. Absent or delayed 
prenatal care, acute primary infection in late pregnancy, and the continued increase in 
incidence of HIV infection in women of childbearing age are among the most important 
obstacles to fully eliminate perinatal transmission in the United States and other 
resource-rich countries.2
In current US and European treatment guidelines for HIV type 1 (HIV-1) infection in 
pregnancy, preferred combined antiretroviral agents include 2 nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs) in combination with the protease inhibitors 
lopinavir or atazanavir boosted with ritonavir or the nonnucleoside reverse transcriptase 
inhibitor nevirapine. Regimens including the HIV-1 integrase inhibitor raltegravir can be 
considered for use in special circumstances because information on the pharmacokinetics 
and the safety of raltegravir in pregnancy is limited. Examples of these special circumstances 
could be pregnant women who present late in care (>28 weeks gestational age) or whose 
HIV RNA load is not undetectable at the third trimester.2-4 HIV integrase inhibitors such as 
raltegravir have been shown to rapidly reduce HIV RNA load, with shorter times to achieve 
virological suppression compared with agents from other drug classes.5 Case reports and 
small case series suggest that raltegravir could play an important role when a rapid decline 
in maternal plasma HIV RNA is needed to prevent MTCT during delivery or as an alternative 
antiretroviral drug in complex treatment-experienced HIV-infected pregnant women.6-17 
In a pilot study including 28 pregnant HIV-infected women, which was presented as 
abstract at a conference, the use of raltegravir seemed safe in both women and infants.18 
Pregnancy is associated with considerable physiological changes such as changes in gas-
trointestinal, hepatic, and renal function as well as alterations in the expression and activity 
of transport proteins and metabolic enzymes. Pregnancy may influence the pharmacoki-
netic profile of antiretroviral agents and lead to decreased drug exposure. Suboptimal 
drug exposure can result in HIV RNA rebound, the selection of resistant virus and an 
increased risk of HIV-1 transmission to the infant.19,20 
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Published information on the pharmacokinetics of raltegravir during pregnancy is 
limited.21,22 Watts et al describe a 50% reduction in median exposure to raltegravir during 
pregnancy versus postpartum and a large variability in raltegravir pharmacokinetics. The 
authors report that 92% of women had an HIV RNA load of <400 copies/mL at delivery and 
none of the infants were confirmed to be infected. Additional well-controlled studies are 
needed to confirm that raltegravir can be used safely in this special patient population. 
We studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety 
and efficacy in pregnant HIV-infected women. 
Methods
Study design and participants
This multicentre, phase 4 study was designed as a nonrandomized, open-label trial in 
HIV-infected pregnant women and coordinated by the PANNA (Pharmacokinetics of 
Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women) network study 
group. The PANNA network is a European network of 19 hospitals in seven countries with 
the primary aim to collect pharmacokinetic data during pregnancy on antiretroviral 
agents for which no or limited data are available (www.pannastudy.com). We enrolled 
HIV-infected pregnant women (aged ≥18 years) who were on a cART regimen containing 
raltegravir 400 mg twice daily. Patients were eligible for inclusion if they were on raltegravir 
treatment for at least 2 weeks prior to the first pharmacokinetic assessment in the third 
trimester of pregnancy. Exclusion criteria were a medical history or current condition that 
might interfere with drug absorption, distribution, metabolism, or excretion (such as renal 
failure or hepatic failure), and grade III/IV anaemia (ie, hemoglobin <4.6 mmol/L or <7.4 g/
dL). The study was conducted in compliance with the principles of the Declaration of 
Helsinki. Informed consent was obtained from each participant before undergoing any 
protocol-specified procedures. The study was approved by the appropriate medical 
ethical committee of each centre and by the national authorities where applicable. The 
trial is registered at ClinicalTrials.gov (identifier NCT00825929). 
Procedures
Inclusion screening consisted of clinical evaluations (medical history and physical 
examination) and laboratory assays (serum biochemistry, hematology, qualitative 
urinalysis, HIV-1 RNA load, and CD4 cell count). Blood samples for safety and efficacy 
assessments were obtained on pharmacokinetic sampling days and analyzed at local 
laboratories. Adverse events were recorded at each visit and graded according to the 
Division of AIDS toxicity table (2004). Infant birth weight, gestational age at birth, 
congenital abnormalities, and HIV infection status were collected. Safety outcomes were 
maternal adverse events and congenital abnormalities. Efficacy outcomes were an 
undetectable HIV RNA load (<50 copies/mL) measured at or prior to delivery, and infant 
HIV infection status measured by HIV DNA polymerase chain reaction test.
Pharmacokinetic assessment took place in the third trimester (approximately at week 33) 
and at least 2 weeks postpartum (approximately 4-6 weeks postpartum). Blood samples 
for pharmacokinetic assessment were collected during a 12-hour period at 0 (predose), 
0.5, 1, 2, 3, 4, 6, 8, and 12 hours after observed intake of 400 mg of raltegravir after a 
standard breakfast (650 kCal; 30 g fat). Where possible, umbilical cord blood and matching 
maternal blood samples were obtained at delivery to assess placental transfer. Plasma was 
separated and stored at -18°C or lower until shipment on dry ice to the laboratory of the 
pharmacy of the Radboud University Medical Center (Nijmegen, The Netherlands). 
Concentrations of raltegravir in plasma were analyzed using validated reversed-phase 
high-pressure liquid chromatography with fluorescence detection. The linear calibration 
ranges in plasma were 0.014-10.0 mg/L with a lower limit of quantification of 0.014 mg/L. 
The raltegravir assay was externally validated through the International Interlaboratory 
Quality Control Program for Measurement of Antiretroviral Drugs in Plasma as well as by 
the Clinical Pharmacology Quality Assurance and Quality Control Program (CPQA).16,23
Statistical analysis
Pharmacokinetic parameters were determined using a noncompartmental model in 
WinNonlin/Phoenix version 6.3 (Pharsight Corporation). Based on the individual plasma 
concentration-time data, the following pharmacokinetic parameters of raltegravir were 
determined: the area under the plasma concentration-time curve from 0 to 12 hours after 
intake using the trapezoidal rule (AUC
0-12h
), the trough concentration (C
12h
) defined as the 
sample taken at 12 hours, the maximum plasma concentration of the drug (C
max
), the time 
to reach C
max
 (t
max
), the apparent volume of distribution (V/F), the apparent oral clearance 
being the dose divided by AUC
0-12h
 (CL
ss
/F), and the apparent elimination half-life (t
1/2
). 
Patients from whom a curve was taken during pregnancy were included in demographic, 
safety analyses, and descriptive statistics of the pharmacokinetic parameters. Pharmacoki-
netic parameters are reported as geometric means with 95% confidence intervals (CIs). We 
calculated geometric means ratios (GMRs) and 90% CIs of raltegravir pharmacokinetic 
parameters of third trimester versus postpartum using a mixed-effects model in 
WinNonlin/Phoenix. Cord blood/maternal blood plasma concentration ratios were 
determined and described. 
102 103
Chapter 6 Pharmacokinetics of raltegravir in HIV-infected pregnant women
Results
Twenty-two HIV-infected pregnant women receiving raltegravir 400 mg twice daily were 
enrolled in 10 European hospitals during 2010 to April 2014. The characteristics of the 
study population are presented in Table 1. Four patients (18%) were diagnosed with HIV 
after conception at 12, 16, 18 and 23 weeks of gestational age, respectively. Of the 18 
pregnant women who were already aware of their HIV-positive status, 14 were on cART at 
the time of conception with a median duration of approximately five years (257 weeks). 
Seven patients (32%) were using raltegravir 400 mg twice daily prior to conception. If not 
used prior to conception raltegravir was started mainly during the second (27%) and 
third (32%) trimester of the pregnancy. Only two patients (9%) started a raltegravir-based 
regimen during the first trimester, of whom 1 patient was unaware of her pregnancy at 
that time. Various indications for raltegravir in this special patient population were 
presented: Raltegravir was either started as part of the first cART regimen to obtain a rapid 
decline in HIV RNA viral load with raltegravir as the fourth agent, added to the current 
regimen to optimize or intensify treatment in patients with a detectable viral load, or used 
as alternative to a preferred antiretroviral agent due to side effects (gastrointestinal or 
 hyperbilirubinemia). 
Concomitant HIV and non-HIV medication that could possibly influence raltegravir 
exposure was the use of ritonavir-boosted atazanavir in 4 patients, the use of acid reducing 
agents (ranitidine 150 mg twice daily or sodium alginate as needed) in 2 patients, the use 
of a calcium carbonate supplement in 2 patients, and the use of a magnesium supplement 
(in combination with atazanavir) in 1 patient. All potential drug-interacting agents were 
used during both pharmacokinetic assessments, limiting its influence on the comparison 
between the exposure in third trimester versus postpartum. 
Pharmacokinetic assessment in the third trimester took place at a median gestational age 
of 33 weeks (interquartile range [IQR], 32-35 weeks). A total of 21 evaluable raltegravir 
pharmacokinetic curves were obtained. One pharmacokinetic profile sampling was 
stopped at 3 hours at the volunteer’s request and these plasma concentrations could only 
be partly included in the analysis. Pharmacokinetic assessment postpartum took place at 
a median of 5 weeks (IQR, 4-6 weeks) and a minimum of 3 weeks after delivery in 18 
evaluable pharmacokinetic postpartum curves. Four patients did not have a postpartum 
curve because they withdrew consent. The mean plasma concentration-time profile of 
raltegravir in the third trimester and postpartum are presented in Figure 1, and summary 
statistics of the pharmacokinetic parameters are listed in Table 2.
Table 1  Patient characteristics and pregnancy outcomes (n=22)
Characteristics No. (%)
Age at delivery, y, median (IQR) 33 (29-36)
Race/ethnicity
White 9 (41%)
Black 12 (55%)
Other 1 (5%)
Smoking 0 (0%)
Alcohol use 0 (0%)
Drug use 0 (0%)
ARV treatment at start of pregnancy 14 (64%)
ARV treatment duration before pregnancy, 
wk, median (IQR)
257 (110-440)
Start raltegravir
Before conception 7 (32%)
1st trimester 2 (9%)
2nd trimester 6 (27%)
3rd trimester 7 (32%)
Concomitant ARVs
NRTI 15 (68%) (11 [50%] tenofovir + emtricitabine; 3 [14%] 
tenofovir; 1 [5%] zidovudine + lamivudine)
Protease inhibitora 13 (59%) (8 [36%] DRV/r; 3 [14%] ATV/r; 2 [9%] LPV/r)
NNRTI 2 (9%) etravirine
Entry inhibitor 2 (9%) maraviroc
Third trimester
Gestational age, wk, median (IQR) 33 (32-35)
Weight, kg, median (IQR) 73 (67-79)
HIV RNA detectable (>50 copies/mL) 3 (14%) (74 copies/mL; 144 copies/mL; 242 copies/mL)
CD4 countb, cells/uL, median (IQR) 622 (240-756)
Delivery
Gestational age, wk, median (IQR) 38 (38-39)
Caesarian sectionb 11 (52%)
HIV RNA detectable closest to delivery 
(>50 copies/mL)
3 (14%) (144 copies/mL; 242 copies/mL; 290 copies/mL)
Time between HIV RNA measurement 
and delivery, wk, median (IQR)
3 (0-4) 
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Exposure to raltegravir, which is expressed as AUC
0-12h
, was 29% lower in the third trimester 
versus postpartum by intrasubject comparison. C
max
 and C
12h
 were on average 18% and 
36% lower during pregnancy. The apparent elimination half-life of raltegravir did not 
appear to be influenced by pregnancy. One patient in the third trimester (and none 
postpartum) had a C
12h
 plasma concentration below the suggested threshold of 0.020 
mg/L, which was associated with failure to achieve an undetectable HIV RNA load in 
 treatment-naive patients in the QDMRK study (phase 3 study to compare 800 mg once 
daily versus 400 mg twice daily raltegravir).24 Raltegravir pharmacokinetics was highly 
variable which is best seen in the large 90% CIs around the GMR in Table 2 and graphically 
in Figure 2. Figure 2 shows the individual changes in AUC
0-12h
 and C
12h 
of raltegravir in the 
third trimester of the pregnancy compared with postpartum. Although a mean decrease 
in raltegravir exposure (29%) and C
12h
 plasma concentrations (36%) in the third trimester 
was observed, considerable variation in the amount and direction of the effect is seen 
as well as variation between individual patients. Eleven out of 17 patients with complete 
paired pharmacokinetic curves (65%) showed a decrease in raltegravir exposure in third 
trimester compared to postpartum. 
Table 1  Continued
Characteristics No. (%)
Postpartum (n=18)
Time after delivery, wk, median (IQR) 5 (4-6)
Weight, kg, median (IQR) 64 (59-72)
HIV RNA detectable (>50 copies/mL)c 2 (12%) (99 copies/mL; 650 copies/ml)
CD-4 count, cells/uL, median (IQR) 585 (266-806)
Pregnancy outcomes
Birth weight, g, median (IQR) 3115 (2628-3360)
Small for gestational aged 3 (14%)
Infant HIV DNA PCR test negative 22 (100%)
Data are presented as No. (%) unless otherwise specified. 
Abbreviations: ARV, antiretroviral; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; HIV, human immunodeficiency 
virus; IQR, interquartile range; LPV/r, lopinavir/ritonavir; 
(N)NRTI, (non)nucleoside reverse transcriptase inhibitor; PCR, polymerase chain reaction.
a One subject stopped DRV/r before delivery and one subject switched from LPV/r to ATV/r during pregnancy (prior 
to pharmacokinetic assessments).
b Data available for 21 patients.
c Data available for 17 patients.
d Small for gestational age was determined as <10th percentile of the fetal-infant growth chart by Fenton.25
Table 2   Pharmacokinetic parameters raltegravir during third trimester of pregnancy  
and postpartum
Third trimester
GM (95% CI)
(n=21)
Postpartum
GM (95% CI)
(n=18)
GM ratio (90% CI)  
of third trimester:  
postpartum (n=17)
AUC
0-12h
, mg·h/L 5.00 (3.56-7.01) 7.11 (4.91-10.30) 0.71 (0.53-0.96)
C
max
, mg/L 1.43 (0.93-2.22) 1.76 (1.10-2.80) 0.82 (0.55-1.23)
t
max
, ha 1.98 (0-11.3) 2.03 (0-7.97)
C
12h
, mg/L 0.077 (0.043-0.137) 0.120 (0.074-0.193) 0.64 (0.34-1.22)
t
1/2
, h 2.55b (1.88-3.45) 2.53c (1.91-3.36) 1.04 (0.73-1.47)
CL
ss
/F, L/h 80.1 (57.0-112) 56.2 (38.8-81.4) 1.41 (1.04-1.90)
V/F, L 311b (159-607) 205c (115-367) 1.24 (0.67-2.27)
Abbreviations: AUC, area under the curve; CI, confidence interval; C
12h
, plasma concentration 12 hours after intake, 
CL
ss
/F, apparent oral clearance; C
max
, maximum plasma concentration; GM, geometric mean; t
1/2
, apparent elimination 
half-life; t
max
, time to reach C
max
; V/F, apparent volume of distribution
a t
max
 [median (minimum–maximum)].
b Available for 15 patients.
c Available for 14 patients.
Figure 1  Geometric mean (+upper 95% confidence interval) raltegravir concentration- 
time profiles during the third trimester of pregnancy ( open squares) and postpartum 
(filled circles).
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Nine umbilical cord blood samples were collected with matching maternal blood samples. 
The median time between the reported last dose and cord blood sampling, if available, 
was 10 hours (IQR, 7-11 hours); the median time between cord blood sample and maternal 
sample was 0 minutes (IQR, 0-4 min). The median ratio of raltegravir cord blood/maternal 
blood was 1.21 (IQR, 1.02-2.17; n=9).
No congenital abnormalities were reported. Five patients reported a total of 10 adverse 
events that were considered not to be or unlikely to be related to the cART given. Seven 
events were grade 1 or 2. Grade 3 neuropatic pain was reported as a serious adverse event 
not related to the use of raltegravir. Other grade 3 adverse events were severe anaemia 
due to hemorrhagic delivery and varicella lesions. 
Twenty-two infants were born and they were all tested HIV negative. Three infants (14%) 
were small for gestational age (< 10th percentile of fetal-infant growth chart by Fenton25), 
which is higher than observed in the US for children born from HIV-infected women 
(7.3%).26 Other pregnancy outcomes as well as the results of the maternal HIV RNA viral 
load measurements are shown in Table 1. In summary, 3 of 22 patients (14%) failed to 
achieve an undetectable HIV RNA viral load (<50 copies/mL) close to delivery (144, 242, 
and 290 copies/mL) when measured a median of 3 (IQR, 0-4) weeks before delivery. 
The patient with a C
12h
 level below the threshold of 0.020 mg/L in the third trimester had 
an HIV RNA viral load of 74 copies/mL measured in the third trimester and an undetectable viral 
load on the day of delivery. Adherence, based on self-reporting, was good in all patients.
Discussion
In this study, we evaluated the effect of pregnancy on the pharmacokinetics of raltegravir 
and its safety and efficacy in 22 HIV-infected women. In the third trimester of pregnancy, 
systemic exposure (AUC) to raltegravir was on average 29% lower compared to 
postpartum. However, the pharmacokinetics of raltegravir was highly variable and 
exposure was not consistently decreased in third trimester compared with postpartum. 
Of the 17 women with paired pharmacokinetic curves, 6 (35%) had a higher AUC
0-12h 
in the 
third trimester. A similar effect of pregnancy on C
12h
 plasma levels was observed, leading 
to an average decrease of 36 % of the plasma levels seen postpartum. The magnitude of 
the observed effect is not considered to be of clinical importance. Similar effects of 
drug-interacting agents on the pharmacokinetics of raltegravir are described in the 
product information leaflet without special recommendation to adjust the dosage.27 Viral 
suppression was good in our population with an HIV RNA load <400 copies/mL in all 
women and <50 copies/mL in 86% of women prior to delivery. The women (14%) who 
failed to have an undetectable viral load prior to delivery had adequate C
12h
 levels in third 
trimester. Only 1 patient had a C
12h
 level <0.020 mg/L in the third trimester, which is 
considered to be too low for adequate virological response in treatment-naive patients.24 
She had an undetectable viral load on the day of delivery.
The decrease in AUC (29%) in third trimester compared with postpartum was in line with 
the observations in a previous study with intensive pharmacokinetics of raltegravir during 
pregnancy from Watts et al.21 They describe a more pronounced decrease of approximately 
50% in AUC in the third trimester compared to postpartum. Given the high rate of viral 
suppression at delivery and the lack of a clear pharmacokinetic/pharmacodynamic 
relationship in nonpregnant adults, the authors suggest that a higher dose of raltegravir is 
not necessary during pregnancy. Watts et al reported a median AUC of 5.4 mg·h/L (n=41) 
in the third trimester, which is comparable to the geometric mean AUC in the third 
trimester (5.00 mg·h/L ) found in our study.21 The postpartum median AUC reported by 
Watts et al (11.6 mg·h/L [n=38] measured 3-14 weeks postpartum) was higher than the 
AUC we found ( 7.11 mg·h/L).21 This difference probably causes the more pronounced 
decrease between the third trimester and postpartum found by Watts et al.21 Raltegravir 
C
12h
 levels in the third trimester were comparable between Watts et al and our study 
(0.064 mg/L vs 0.077 mg/L, respectively).21 The postpartum curves in our study are 
consistent with intensive pharmacokinetic profiles in nonpregnant HIV-infected patients 
in the twice-daily treatment arm of the QDMRK study.24 The geometric mean AUC and C
12h
 
(n=20) of raltegravir are 5.84 mg·h/L and 0.114 mg/L, respectively in the QDMRK study 
compared with 7.11 mg·h/L and 0.120 mg/L postpartum (n=18) in our study. This would 
suggest that the pharmacokinetic parameters collected at a median of 5 weeks postpartum 
in our study can be used as reference for the nonpregnant situation. The large inter- and 
Figure 2  Individual raltegravir AUC
0-12h
 (A) and C
12h 
(B) parameters during the third 
trimester of pregnancy and postpartum
Symbols: Filled square  is a detectable (≥50 copies/mL) and an open circle    is an undetectable (<50 copies/mL) 
HIV RNA load close to delivery.
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intrasubject variability in raltegravir pharmacokinetics observed in our study is well 
recognised by others in non-pregnant populations.28,29 Intersubject variability in our study 
might have been caused by drug-drug interactions and differences in patient characteristics. 
These factors together with the time of postpartum pharmacokinetic assessment could 
also have contributed to the differences in pharmacokinetic parameters of raltegravir 
postpartum between Watt et al and our study. 
There are many physiological changes during pregnancy that could alter distribution, 
metabolism and clearance of antiretroviral drugs used in pregnancy.19,20 During pregnancy, 
the apparent volume of distribution increases with subsequent decreases in peak plasma 
concentrations, which was observed in our study as well. Alterations in drug elimination 
clearance during pregnancy can affect steady-state concentrations. Raltegravir is primarily 
metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1. The potential 
effect of pregnancy on UGT1A1 activity has been evaluated and is believed to be increased 
during pregnancy.19,30 Jeong et al suggest that the induction of UGT1A1 expression by rising 
progesterone levels in pregnant women may be responsible for the increase in clearance 
of UGT1A1 substrates.31 This hypothesis is not supported by our study in which the 
apparent elimination half-life of raltegravir in the third trimester was similar to postpartum. 
Raltegravir was well tolerated during pregnancy, and all of the children were tested HIV 
negative. Only 9 infants were exposed to raltegravir during the first trimester, with no birth 
defects reported. To assess prevalence rates of birth defects in infants exposed to 
raltegravir compared to nonexposed infants, more experience of raltegravir in human 
pregnancy is needed. Placental transfer of raltegravir is efficient with a median raltegravir 
cord blood to maternal plasma ratio of 1.21, in agreement with previous reports.12,13,21,32,33 
Unfortunately, the collection of neonatal blood samples to describe the washout pharma-
cokinetics and safety of in utero exposure to raltegravir was not part of this study. UGT1A1 
neonatal enzyme activity is still immature after birth and leads to prolonged elimination 
of raltegravir after delivery. In newborns whose mothers were exposed to raltegravir 
during pregnancy, raltegravir is slowly metabolized with an elimination half-life that is 
highly variable.9,12,33
In conclusion, raltegravir was well tolerated during pregnancy in our study population. 
Raltegravir pharmacokinetics showed extensive inter- and intraindividual variability. Our 
findings show a mean decrease in exposure to raltegravir during third trimester compared 
with postpartum, which is not considered to be of clinical importance. Raltegravir in 
combination with other antiretroviral agents was effective in preventing MTCT by 
reducing and/or maintaining the HIV RNA viral load at an undetectable (<50 copies/mL) or 
low (<400 copies/mL) level. Our data support the use of raltegravir in standard dosages 
in HIV-infected pregnant women for the prevention of MTCT.
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Abstract
Non-Hodgkin lymphoma (NHL) is one of the most frequently diagnosed malignancies 
among human immunodeficiency virus (HIV)-infected individuals. Since the introduction 
of combination antiretroviral treatment most HIV-infected patients with NHL or other 
types of cancer can be treated with standard intensive high-dose chemotherapy similar 
to the HIV-negative population. Concomitant use of antiretroviral treatment with 
chemotherapy is complicated because of drug-drug interactions. Raltegravir, an HIV 
integrase strand-transfer inhibitor, has a favorable drug-interaction profile compared to 
other antiretroviral drug classes, such as protease inhibitors and non-nucleoside  reverse- 
transcriptase inhibitors. Therefore, raltegravir is increasingly recommended as antiretroviral 
agent in HIV-infected patients with cancer who use chemotherapy. Despite its use in this 
setting, little is known about the pharmacokinetics of raltegravir in this special patient 
population. We present a case series of three HIV-infected patients who received 
chemotherapy for the treatment of advanced stage NHL in whom therapeutic drug 
monitoring of raltegravir was performed. Raltegravir trough plasma concentrations, which 
is seen as the most important parameter with respect to virological efficacy, was adequate 
(>0.020 mg/L) in all three patients. The observed decrease in exposure to raltegravir was 
not considered to be of clinical importance. However, chemotherapy- induced intestinal 
mucositis can influence the absorption of raltegravir. In these cases therapeutic drug 
monitoring by measuring raltegravir plasma concentrations could be a useful tool to 
monitor raltegravir treatment. 
Introduction
Antiretroviral therapy has significantly decreased overall morbidity and mortality of 
AIDS-related complications in HIV-infected patients, including HIV-related hematological 
malignancies such as non-Hodgkin lymphoma (NHL). 1,2 The contribution of HIV-infected 
cases to the total number of NHL cases in the United States has declined over time from 
12.5% in 1992-1995 to 3.6% in 2005-2009.3 Nonetheless, the risk in HIV-infected patients for 
the development of NHL remains greatly elevated relative to the general population and 
is approximately 15 to 50-fold depending on the NHL subtype.4,5 Most common subtypes 
within the HIV population are diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma 
and primary lymphomas of the central nervous system (CNS). NHL is still one of the 
most frequently diagnosed malignancies among HIV-infected individuals and comprises 
up to 23% of all cancer diagnoses within the HIV-infected population.6 AIDS-defining 
malignancies together with a steep increase of non-AIDS-defining malignancies currently 
account for an estimated of one-third of all cause mortality among HIV-infected 
individuals.7
Since the introduction of combination antiretroviral therapy (cART) most HIV-infected 
patients with NHL or other types of cancer will be treated with standard intensive-dose 
chemotherapy similar to HIV-negative patients, with improved overall survival.8-10 
Recommended antiretroviral regimens in general include a minimum of three active 
antiretroviral agents from at least two different drug classes.11 Most commonly used 
regimens consist of two nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs) 
and one antiretroviral agent of the following drug classes: nonnucleoside reverse-tran-
scriptase inhibitors (NNRTIs), protease inhibitors (PIs) or integrase strand-transfer inhibitors 
(INSTIs). Concomitant use of cART with chemotherapy is complicated due to drug-drug 
interactions and overlapping toxic effects.12,13 The drug interaction potential of antiretroviral 
agents in general is well documented but specific information on interactions with 
cytotoxic agents and practical guidelines for dose adjustments is very limited. The NRTI 
backbone used in HIV treatment has little propensity to interact with other agents but 
interactions might occur through change of renal drug clearance or overlapping 
nephrotoxicity and hematologic toxic effects. PIs and NNRTIs are extensively metabolized 
by cytochrome P450 (CYP) enzymes and induce or inhibit CYP enzymes. Because many 
chemotherapeutic agents are metabolized via the CYP450 pathway the potential for 
drug-drug interactions between chemotherapy and PIs and NNRTIs is high. Combination 
could result in drug accumulation and increased toxicity, or decreased exposure, reduced 
efficacy, and potential HIV drug resistance for antiretroviral agents.12-14 Raltegravir, the first 
INSTI approved by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA), has a favorable drug interaction profile because it does not 
influence CYP enzymes.15,16 Given the concerns with drug-drug interactions or tolerability 
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with NNRTIs and PIs, clinicians may consider to start or switch to a raltegravir-based 
regimen in patients with chemotherapy.12,13,17,18
Although raltegravir is increasingly being recommended and used in clinical practice in 
HIV-infected patients with cancer, surprisingly little is known on the efficacy, safety and 
pharmacokinetics of raltegravir in this setting in comparison with other more frequently 
used antiretroviral agents.16,18-21 To our knowledge, information on the pharmacokinetics 
of raltegravir in combination with various chemotherapeutic agents in HIV-infected 
patients is limited to a study presented on a conference in which they found an adequate 
trough plasma concentration of raltegravir in eight patients.19 Whether chemotherapy-in-
duced severe intestinal mucositis influences the absorption and total exposure to 
raltegravir has not been investigated. 
This short case series describes three HIV-infected patients with advanced stage NHL who 
were treated with standard intensive chemotherapy and in whom therapeutic drug 
monitoring (TDM) of raltegravir was performed by means of a limited plasma sampling 
method to estimate the exposure to raltegravir.
Methods
The patients presented here were admitted to the department of hematology at the 
Radboud university medical center (Nijmegen, The Netherlands) in the years 2011-2013. 
The management of complex HIV-infected patients with NHL is performed by a multidis-
ciplinary team of hematologists, infectious diseases specialists and clinical pharmacolo-
gists/hospital pharmacists with expertise on drug-drug interactions and TDM. The 
patients presented here received standard chemotherapy in accordance with national 
and international guidelines.11 All three patients received raltegravir 400 mg twice daily 
orally according to the product labelling (Isentress, Merck Sharp & Dohme Ltd).15,16 In our 
medical center TDM of raltegravir is available as regular patient care. Systemic exposure to 
raltegravir is best represented by the area under the plasma concentration-time profile 
(AUC) from 0 until 12 hours after intake of raltegravir. To reduce patient burden, practical 
issues and costs around 12-hour multiple blood sampling, an alternative limited sampling 
strategy was used in which an abbreviated AUC from 0 to 3 hours (AUC
0-3h
) is calculated 
and extrapolated to AUC
0-12h
 as described previously.22
 
Pharmacokinetic assessment of raltegravir was scheduled prior to and/or during 
chemotherapy as discussed within the multidisciplinary team. Pharmacokinetic sampling 
was performed at steady-state conditions at the following time-points: predose and 0.5, 
1.0, 1.5, 2.0 and 3.0 hours after intake of raltegravir 400 mg on an empty stomach. Breakfast 
was served 2 hours after intake of raltegravir. Blood samples were collected into lithi-
um-heparinised tubes and centrifuged for 5 minutes at 1900 x g at 20°C. Plasma was 
transferred to polypropylene tubes and kept refrigerated until further bioanalysis. 
Concentrations of raltegravir in plasma were analyzed using a validated reversed-phase 
high-pressure liquid chromatography with fluorescence detection as previously 
described.23 The linear calibration range in plasma was 0.014-10.0 mg/L. The raltegravir 
assay was performed at the laboratory of the Pharmacy of the Radboud university medical 
center (Nijmegen, The Netherlands) and externally validated through international Quality 
Assurance and Quality Control Programs for measurement of antiretroviral drugs in 
plasma.20,24,25
Based on the individual plasma concentration-time data the area under the plasma con-
centration-time curve from 0 to 3 hours (AUC
0-3h
) was calculated using the trapezoidal rule. 
The AUC
0-12h 
was estimated based on the following equation: AUC
0-12h 
= 1.321*AUC
0-3h 
+ 
1.209, r2 = 0.929. The trough plasma concentration (C
trough
) was defined as the sample taken 
immediately prior to intake of 400 mg raltegravir at time-point 0 hours. Interpretation of 
the pharmacokinetic parameters was done by a hospital pharmacist based on a Dutch 
TDM guideline for raltegravir. The following population reference values were used 
(unpublished data): 6.89 mg·h/L for AUC
0-12h
, 4.30 mg·h/L for AUC
0-3h
 with a peak plasma 
concentration at approximately 2 hours after intake of raltegravir on an empty stomach. 
From 2012 onwards the target trough plasma concentrations of rategravir has been 
defined as  >0.020 mg/L.26
Case series
Case 1: HIV-associated Burkitt lymphoma
A 44-year-old HIV-infected man was referred to our institution in 2012 by his general 
practitioner. A summary of his clinical characteristics, his treatment and the pharmacoki-
netic parameters of raltegravir are given in Table 1. At presentation, he started a raltegra-
vir-based antiretroviral regimen to obtain a rapid virological response and to reduce the 
risk of potential drug-drug interactions with chemotherapeutic agents. Induction 
chemotherapy was started immediately according to the acute lymphoblastic leukemia 
(ALL) 4 protocol.27 
TDM of raltegravir was performed during cyclophosphamide infusion 750 mg/m2 to 
evaluate the pharmacokinetics of raltegravir in this setting. We measured an adequate 
raltegravir C
trough
 (>0.020 mg/L) and an exposure to raltegravir (AUC
0-12h
) that was 65% 
lower compared to our population reference value of 6.89 mg·h/L. However the maximum 
plasma concentration between the 0 to 3 hour time-window was measured at 3.0 hours 
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Table 1  Clinical characteristics and raltegravir pharmacokinetic parameters
Clinical characteristics  Case 1 Case 2 Case 3
Year of presentation 2012 2011 2013
Diagnosis Burkitt lymphoma (c-Myc+) Burkitt lymphoma (c-Myc+) DLBCL (relapsed), initial diagnosis in 2009
Ann-arbor stage IV IVB IVB
CNS involvement Suspected Yes Yes
HIV status Confirmed HIV infection since 7 years, treatment-naive Recent HIV diagnosis Confirmed HIV infection since 8 years, cART since 
2007 with good virological response
CD4+ cell count (cells/ µL) 810 280 Unknown
HIV RNA load (copies/mL) 20 000 100 000 80
Antiretroviral therapy raltegravir 400 mg BID
tenofovir + emtricitabine QD
Initiated before start chemotherapy
raltegravir 400 mg BID
tenofovir + emtricitabine QD
Initiated before start chemotherapy
raltegravir 400 mg BID (switch from boosted darunavir), 
tenofovir + emtricitabine QD
Chemotherapy ALL4 (cyclophosphamide, daunorubicine, vincristine and 
prednisolon) + intrathecal methotrexate + rituximab
HOVON 63 with R-CHOP + intrathecal methotrexate R-DHAP + R-VIM , followed by BEAM + ASCT
Pharmacokinetic assessment raltegravir
Timing Cycle 1, day 8 during cyclophosphamide infusion Day before 2nd cycle R-CHOP Before start BEAM 6 days after last  
dose BEAM
Intestinal mucositis None None None Severe, watery stools
Non-HIV concomitant medication cyclophosphamide, ondansetron, sulphamethoxazole/tri-
methoprim, temazepam, colistine
omeprazol, bisacodyl, oxycodon, oxazepam, sulpha-
methoxazole/trimethoprim, fluconazol, acetylsalicylic 
acid, osmotic laxative
pantoprazol, 
sulphametoxazol/
trimethoprim
valaciclovir, pantoprazol, 
ceftazidim
AUC
0-12h
 (mg·h/L) 2.46 (±65%↓) 3.79 (±50%↓) 9.37 (±40%↑) 4.20 (±65%↓ than 
baseline)
C
trough
/C
0
 (mg/L) 0.200 0.091 0.114 0.147
t
max
 (h) ≥ 3 0.5-1.0 1.7 ≥ 3
Follow up
NHL status Complete remission after BEAM and ASCT Clinical progression, died within one year after diag-
nosis of HIV/AIDS.
Good clinical response, additional radiotherapy for 
suspect lesion
HIV clinical parameters HIV RNA load <50 copies/mL after 7 weeks of cART HIV RNA load <50 copies/mL after 4 weeks of cART HIV RNA <50 copies/mL 2 weeks after BEAM
Abbreviations: ALL, acute lymphoblastic leukemia; ASCT, autologous hematopoietic stem-cell transplantation; BEAM, 
high-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan; BID, twice daily; cART, combination 
antiretroviral therapy; CNS, central nervous system; DBLC, diffuse large B-cell lymphoma; QD, once daily; R-CHOP, 
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-DHAP, rituximab, dexamethason, 
cytaribine, cisplatin; R-VIM, rituximab, etoposide, ifosfamide, methotrexate; t
max
, time to reach the maximum plasma 
concentration (absorption peak). 
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and was relatively low (0.425 mg/L), suggesting that the peak plasma concentration had 
not been reached and the extrapolated AUC
0-12h
 may be an underestimation. A possible 
explanation for the delay in absorption could be that raltegravir was taken with food as 
opposed to fasted. We were unable to recall the timing of breakfast. The patient had no 
complaints of vomiting and diarrhea that could have contributed to the observed 
decrease in absorption. Based on the metabolic profile of raltegravir a clinically significant 
drug-drug interaction with cyclophosphamide or the other co-medication used at the 
time of raltegravir blood sampling was not expected theoretically. Because the patient 
had an adequate raltegravir trough level no follow-up TDM was performed and the 
patient continued his antiretroviral regimen with success.
Case 2: HIV-associated Burkitt lymphoma
A 52-year-old man was referred to our institution in 2011 for treatment of a recently 
diagnosed HIV-infection and HIV-associated Burkitt lymphoma (Table 1). TDM of raltegravir 
was performed a day before the second cycle of R-CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisone ) was given. We intended to schedule it on the 
same day to evaluate concomitant use of raltegravir with the chemotherapeutic agents, 
but the second R-CHOP cycle was postponed at the very last minute due to leukopenia. 
We measured an adequate raltegravir C
trough
 well above 0.020 mg/L. Raltegravir AUC
0-12h
 
was approximately 50% lower compared to our reference values. Based on the concomitant 
use of omeprazol an increase of AUC would have been more likely. A drug-drug interaction 
study showed that omeprazol increased the AUC of raltegravir by 37% due to improved 
raltegravir solubility and oral absorption at higher gastric pH values. This drug-drug 
interaction is not clinically relevant according to the product labeling.12 In our case we 
continued with a standard dosage of raltegravir as we considered the 50% decrease in 
AUC not clinically relevant. A rapid viral suppression was seen after one month of cART. 
Despite additional intensive chemotherapy no clinical improvement was achieved and 
the patient died of AIDS and Burkitt lymphoma within one year after clinical manifestation 
and diagnosis of HIV/AIDS. 
Case 3: relapsed HIV-related DLBCL and intestinal mucositis
A 64-year-old HIV-infected man was admitted to our institution with disease progression 
of HIV-related high-grade DLBCL in 2013 (Table 1). In order to reduce the risk for potential 
drug-drug interactions between his antiretroviral regimen and chemotherapeutic agents, 
ritonavir-boosted darunavir was switched to raltegravir 400 mg twice daily prior to the 
start of chemotherapy. 
TDM of raltegravir was performed to evaluate the potential influence of severe intestinal 
mucositis on the absorption of raltegravir. Blood sampling was scheduled at two different 
occasions: baseline pharmacokinetic assessment before start of BEAM chemotherapy 
(high-dose carmustine, etoposide, cytarabine and melphalan) and a second evaluation 
6 days after the last dose of BEAM chemotherapy. At the time of the first scheduled 
abbreviated AUC
0-3h 
the patient was in a relatively good clinical condition with no 
complaints of abdominal discomfort and a normal defecation pattern. We measured a 
normal raltegravir trough plasma concentration and an exposure to raltegravir (AUC
0-12h
) 
which is approximately 40% higher compared to our population reference values. The 
increase in AUC could be a result of the concomitant use of pantoprazol which increases 
gastric pH and could increase oral absorption of raltegravir. Although the combination of 
raltegravir and pantoprazol has not been studied, omeprazol, another proton pump 
inhibitor, has shown this effect as mentioned before. During the second assessment the 
patient suffered from severe intestinal mucositis with painfull abdominal cramps, nausea, 
vomiting, and diarrhea with frequent loose and watery stools. The plasma albumin level 
had decreased to 26 gr/L (normal range, 35-45 gr/L). The raltegravir trough concentration 
was slightly higher than at baseline. However, AUC
0-12h 
was approximately 65% lower 
compared to baseline and 40% lower compared to our reference values. The peak plasma 
concentration measured at baseline was 4.55 mg/L at 1.7 hours after intake compared 
with 1.53 mg/L at 3.0 hours after intake at the second pharmacokinetic assessment. The 
limited sampling strategy that was used to extrapolate to 12 hours may underestimate the 
total exposure because the time to reach the absorption peak was ≥ 3 hours. The decrease 
in exposure could been have been (partly) a result of impaired and/or a delay in absorption 
due to intestinal mucositis. We advised to continue the normal dosage of 400 mg twice 
daily as the trough level remained normal and the decrease in AUC
0-12h 
was not considered 
clinically relevant. HIV RNA load was measured regularly to monitor virological efficacy of 
his antiretroviral regimen. 
General discussion
The optimal antiretroviral treatment for HIV-infected patients with malignancies and use 
of chemotherapy is complicated because of drug-drug interactions and overlapping 
toxicity.12,13 To avoid potential drug-drug interactions via the CYP450 pathway we started 
or switched to a raltegravir-based antiretroviral regimen in three HIV-infected patients 
with advanced stage NHL and concomitant use of chemotherapy. We used a limited 
sampling strategy to estimate the exposure (AUC
0-12h
)
 
to raltegravir in this setting.22,28 All 
three patients had adequate raltegravir trough levels (>0.020 mg/L) measured at various 
stages of their chemotherapy and a good virological response. The observed decrease in 
exposure (AUC) to raltegravir was not considered to be of clinical importance. The 
decrease in exposure in case 3 could be a result of reduced drug absorption caused by 
severe chemotherapy-induced intestinal toxicity. 
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Intestinal mucositis is tissue damage of the mucosal barrier and a common side effect of 
intense cytotoxic therapy and radiotherapy.29 The impact of damage to intestinal villi on 
the pharmacokinetics of oral drugs remains poorly understood but may be associated 
with altered drug absorption due to accelerated or delayed gastric emptying, increased 
permeability of the mucosa, changes in intraluminal pH and decreased intestinal surface 
area. Whether this condition could have a clinically relevant impact on raltegravir 
absorption and efficacy is unknown. It is known that the solubility of raltegravir is highly 
dependent on gastric and intraluminal pH, as well as gastric transit time.30,31 When patient 
3 had complications of severe intestinal mucositis the exposure to raltegravir was reduced 
by approximately 65% compared to baseline measurements. The maximum plasma 
concentration of the absorption peak was lower and the time to reach this peak was 
delayed up to 3 hours or more after intake of raltegravir. Although this could have been a 
result of impaired absorption, we cannot rule out that this is partly due to intra-individual 
variation as we have not repeated the measurements. In addition to this we might 
underestimate the exposure because we did not sample beyond 3 hours and have missed 
(part of) the absorption peak. Despite potential impaired absorption, the magnitude of 
this effect was acceptable (40% reduction) compared to our population reference values. 
This is probably due to the concomitant use of intraveneous pantoprazol which has a 
positive effect on the extent of the absorption of raltegravir.
An important limitation in all three of the cases presented here and in the use of TDM of 
raltegravir in general is that the pharmacokinetic profile of raltegravir is known for its the 
extensive intraindividual variability.32-34 Therefore the results of individual plasma 
concentrations of raltegravir should always be interpreted with caution as the plasma 
concentrations measured could have been subject to normal intrapatient variation.
 
The introduction of cART has reduced the risk of AIDS-defining malignancies and 
dramatically prolonged survival. As a result the HIV population is growing older and is 
increasingly more at risk for development of non-AIDS-defining malignancies that typically 
occur at older ages. Although the type of cancer that HIV-infected patients are diagnosed 
with is changing, the need for treatment with chemotherapy in combination with cART is 
increasingly common while the optimal antiretroviral treatment in this special patient 
population remains unknown. Some guidelines and articles on the management of 
cancer in HIV-infected patients recommend to use raltegravir as an alternative for NNRTIs 
and PIs to avoid potential pharmacokinetic drug-drug interactions via the CYP450 
pathway. 12,13,17,18 Nonetheless, limited research has been performed on the efficacy, safety 
and pharmacokinetics of raltegravir in this setting in comparison with other antiretroviral 
agents and most publications are from recent years. The first publication was a case report 
in 2010 on the successful use of a raltegravir-based regimen in a treatment-naïve patient 
with DLBCL and chemotherapy with CHOP.35 More recently Wong et al reported similar 
toxicity and efficacy of CHOP when combined with a PI versus non-PI-based regimen in 
patients with DLBCL.36 Unfortunately, in this retrospective pilot study the non-PI-based 
regimen included patients using raltegravir or efavirenz (a NNRTI). NNRTIs may induce 
doxorubicine and cyclophosphamide metabolism via CYP3A4 which could have 
influenced efficacy and toxicity rates of the chemotherapy in this cohort. Another 
retrospective study analyzed the efficacy, defined as the absence of virological failure, and 
safety of different cART regimens in HIV-infected patients with NHL or other types of 
cancer.12 The authors conclude that cART including PIs were the least favorable in terms of 
virological efficacy and safety. NNRTIs and INSTIs (raltegravir) had comparable efficacy, but 
raltegravir appeared to be better tolerated. Raltegravir in combination with various che-
motherapeutic agents in a prospective longitudinal study in 28 HIV-infected patients was 
found to be safe and effective, regardless of the type of tumor and type and duration of 
chemotherapy.19 This study, which was presented on a conference, is to our knowledge 
the only study that has reported pharmacokinetics of raltegravir. They measured adequate 
trough levels (median 0.143 mg/L; n=8) which is comparable to our findings.
We have presented a series of three cases on the value of TDM of raltegravir in HIV-infected 
patients with typical HIV-associated hematological malignancies. Raltegravir trough 
plasma concentrations, which is the most important parameter with respect to virological 
efficacy, was adequate in all three patients when using the standard dosage of 400 mg 
twice daily. Severe chemotherapy-induced intestinal toxicity may negatively influence the 
absorption of raltegravir. If severe diarrhea and vomiting occurs, TDM could be used to 
monitor raltegravir treatment. The cases we described do not represent the general HIV 
population with cancer. However, they are illustrative for the complexity that clinicians 
face when managing drug-drug interactions in HIV-infected patients with chemotherapy. 
More research is needed on the safety and efficacy of raltegravir and other antiretroviral 
agents in combination with chemotherapeutic agents with special attention to pharma-
cokinetic drug-drug interactions and intestinal complications which could potentially 
influence the oral absorption or antiretroviral agents.
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Abstract
Raltegravir is the first human immunodeficiency virus type 1 (HIV-1) integrase strand 
transfer inhibitor approved by the US Food and Drug Administration and the European 
Medicines Agency for the treatment of HIV infection in combination with other 
antiretroviral agents in children from ≥4 weeks to ≤18 years. The experience in the use of 
raltegravir in pediatric HIV care and information on the pharmacokinetics of raltegravir in 
children is still limited. We discuss our experience with therapeutic drug monitoring and 
dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected patient, as 
well as provide a review of the available literature and information on the pharmacokinet-
ics of raltegravir in children. The presented case illustrates our concern of low raltegravir 
trough values when using chewable tablets in young HIV-infected patients.
Introduction
Worldwide 3.2 million children under 15 are living with human immunodeficiency virus 
(HIV), comprising 9.1% of the HIV-infected population.1 The majority of children become 
infected through mother-to-child HIV transmission (MTCT) during pregnancy, delivery or 
breastfeeding. HIV-infected children need long-life antiretroviral treatment to improve 
survival, reduce opportunistic infections and other complications of HIV infection. 
Pediatric guidelines recommend an antiretroviral regimen including a minimum of three 
drugs from at least two different drug classes.2 Antiretroviral drug-resistant virus can 
develop because of poor adherence, an ineffective regimen, or a combination of these 
factors. The availability of effective age-appropriate formulations of new antiretroviral 
drug classes is urgently needed for those children who fail on first-line antiretroviral 
therapy and have limited therapeutic options. 
Raltegravir is the first HIV integrase strand transfer inhibitor (INSTI) approved by the US 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the 
treatment of HIV infection in combination with other antiretroviral agents in children and 
adolescents.3,4 In December 2011, raltegravir was approved by the FDA for use in children 
between 2 and 18 years of age followed by an additional change of the label to include 
infants ≥ 4 weeks of age and ≥ 3 kilogram. Raltegravir is available as film-coated tablet and 
in two special formulations suitable for infants and young children who are unable to 
swallow whole tablets; chewable tablets and granules which are administered as oral 
suspension. Although published safety and efficacy data of raltegravir in children are 
promising, its use and experience in pediatric HIV care is still limited.5-8 In particular, little is 
known on the pharmacokinetics and treatment outcomes of the recently marketed 
formulations in young children. 
Therapeutic drug monitoring (TDM) of antiretroviral therapy in HIV infection by measuring 
plasma concentrations of antiretroviral agents may be used as a means to optimize and 
monitor treatment response.9,10 TDM can be a useful tool in patient populations with a large 
 interindividual variation in pharmacokinetics, including children, whose developmental 
changes occurring with age could alter the pharmacokinetics of drugs.10-13
We describe a 4-year-old HIV-infected patient in whom therapeutic drug monitoring and 
individualisation of therapy with raltegravir chewable tablets was performed based on 
measurement of raltegravir plasma concentrations, and give a review of the literature 
on the pharmacokinetics of raltegravir in children, with a focus on the age group ≥ 2 to 
< 6 years old.
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Case
A 4-year-old HIV-infected boy presented with first-line virological failure (plasma HIV-1 
RNA 59400 copies/mL) in December 2011. He had recently migrated from sub-Saharan 
Africa where he was diagnosed to be HIV-infected at the age of 3 years. Two nucleoside 
reverse transcriptase inhibitors (NRTIs) zidovudine and lamivudine, and the nonnucleoside 
reverse-transcriptase inhibitor (NNRTI) efavirenz was started as first-line antiretroviral 
therapy approximately a year prior to his arrival in the Netherlands. His clinical condition 
was good, CD4 T-cells were 394/mm3 (22.4 %), and hepatitis B and C serology was negative. 
Genotypic resistance testing was performed to collect information about patterns of HIV 
drug resistance that might explain treatment failure to his current regimen. Several 
drug-resistance mutations were found which had resulted in NNRTI resistance and 
reduced susceptibility to several NRTIs due to thymidine analogue mutations (TAMs). 
Because of the extensive drug-resistance pattern with an increased plasma HIV-1 RNA to 
429000 copies/mL, the patient was switched to a regimen including a protease inhibitor 
(ritonavir-booster lopinavir), a dual NRTI backbone of tenofovir and lamivudine, and 
raltegravir (Isentress, Merck Sharp & Dohme Ltd, Hoddesdon, United Kingdom). At that 
time (February 2012) the raltegravir chewable tablets for oral use in children from the age 
of 2 years were not yet approved by the EMA and were not available on the European 
market. Fortunately our patient could receive raltegravir chewable tablets on a named- 
patient program by the manufacturer of raltegravir. He was administered raltegravir 100 mg 
chewable twice daily corresponding with the dosage guidelines for children in weight 
band 14 - 20 kg (Table 1). 
Ten days after initiation of raltegravir TDM was performed by measuring raltegravir plasma 
concentrations. A validated liquid chromatography-tandem mass spectrometry method 
was used with a lower limit of quantification (LLOQ) of the assay of <0.014 mg/L. A pharma-
cokinetic sample 10 hours post dose after observed intake was below the LLOQ (<0.014 
mg/L) and below the threshold for trough levels (Ctrough) for adult patients, which is <0.020 
mg/L. The following day pharmacokinetic sampling was performed predose and between 
0-3.5 hours after intake. The predose C
trough
 value was <0.014 mg/L and the maximum 
plasma concentration was 1.6 mg/L. Since our patient repeatedly showed low trough 
levels despite good adherence, the dosing interval was shortened and the dosing regimen 
was switched from 100 mg twice daily to 100 mg three times daily. We realized that the 
three-times-daily dosing regimen was very unpractical, especially in a young child 
sleeping 10-12 hours a night. However, our main concern at that time was the high plasma 
HIV-1 RNA and repeated suboptimal plasma concentrations of raltegravir. 
Follow-up with TDM on two occasions indicated adequate C
trough
 levels (0.10 mg/L and 
0.17 mg/L). The clinical condition of the patient remained well, plasma HIV-1 RNA had 
dropped from 423000 copies/mL at the start of the new antiretroviral regimen to 64 
copies/mL after 6 weeks of treatment and CD4 T-cells had increased to 637/mm3 (23.4 %). 
Because of the limited safety experience in children there were some concerns regarding 
the total daily dose of raltegravir being 150% of that recommended in the prescribing 
information. Approximately 4 months after the start of the new regimen, the plasma HIV-1 
RNA concentration had reached undetectable levels (<50 copies/mL) and raltegravir was 
temporarily switched back to 100 mg chewable tablets twice daily. The patient was 
admitted to the hospital for pharmacokinetic blood sampling. Plasma concentrations 
predose (C
trough
 morning) and respectively 4, 8 and 12 hours (C
trough
 evening) after observed 
intake on an empty stomach were 0.018 mg/L, 0.09 mg/L, 0.03 mg/L, and <0.014 mg/L. 
Because of persistent low plasma levels, the raltegravir dosage was changed to 75 mg 
three times daily which was assumed to deliver adequate C
trough
 levels due to shortening 
of the dosing interval. With this regimen, the total daily dose of 225 mg was closer to the 
daily dose of 200 mg as recommended by the prescribing information. 
The patient continued with raltegravir 75 mg three times daily throughout his fifth year. 
Every three months TDM was performed and C
trough
 levels taken approximately 7 hours 
after intake were all adequate, ranging from 0.07 to 0.24 mg/L. Plasma HIV-1 RNA was low 
Table 1   Recommended dose for raltegravir granules for suspension, chewable tablets 
and film-coated tablets in children ≥ 4 weeks old and adolescents ≤ 18 years 
old according to body weight.3,4
Body weight and age Raltegravir dose (mg) to be administered
Granules  
for suspensiona
Chewable  
tabletsa
Film-coated tablets
≥ 3 to < 4 kg and ≥ 4 wks old 20 mg twice daily
≥ 4 to < 6 kg and ≥ 4 wks old 30 mg twice daily
≥ 6 to < 8 kg and ≥ 4 wks old 40 mg twice daily
≥ 8 to < 11 kg 60 mg twice daily
≥ 11 to < 14 kg 80 mg twice daily 75 mg twice daily
≥ 14 to < 20 kg 100 mg twice daily 100 mg twice daily
≥ 20 to < 25 kg 150 mg twice daily
≥ 25 to < 28 kg 150 mg twice daily 400 mg twice daily
≥ 28 to < 40 kg 200 mg twice daily 400 mg twice daily
≥ 40 kg 300 mg twice daily 400 mg twice daily
a The weight-based dosing recommendation is based on approximately 6 mg/kg/dose twice daily.
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but detectable during this period (50 to 200 copies/mL). When the boy turned 6 years old, 
the raltegravir dose was increased to 100 mg three times a day. C
trough
 levels remained 
adequate and plasma HIV-1 RNA was undetectable (<50 copies/mL) for over a year. 
The dosing schedule was then simplified to 150 mg twice daily following a weight gain to 
approximately 25 kg. TDM was performed and intensive pharmacokinetic sampling was 
scheduled. C
trough
 was 0.06 and 0.10 mg/L in respectively the morning and evening, C
max
 
was 4.16 mg/L and area under the curve up to 12 hours after intake (AUC
0-12h
) was 10 mg·h/L 
calculated by noncompartmental analysis by WinNonlin/Phoenix version 6.3 (Pharsight 
Corporation, St. Louis, MO, USA). These pharmacokinetic parameters were in line with 
geometric mean values observed in children in the age group of ≥6 to <12 years who 
used the chewable tablets in a mean dose of 6.47 mg/kg (cohort IIB, IMPAACT P1066 
study).8 The patient remained on raltegravir 150 mg chewable tablets twice daily, 
combined with tenofovir, lamivudine, and ritonavir-boosted lopinavir. His plasma HIV-1 
RNA load is still undetectable. 
Raltegravir pharmacokinetics in children
Raltegravir was the first INSTI approved by the FDA and EMA for treatment of HIV infection 
in the pediatric population in combination with other antiretroviral agents. In December 
2011, raltegravir was approved by the FDA for children and adolescents (age group 2-18 
years) followed by an additional change of the label to include infants ≥ 4 weeks of age 
and ≥ 3 kilogram in December 2013.3 EMA approval for the age group 2-18 years and 
infants ≥ 4 weeks of age and ≥ 3 kilogram was obtained in December 2012 and June 2014 
respectively.4 The approved dose recommendations in the pediatric population are 
displayed in Table 1. The primary study to support its use in the pediatric population is a 
phase I/II open-label multicenter trial (protocol P1066) in treatment-experienced, integrase 
inhibitor-naive children and adolescents ranging from ≥ 4 weeks to ≤ 18 years of age.3,6 
The clinical trial was conducted by the International Maternal Pediatric Adolescents Aids 
Clinical Trials (IMPAACT) network and designed to evaluate pharmacokinetics, safety, 
tolerability ,and efficacy of 48 weeks of raltegravir. All subjects were enrolled in 6 cohorts with 
5 different age groups and three formulations of raltegravir. Cohort I (≥12 years to <19 years 
of age), and cohort IIA (≥6 to <12 years of age) were assigned to receive film-coated 
poloxamer adult tablets. Cohort IIB (≥6 to <12 years of age), and cohort III (≥2 to <6 years 
of age) were assigned to receive ethylcellulose chewable tablets. Cohort IV (≥6 months to 
<2 years of age), and cohort V ( ≥4 weeks to <6 months of age) were assigned to receive 
granules for oral suspension. The study was conducted in two stages: (I) evaluation of 
intensive pharmacokinetics (PK) and short term safety data for dose selection and (II) 
assessment of long-term safety and efficacy data. Enrolment began with cohort I and 
progressed to the younger cohorts once raltegravir dose requirements were determined 
for this age group and considered acceptable in terms of safety and tolerability. Cohorts IV 
and subsequent cohort V were opened for inclusion after the pharmacokinetic data in 
the older cohort was fully evaluated. Therefore, the application to add the younger age 
groups (≥4 weeks <2 years) to the product labeling of raltegravir was done in a later stage. 
The PK objective was to achieve a PK profile similar to the approved raltegravir dosage of 
400 mg twice daily (film-coated tablet) in adults. The geometric mean of the specific PK 
target included the AUC
0-12h
 between 6.2 and 11 mg·h/L and a geometric mean 12-hours 
post-dose concentration (C
12h
) exceeding 0.015 mg/L.3 The AUC target range was based 
on values observed in phase 2 trials (Merck protocol 004) in HIV-infected adults with an 
AUC geometric mean value of 6.3 mg·h/L for raltegravir 400 mg twice daily monotherapy 
and 11.2 mg·h/L for raltegravir in combination with tenofovir and lamivudine.14-16 The 
threshold of 0.015 mg/L corresponds with the in vitro concentration at which 95% of 
virological replication is inhibited (IC
95
 value).
Table 2   Raltegravir steady-state pharmacokinetic parameters following final 
 recommended doses of granules for oral suspension, chewable tablets,  
and film-coated tablets twice daily in HIV-infected children in different age 
groups from ≥ 4 weeks to ≤ 18 years and HIV-infected adults.6, 14, 17
Age group  
by formulation
n Mean Geometric mean (CV%)
Dose 
(mg)
Dose 
(mg/kg)
AUC0-12h 
(mg·h/L)
Cmax
b 
(mg/L)
C12h 
(mg/L)
Granules for suspension
≥ 4 wks to < 6 m (Cohort V) 11 31.4 5.70 9.9 (40) 0.0518 (68)
≥ 6 m to < 2 y (Cohort IV) 8 51.3 5.93 8.8 (34) 0.0481 (52)
Chewable tablet
≥ 2 to < 6 y (Cohort III) 12 89.6 6.24 8.0 (59) 4.33 (57) 0.0316 (56)
≥ 6 to < 12 y (Cohort IIB) 10 230 6.47 10.0 (34) 4.66 (53) 0.0576 (88)
Film-coated tablet
≥ 6 to < 12 y (Cohort IIA) 11 400 13.4 7.0 (120) 2.14 (130) 0.1094 (221)
≥ 12 to ≤ 18 y (Cohort I) 11 391 9.28 7.0 (98) 1.78 (95) 0.1478 (78)
Adults, monotherapya 6 400 - 6.3 2.00 0.0629
Adults, TDF + 3TCa 6 400 - 11.2 3.82 0.1063
a CV% unknown.
b C
max
 values not reported for Cohort IV and V. 
Micromolar values were converted to mg/L by multiplying by 0.4444 (molecular weight of raltegravir is 444.4 g/mol). 
Abbreviations: 3TC, lamivudine; CV%, percent coefficient of variation; AUC
0-12h
, area under the plasma concentra-
tion-time curve up to 12 hours after intake; C
max
, maximum plasma concentration; C
12h
, plasma concentration 12 hours 
after intake; wks, weeks; m, months; y, years; TDF, tenofovir.
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Intensive 12-hour PK sampling during stage I of the P1066 trial was performed predose 
and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after observed intake of the raltegravir dose on an 
empty stomach. Additional sparse PK sampling was performed at intervals until week 48. 
Table 2 shows the results of the pharmacokinetic parameters of raltegravir for cohort I to 
V after intensive PK sampling at the final recommended dose that met the prespecified PK 
targets for AUC
0-12h 
and C
12h
.6,15-17 The PK parameters of raltegravir in HIV-infected adults 
from the Phase 2 study (Merck protocol 004) on which the PK-objective for AUC
0-12h
 in the 
P1066 trial is based, are added to Table 2 for comparison.14 These small cohorts of 
HIV-infected patients (n=6) have used raltegravir 400 mg twice daily monotherapy or 
raltegravir with a background treatment with tenofovir and lamivudine. 
The background antiretroviral treatment at the time of intensive PK sampling during stage I 
of the study for Cohorts I to III was not specifically reported by Nachman et al.6 Overall the 
most common concomitant antiretroviral agents were tenofovir (47.9%), ritonavir (as 
booster, 49%), lamivudine (41.7%), lopinavir/ritonavir (40.6%), and darunavir (39.6%) with 
few differences across cohorts I to III.6 
All cohorts had average C
12h
 values above the IC
95
 value of 0.015 mg/L. The lowest 
geometric mean C
12h
 value was 0.0316 mg/L and observed in cohort III with children 
(n=12) from ≥ 2 to < 6 years of age using the chewable tablets in a mean dose of 6.24 mg/kg. 
This C
12h
 value is approximately half of that observed in adults on monotherapy with 
raltegravir 400 mg twice daily and approximately one third of the values in adults who use 
raltegravir with an antiretroviral backbone of tenofovir and lamivudine. The AUC
0-12h 
in cohort III was 8.0 mg·h/L which was well within the range of the PK target from 
6.3-11.2 mg·h/L in adults (Table 2). 
An important question is whether the downward trend in mean C
12h
 in the younger age 
groups is clinically relevant. Results from the QDMRK study in treatment-naive adults with 
800 mg raltegravir once daily versus 400 mg raltegravir twice daily indicate that the C
trough
 
values (which is C
12h
 for twice daily dosing) and not the AUC is best correlated with 
efficacy.18 Although it was not possible to identify a robust threshold, the available PK data 
in the once-daily treatment arm in the QDMRK study suggest a threshold value of 0.020 
mg/L, which is just above the IC
95
 value of 0.015 mg/L. In all cohorts in the IMPAACT P1066 
trial mean C
12h
 values were above 0.015 mg/L, the PK objective for C
12h
. However, no details 
on the number of individual patients in the intensive PK group with C
12h
 concentrations 
below 0.015 mg/L or 0.020 mg/L were reported by Nachman et al.6 This information is 
available in the Assessment Reports from the EMA for the chewable tablets and the 
granules for suspension and displayed in Table 3.3,6 Data from the QDMRK study with 
treatment arms of 400 mg twice daily versus 800 mg once daily are added to Table 3 for 
comparison.3,6,18 The QDMRK study showed that failure to achieve an HIV-1 RNA <50 
copies/mL appeared predominantly at high baseline HIV RNA load and was associated 
with lower values of geometric mean C
trough
 in the 800 mg once-daily arm. In cohort III 
2/11 patients (17%) had a C
12h
 level <0.020 mg/L compared to 12/22 patients (55%) in 
the 800 mg once-daily treatment arm in adults. Although the patient group in cohort III 
(≥2 to <6 years of age, chewable tablet) seems to contain the highest percentage of 
patients with low C
trough
 levels, it is not possible to draw any conclusions based on the results as 
shown in Table 3. The number of patients in the intensive PK sampling group is limited 
and one of the two patients in cohort III <0.020 mg/L was not an actual measured value 
but extrapolated from 8 hours postdose which could have been an underestimated value. 
In the IMPAACT 1066 trial additional sparse PK sampling was performed at intervals until 
week 48 and compared with the sparse PK data in the QDMRK study in the EMA 
Assessment report of the chewable tablets.6 The results of the sparse PK sampling in 
cohort I to III showed that the percentage of patients with C
trough
 levels <0.020 mg/L were 
2% (n=50) in cohort I, 0% (n=2) in cohort IIA, 18% (n=11) in cohort II B and 11% (n=19) in 
cohort III compared to 27% (n=245) in the once daily 800 mg treatment arm in QDMRK. 
Cohort IIB (≥6 to <12 years of age, chewable tablets) had the highest percentage (18%) 
of patients with C
trough
 values <0.020 mg/L which was considerable lower ( 0%) in the 
Table 3   Geometric mean trough values of raltegravir and corresponding proportion  
of patients with a C
trough
 below 0.020 mg/L for each cohort (I-V) of the IMPAACT 
study 1066 and both treatment arms of Protocol 071 (QDMRK).15, 17
Cohort or study arm:
(age group and formula-
tion)
N Dose Geometric Mean Ctrough 
in mg/L (%CV)
N (%) of patients
<0.020 mg/L
Granules for suspension
≥4 wks to <6 m (Cohort V) 11 5.70 mg/kg 0.0518 (68) 1 (9%)
≥6 m to <2 y (Cohort IV) 8 5.93 mg/kg 0.0481 (52) 0 (0%)
Chewable tablet
≥ 2 to <6 y (Cohort III) 12 6.24 mg/kg 0.0316 (56) 2 (17%)
≥ 6 to <12 y (Cohort IIB) 10 6.47 mg/kg 0.0576 (88) 0 (0%)
Film-coated tablet
≥6 to <12 y (Cohort IIA) 11 13.4 mg/kg 0.1094 (221) 1 (9%)
≥12 to ≤18 y (Cohort I) 11 9.28 mg/kg 0.1478 (78) 0 (0%)
Adults, twice daily QDMRK 20 400 mg BID 0.1142 (167) 1 (5%)
Adults, once daily QDMRK 22 800 mg QD 0.0178 (111) 12 (55%)
Abbreviations: BID, two times a day; QD, once a day; CV%, percent coefficient of variation; TDF, tenofovir; 3TC, 
lamivudine.
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intensive PK group of cohort IIB (both included only 11 patients). In the intensive PK group 
the C
12h
 levels were measured 12 hours after observed intake of the raltegravir dose 
whereas the sparse PK samples are collected after unobserved intake. Therefore raltegravir 
plasma concentrations <0.010 mg/L, which is the LLOQ in the IMPAACT trial, were 
considered as missing values assuming these were the result of nonadherence rather than 
suboptimal dosing.15 It is unclear whether this assumption is correct and also based on 
adherence data and pill count. 
Discussion
We presented a case of a 4-year-old patient with first-line virological failure who switched 
to an antiretroviral regimen including raltegravir chewable tablets in the recommended 
dosage of 100 mg (approximately 6 mg/kg) twice daily. With TDM of raltegravir, inadequate 
raltegravir trough plasma concentrations (< 0.014 mg/L) were repeatedly measured. 
Shortening the dose interval is considered the most successful approach to increase 
trough levels to acceptable values. Therefore the raltegravir dose was adjusted from 100 
mg twice daily to 100 mg three times daily. This intervention was successful as follow-up 
TDM showed adequate plasma levels and a good clinical response without adverse 
events. The dosage was further optimized to 75 mg three times daily with remaining 
adequate C
trough
 levels. At the age of 7 the patient was successfully switched back to a 
normal twice-daily regimen of 6 mg/kg raltegravir chewable tablets. 
We do not have a good explanation why the raltegravir plasma concentrations were too 
low in this patient at the age of 4. Self-reported adherence was good and low C
trough
 levels 
were also measured after observed intake of raltegravir in the hospital when intensive PK 
sampling was planned. The patient did not use concomitant medication that is known to 
influence the pharmacokinetics of raltegravir other than tenofovir which gives a clinically 
not relevant increase in the exposure to raltegravir in adults.14 
Information on the PK of raltegravir in children and subsequent dose selection is limited 
to the results of the IMPAACT P1066 study published by Nachman et al. with some 
additional data in the Clinical Pharmacology and Assessment reports by the FDA and 
EMA.6,15-17 The results show that the lowest mean C
12h
 value (0.0316 mg/L) in this study was 
observed in children using the chewable tablets in the age group ≥2 to <6 years old, 
which is the age group of our patient. In this small cohort the number of individual 
patients with C
12h
 levels <0.020 mg/L after observed intake was the highest (2/12 patients, 
17%). After sparse PK sampling this percentage was 11% (2/19 patients). This could be an 
underestimation as plasma concentrations below <0.010 mg/L were considered as 
missing values assuming these were the result of non-adherence rather than suboptimal 
dosing. Although it is not possible to draw any definite conclusions due to the limited 
number of included patients, it seems that some young patients, including our patient, fail 
to reach adequate trough levels of raltegravir when using the recommended dosage of 
6 mg/kg raltegravir chewable tablets twice daily.
 The evaluation of intensive PK in children and dose selection in the IMPAACT P1066 
study was based on two PK objectives: a geometric mean C
12h
 >0.015 mg/L (IC
95
) and a 
geometric mean AUC based on PK data in adults (6.2-11 mg·h/L). Although in general it is 
an acceptable approach to evaluate the PK in children based on PK targets in adults, one 
could question whether the chosen AUC is an appropriate target for the pediatric 
formulations of raltegravir as these new formulations are not considered bioequivalent to 
the film-coated tablet and have a different PK profile. A bioequivalence single-dose study 
in healthy adults showed that both the chewable tablets and the granules for oral 
suspension demonstrate higher AUC
 
and peak plasma concentrations (C
max
) with similar 
C
12h
 values compared to the film-coated tablet.19 The geometric mean ratios (GMRs) and 
90% confidence intervals (CIs) of the chewable tablet 4x 100 mg versus the film-coated 
tablet 400 mg when taken in a fasted state were 3.22 (2.37-4.38) for C
max
, 1.78 (1.47-2.15) for 
AUC
0-12h 
and 0.90 (0.70-1.18) for C
12h
. 
 This may explain why the geometric mean C
12h
 level in cohort III (0.0316 mg/L) was 
lower compared with those in adults using the film-coated tablet while the observed 
AUC in cohort III was within the adult target range. The PK objective for C
12h
 was met 
because the geometric mean C
12h
 level in cohort III is above 0.015 mg/L (IC
95
). However, 
large interindividual variability in PK was observed in all cohorts which is consistent with 
the known PK profile of raltegravir.20-22 Therefore it is not surprising that some patients 
have C
12h
 values that we would consider too low (<0.020 mg/L) in clinical practice despite 
a mean value that is 2-fold higher than the IC
95
.
The pharmacokinetics of the chewable tablets were also studied in children from ≥ 6 to 
<12 years who used a mean dosage of 6.47 mg/kg raltegravir twice daily. In this cohort the 
AUC
0-12h 
and C
12h
 values were approximately 1.3 and 1.8 times higher than in children from 
≥2 to <6 years who used a similar dosage of 6.24 mg/kg raltegravir twice daily. In the case 
presented we repeatedly observed very low trough levels at the age of 4 when the patient 
used 6 mg/kg twice daily, while plasma concentrations returned to normal values when 
the patient used the same weight-based dosage at the age of 7. This could suggest that 
age-related differences in metabolism of raltegravir chewable tablets lead to distinctly 
lower C
12h
 values in children in the age group ≥2 to <6 years of age as compared with 
children ≥6 to <12 years of age. It is known that developmental changes can alter the 
pharmacokinetics of drugs.11,12 
Raltegravir is primarily metabolized by glucuronidation via UDP-glucuronosyltransferase 
(UGT) 1A1 in the liver, with minor contributions from UGT1A3 and UGT1A9.23 Considerable 
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differences occur in hepatic glucuronidation during development from fetal to adult liver. 
Currently, there is no evidence supporting the hypothesis that hepatic glucuronidation of 
raltegravir is increased in the age group 2 to 6 years old compared to older children and 
adults. The enzyme activity of UGT1A1, which is also responsible for bilirubin glucuronidation, 
is still immature after birth, especially in preterm neonates, but reaches adult levels within 
3 to 6 months.24,25 In contrast, results from physiology-based pharmacokinetic modelling 
suggest that hepatic clearance of UGT1A9 substrates could be higher at younger age and 
drops to adult levels during late adolescence. Although these results should be interpreted 
with caution, it may explain why propofol which is over 50% glucuronidated by UGT1A9, 
shows higher clearance at 5 years of age compared to adults.26 UGT1A3 expression was 
not detected in fetal liver tissue but seems to be upregulated at approximately 6-12 
months of age.24 Developmental changes from one UGT-isoform cannot be extrapolated 
to others and there is still a lot to learn on the actual impact of these changes in hepatic 
glucuronidation on pediatric drug clearance in vivo in different age groups.12 
We did question whether the oral bioavailability of raltegravir could be decreased if the 
chewable tablets are swallowed whole instead of chewed. The patient presented in our 
case had always swallowed the chewable tablets. The product labeling indicates that the 
chewable tablets can be either chewed or swallowed whole. This is not supported by in 
vivo pharmacokinetic data, apart from a single steady-state C
12h
 from a subject in cohort IIB 
of 0.0480 mg/L which was judged to be normal compared to the geometric mean C
12h
 
value in cohort IIB of 0.0576 mg/L.15 Given the product composition, characteristics of the 
active ingredient, and in vitro performance in multiple dissolution tests (including its rapid 
disintegration), in vivo drug release following ingestion would be expected to be similar 
chewed or swallowed (Biopharmaceutics Product Quality Review by the FDA).16 Although 
there is no reason to believe that the oral bioavailability of the chewable ethylcellulose 
tablets is different when swallowed whole, one may expect raltegravir peak plasma 
concentrations to be lower and occur later compared to chewing. Therefore we cannot 
rule out that this has contributed to the lower raltegravir trough plasma concentrations 
measured. 
Summary and conclusion
Raltegravir represents a new antiretroviral drug class in pediatric HIV care. Currently, clinical 
experience with raltegravir chewable tablets is limited. In this context, we described 
our experience with dose optimization of raltegravir chewable tablets in a 4-year-old 
HIV-infected patient based on TDM of raltegravir. Despite following the approved dose 
recommendations for raltegravir chewable tablets in children, we repeatedly measured 
low raltegravir trough plasma concentrations. To ensure adequate raltegravir trough levels 
we changed successfully from a twice-daily dose regimen to an off-label three-times daily 
regimen for a period of 2.5 years. At the age of 7 the patient could switch back to a normal 
twice-daily dosage of raltegravir chewable tablets with remaining adequate raltegravir 
plasma concentrations. 
 We reviewed the available literature and information on the pharmacokinetics of 
raltegravir in children which has resulted in the approved dose recommendations for the 
use of raltegravir in children ≥4 week to <18 years.6,15-17 In a small cohort of children from 
≥2 to <6 years who used the chewable tablets, the mean raltegravir trough level was 
lower compared to the trough levels observed in other age groups or reference values in 
adults.6,15,18 Based on these pharmacokinetic data we are concerned that some individual 
young patients who use chewable tablets in the recommended dose might experience 
suboptimal trough levels in clinical practice as illustrated by our case. This could especially 
be problematic in children who have a high viral load before starting a raltegravir-based 
regimen. In these patients TDM could be a useful tool to monitor and if necessary adjust 
the raltegravir dose regimen. Additional well-controlled post-marketing studies on the 
pharmacokinetics, safety, and efficacy of raltegravir in HIV-infected children between 
2 and 6 years of age are needed to reassess optimal dosing in this age group.
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Introduction
Knowledge of the clinical pharmacology of antiretroviral drugs is essential for their safe 
and effective use within the HIV-infected patient population. Drug-drug interactions, as 
well as intra- and interpatient variability in the pharmacokinetics of antiretroviral agents 
are some of the main causes for suboptimal drug exposure or toxicity. This could 
potentially lead to treatment failure and adherence issues in HIV-infected patients.
 
Raltegravir obtained accelerated approval in 2007 as the first of a new class of antiretroviral 
agents called HIV-1 integrase inhibitors. Immediately after the introduction of raltegravir 
with its new mechanism of action it played an important role in HIV management.
The general aim of this thesis was to study the clinical pharmacology of the HIV integrase 
inhibitor raltegravir to optimize its safe and effective use in HIV-infected patients in clinical 
practice. The first part of this thesis focused on pharmacokinetic drug-drug interactions 
between raltegravir and other frequently used concomitant medication. The pharmacoki-
netics of raltegravir in pregnant HIV-infected women and the application of therapeutic 
drug monitoring (TDM) of raltegravir in special patient populations were addressed in the 
second part of this thesis.
In the present chapter the results are discussed focussing on the following main topics: 
pharmacokinetic drug-drug interaction studies, the variability in the pharmacokinetics of 
raltegravir and potential influencing factors, the relationship between the pharmacoki-
netics and the pharmacodynamics of raltegravir, and the role of TDM in clinical practice. 
The general discussion will conclude with some closing remarks.
Pharmacokinetic research
The ultimate goal of drug development is to deliver the right drug in the right dose to the 
right patient. This requires detailed knowledge of the relationship between the dose and 
the clinical response in a variety of patients. Understanding what goes on between dose 
and response by use of pharmacokinetics gives insight on how to choose the dosages at 
which to evaluate a drug and on how best to use a drug in a (sub)population and in 
individual patients. Research on the pharmacokinetics of a new compound is an important 
part of drug development. Figure 1 gives a schematic overview of the application of 
 pharmacokinetic research during the different phases of drug development.1
To characterize the pharmacokinetics of the investigational drug and its relationship with 
efficacy and safety, a diversity of studies are performed throughout drug development. 
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Intensive pharmacokinetic sampling schedules are used in single and multiple dose- 
ascending studies, in trials investigating the bioavailability of the drug, drug-drug or 
food-drug interactions, or the pharmacokinetics in special patient populations. In long- 
term phase II/III clinical trials in patients, extensive pharmacokinetic assessment is usually 
only feasible in a small subset of patients or over a limited period of time. Sparse pharma-
cokinetic sampling is obtained from as many patients at the time of clinical assessments 
and combined with rich pharmacokinetic data to characterize the relationship between 
drug exposure and efficacy in larger populations. Similar strategies apply for the 
 exposure-safety relationship to evaluate the risk-benefit balance.2
At the moment of drug approval there is still a degree of uncertainty about the safety and 
efficacy in daily clinical practice, including its value within the current treatment options. 
Especially when a drug has obtained accelerated approval, such as raltegravir. This is a well 
known and accepted consequence of drug evaluation before approval during which 
there is a relatively short follow-up with small study populations. Furthermore the setting 
of the clinical trial and characteristics of the study population are often seen as more 
idealistic than one would encounter in actual practice. After the investigational drug has 
been approved, pharmacokinetic research is continued in the post-approval phase to 
increase the knowledge on the pharmacokinetics of the drug needed to optimize or 
extend its use in clinical practice in a variety of patients. 
Drug-drug interaction studies
General aspects
The overall objective of drug interaction studies is to determine whether any interactions 
occur that are sufficiently large to necessitate dose adjustment, the need for additional 
therapeutic monitoring, or whether the combination should be contraindicated. 
Knowledge about the interaction potential of a newly developed drug should be gained 
as early as possible to assure safety during clinical drug development and is generally 
required before the drug is being used in phase III studies. The drug interaction potential 
is usually investigated through in vitro studies followed by in vivo studies in healthy 
volunteers. The in vivo studies that are performed at this stage generally have a mechanistic 
approach and are performed with known strong or moderate inhibitors or inducers of 
enzymes that are involved in the metabolism of the particular drug. Other studies may be 
performed by the pharmaceutical industry with commonly used comedication that may 
be expected to interact with the developed new agent. 
Phase II enzymes, which are enzymes that are involved in conjugation reactions, such as 
glucuronic acid, sulfonates, and glutathione, have historically gained less attention in 
drug-interaction evaluations than phase I metabolizing CYP enzymes. Nowadays there is 
deservedly so an increased interest in drug-drug interactions involving UDP-glucuronosyl-
transferase (UGT)-enzymes because several UGT isoforms play an important role in the 
biotransformation of many drugs. If glucuronidation is the predominant pathway for drug 
elimination, as is the case for raltegravir, in vitro studies will be conducted at an early stage 
of drug development using recombinant human UGTs to identify which UGT isoforms 
are responsible for metabolism. However, determination of the contribution of each UGT 
isoform to the overall elimination is not as straightforward as that for CYP enzymes 
because of the absence of data on the abundance of these isoforms in drug eliminating 
organs and the lack of specific and selective inhibitors. 
Although the evaluation of potential drug-drug interactions is part of the drug 
development and approval process, many questions remain unanswered or are still not 
discovered until after the introduction into clinical care. The importance of this issue is 
illustrated by the fact that half of the drugs withdrawn for safety reasons from the US 
market were associated with important drug-drug interactions. Therefore additional phar-
macokinetic drug-drug interaction studies are often needed post-approval to optimize 
safe and effective use of drug-treatment combinations.3-5 
Methodological aspects
The recommended design for pharmacokinetic drug-drug interaction studies is a 
crossover or sequential design in which the same subjects receive the investigational 
Figure 1  Application of pharmacokinetics (PK) in Phase I to III of drug development.
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drug alone (reference treatment) and with the potential interacting drug (test treatment). 
The advantage of a crossover or sequential design is that it allows a within-subject (or 
intrasubject) comparison between the reference and the test treatments, as each subject 
serves as its own control. In a crossover design, subjects are randomly assigned to receive 
a sequence of treatments, which contain all the treatments in the study. Therefore it is 
possible to correct for bias emerging from period effects. In a sequential design the 
treatment periods or sequences are not randomized but fixed. 
Alternative strategies such as a parallel group design are usually chosen when a crossover 
or sequential design is not feasible. Although not recommended by the regulatory 
authorities it is possible to use pharmacokinetic data that is collected as part of a clinical 
trial that was not primarily designed to investigate a drug-drug interaction. In that case 
the collected pharmacokinetic data is usually compared with historical controls. The 
quality and evidence of those trials for the purpose to evaluate drug-drug interactions is 
low when compared with a crossover or sequential trial. It does, however, provide insight 
in potential interactions that may otherwise not have been investigated and it could be 
an incentive to perform a high-quality drug-drug interaction study.4-6 
Drug-drug interaction studies are usually performed in healthy adults unless for specific 
tolerability and safety reasons patients are preferred. Historically the number of subjects in 
drug interaction studies have been small. The number of included subjects should be 
determined taking into account the intrasubject variability in pharmacokinetics, and the 
magnitude of the effect that is considered to be clinically relevant. It is recommended to 
analyze the pharmacokinetic data obtained in the drug-drug interaction studies according 
to an equivalence approach. Results should be reported as geometric mean ratio (GMR) 
and 90% confidence intervals (CIs) of the observed pharmacokinetic parameters of the 
investigational drug with the interacting agent versus without the interacting agent. The 
confidence intervals give an estimate of the distribution of the observed GMR as well as 
provide insight in the probability of the interaction. Tests of significance (p <0.05) are not 
appropriate to use, as small but consistent differences in exposure can be statistically 
significant but not clinically relevant. 
For the interpretation of the results specific boundaries or clinical equivalence intervals 
are used to indicate whether an observed interaction is clinically relevant. The standard 
equivalence range used for the interpretation of the GMR and the 90% CI is 0.80 to 1.25 (or 
80-125%). When GMR and the 90% CI fall entirely within this range one can conclude that 
no clinically relevant interaction is present. This is, however, a conservative approach as in 
fact the relationship between the pharmacokinetic parameters and the pharmacodynamic 
response (efficacy and toxicity) defines whether a pharmacokinetic interaction is considered 
clinically relevant.6 A wider equivalence range could be considered for highly variable 
drugs (intrasubject coefficient of variation >30%), if this range in pharmacokinetic 
parameters is not considered to be clinically meaningful.7
Overview studies with raltegravir
The risk for drug-drug interactions in HIV-infected patients is likely to be reduced if an 
antiretroviral regimen is chosen with little propensity to interact with concomitant 
medication. This has become even more relevant as an increasing number of HIV-infected 
patients is being treated with multiple drugs. In contrast with many other antiretroviral 
agents raltegravir it is not known to inhibit or induce CYP450 enzymes which is a common 
hepatic metabolic route for many drugs. Therefore, raltegravir may be a good choice as 
antiretroviral agent if potential pharmacokinetic interactions are a concern. However, 
raltegravir could also be the victim drug, in other words the drug affected by the drug-drug 
interaction. Reduced exposure to raltegravir may have serious consequences for the 
development of resistance and the occurrence of virological failure. Furthermore, the 
metabolic profile of raltegravir or its transport via drug transporters, and therefore its role 
in potential drug interactions, may not be fully elucidated. 
In Table 1 an overview is given of all pharmacokinetic drug-drug interaction studies in 
human, in which the effect of a drug on the pharmacokinetics of raltegravir has been 
investigated. In total 27 different potential interacting agents (or combinations) were 
studied in 35 drug-drug interaction studies in healthy volunteers and HIV-infected 
patients. The potential interacting agents represent 9 different therapeutic groups. 
Among the largest therapeutic groups are the antiretroviral agents, the antivirals for 
the treatment of hepatitis C virus (HCV), and the antimycobacterials. Approximately 
60% of the drug-drug interaction trials were conducted by the pharmaceutical industry, 
mostly by Merck, the manufacturer of raltegravir. The remaining 40% of the trials fall 
into the category investigator-initiated academic research. Although investigator-initiated 
research is not industry-driven, the funding that is required to perform this type of 
 pharmacokinetic research is often (partly) provided by the pharmaceutical industry. 
Due to the lag time between the availability of the study results and the actual publication 
date in peer-reviewed journals, it is difficult to distinguish between drug-drug interaction 
studies performed as part of drug development and the studies that were conducted 
after the introduction of raltegravir onto the market at the end of 2007. Assuming that the 
publications in the year 2008 and 2009 by Merck were part of their drug development 
program, approximately two-thirds of the current drug-drug interaction studies can be 
labelled as post-approval studies. 
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Table 1  Overview of the pharmacokinetic drug-drug interaction studies with raltegravir.
Co-medication  
per therapeutic group
Design, Single Dose (SD)/ 
Multiple Dose (MD)a
Study population and number  
for PK evaluation
Effect (GMR and 90% CI)b of 
co-medication on raltegravir PK
Mechanism / Conclusion Year,  
sponsor 
Ref.
Analgesics
buprenorphine/naloxone Comparison of RAL MD + 
buprenorphine and naloxone with 
historical controls of RAL alone
12 opioid-dependent HIV-uninfected 
subjects
GM (95% CI):
AUC
0-12h
 5.54 (3.60-8.54 )mg·h/L
C
max
 1.07 (0.640-1.78) mg/L
C
12h
 0.196 (0.081-0.477) mg/L
No significant effect. 2013, II, $ 64
Antidepressants
citalopram 
(Chapter 3)
C/S, MD, citalopram 20 mg 22 healthy volunteers AUC
0-12h
 0.77 (0.50-1.19)
C
max
 0.64 (0.38-1.09)
C
12h
 1.03 (0.71-1.50)
No clinically relevant decrease in RAL 
exposure.
II, $ 65
Antimycobacterials
rifabutin C/S, MD, rifabutin 300 mg QD 19 healthy volunteers AUC
0-12h
 1.19 (0.86-1.63)
C
max
 1.39 (0.87-2.21)
C
12h
 0.80 (0.68-0.94)
Minor UGT1A1 inhibition. No clinically 
relevant effect. Could be an alternative 
for rifampicin.
2011, Merck 66
rifampicin Part I: C/S, RAL SD, rifampicin 600 mg 
QD
10 healthy volunteers AUC
0-∞
 0.60 (0.39-0.91)
C
max
 0.62 (0.37-1.04)
C
12h
 0.39 (0.30-0.51)
Significant reduction of C
12h
 due 
to strong induction of UGT1A1. 
Combination is not contraindicated but 
should be used with caution. 
2009, Merck 67
rifampicin Part II: C/S, MD, RAL 400 mg BID versus 
RAL 800 mg BID + rifampicin
18 healthy volunteers AUC
0-12h
 1.27 (0.94-1.71)
C
max
 1.62 (1.12-2.33)
C
12h
 0.47 (0.36-0.61)
See Part I (above). Doubling the dose 
of RAL compensates for the effect 
of rifampicin on RAL exposure but 
not fully on the effect on C
12h.
 Clinical 
studies are recommended.
2009, Merck 67
rifampicin C/S, rifampicin intermittent dosing 3 
times per week + respectively RAL MD 
400 mg BID and 800 mg BID versus RAL 
400 mg BID alone as reference
16 healthy volunteers RAL 400 mg BID:
AUC
0-12h
 1.08 (0.71-1.66)
C
max
 1.16 (0.69-1.93)
C
12h
 0.60 (0.44-0.82)
RAL 800 mg BID:
AUC
0-12h
 0.77 (0.50-1.19)
C
max
 0.64 (0.38-1.09)
C
12h
 1.03 (0.71-1.50)
 
% subjects C
12h
 ≤ 0.021 mg/L:
6% with RAL 400 mg BID alone, 25% 
with RAL 400 mg BID + rifampicin, 6% 
with RAL 800 mg BID + rifampicin 
Clinically relevant induction of 
UGT1A1. C
12h
 is significantly reduced 
by intermittent rifampicin when RAL 
normally dosed in 400 mg BID. It is 
recommended to increase RAL dosage 
to 800 mg BID until clinical efficacy data 
suggest otherwise.
2015, II, $ 68
rifapentine C/S, MD, rifapentine two dosing 
strategies: 900 once weekly and 600 
mg QD given 5 out of seven days 
16 healthy volunteers + 900 mg rifapentine once weekly:
AUC
0-12h
 1.71 (1.07-2.71)
C
max 
1.89 (1.04-3.44)
C
12h
 0.88 (0.62-1.25)
+ 600 mg rifapentine QD:
AUC
0-12h
 0.95 (0.59-1.53)
C
max 
1.02 (0.60-1.72)
C
12h
 059 (0.34-1.02)
UGT1A1 is likely to be induced. 
Observed effect is dependent on 
dosing strategy.
Preferred regimen is 900 mg QD 
because the increase in exposure is well 
tolerated and C
12h
 was not significantly 
affected.
2014, II, $ 69
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Table 1  Continued.
Co-medication  
per therapeutic group
Design, Single Dose (SD)/ 
Multiple Dose (MD)a
Study population and number  
for PK evaluation
Effect (GMR and 90% CI)b of 
co-medication on raltegravir PK
Mechanism / Conclusion Year,  
sponsor 
Ref.
Antivirals HCV
boceprevir 
(Chapter 4)
C/S, RAL SD, boceprevir 800 mg TID 22 healthy volunteers AUC
0-12h
 1.04 (0.88-1.22)
 C
max 
1.11 (0.91-1.36)
No clinically relevant effect. 2013, II, $ 70
ABT-450 + ritonavir, 
ombitasvir, dasabuvir 
C/S, MD, RAL with emtricitabine + 
tenofovir
12-24 healthy volunteers ≤ 134% increase of AUC
0-12h
,
C
max
, C
12h
No dose adjustment recommended. 2014, Abbvie 71
faldaprevir C/S, MD, faldaprevir 240 mg QD 23 healthy volunteers AUC
0-12h
 2.72 (1.997–3.707)
C
max
 2.457 (1.685-3.584)
Moderate increase RAL exposure, 
probably due to UGT1A1 inhibition. No 
unexpected safety concerns. 
2015, Boehringer 
Ingelheim
72
grazoprevir C/S, MD, grazoprevir 200 mg QD 12 healthy volunteers AUC
0-12h
 1.43 (0.89-2.3)
C
max 
1.46 (0.78-2.73)
C
12h
 1.47 (1.08-2.00)
Minor UGT1A1 inhibition. No clinically 
significant effect. No dose adjustments 
necessary. 
2014, Merck 73
lersivirine C/S, MD, lersivirine 1000 mg QD 16 healthy volunteers AUC
0-12h
 0.85 (0.64-1.11)
C
max 
0.71 (0.48-1.06)
C
12h
 1.25 (1.03-1.53)
Mechanism unknown. No clinically 
relevant effect. No dose adjustment 
necessary.
2012, Pfizer 74
ribavirin C/S, RAL MD, ribavirin 800 mg SD 14 healthy volunteers GMR (95% CI):
AUC
0-12h
 1.12 (0.74-1.70)
C
max 
1.16 (0.73-1.86)
C
12h
 0.82 (0.36-1.85)
No effect. 2011, II, $ 75
Antivirals HIV
atazanavir RAL: C/S, SD 100 mg;
atazanavir: MD 400 mg (Part I) 
10 healthy volunteers AUC
 
1.72 (1.47-2.02)
C
max 
1.53 (1.11-2.12)
C
12h
 1.95 (1.30-2.92)
Inhibition UGT1A1. No clinically 
important increase in exposure/ 
no dose adjustments. Needs to be 
confirmed in HIV+ patients.
2008, Merck 23
atazanavir + ritonavir RAL: C/S, MD
atazanavir/ritonavir: MD 300/100 mg 
(Part II)
10 healthy volunteers AUC
0-12h
 1.41 (1.12-1.78)
C
max 
1.24 (0.87-1.77)
C
12h
 1.77 (1.39-2.25)
See above (part I), including possible 
minor UGT1A1 induction by ritonavir. 
2008, Merck 23
atazanavir C/S, 1 period, MD, atazanavir 300 mg 
BID
22 healthy volunteers AUC
0-12h
 1.536 (1.135-2.081)
C
max 
1.394 (0.990-1.964)
C
12h
 1.479 (1.083-2.020)
Increased exposure due to UGT1A1 
inhibition caused by atazanavir. 
Coadministration is safe and well 
tolerated.
2010, BMS + Merck 26
atazanavir Designed to compare PK RAL 400 mg 
BID with RAL 400 QD + atazanavir 400 
mg QD
22 healthy volunteers AUC
0-12h
 1.32 (0.62-2.81)
C
max 
1.37 (0.62-3.02)
C
12h
 1.49 (0.59-3.75)
Increased exposure RAL due to UGT1A1 
inhibition. This effect did not result in 
similar trough values of RAL 400 QD 
with atazanavir compared to RAL 400 
mg BID without atazanavir.
2010, II 24
atazanavir Designed to compare PK RAL 400 
mg BID with RAL 800 QD, both with 
atazanavir 600 mg QD
17 HIV-infected patients GM (95%CI) RAL 400 mg with atazanavir:
AUC
0-12h
 7.5 (5.4-10.5) mg·h/L
C
max 
1.9 (1.4-2.6) mg/L
C
12h
 0.09 (0.05-0.16) mg/L
Inhibition UGT1A1. PK parameters were 
not compared with raltegravir alone in 
a C/S design
2013, II 25
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Table 1  Continued.
Co-medication  
per therapeutic group
Design, Single Dose (SD)/ 
Multiple Dose (MD)a
Study population and number  
for PK evaluation
Effect (GMR and 90% CI)b of 
co-medication on raltegravir PK
Mechanism / Conclusion Year,  
sponsor 
Ref.
darunavir + ritonavir Single-arm, MD, darunavir/ritonavir 
800/100 mg QD
15 HIV-infected patients GM (95% CI)
AUC
0-12h 
3.05 (2.53-5.18) mg·h/L
C
max 
0.97 (0.84-2.27) mg/L
C
12h
 0.040 (0.030-0.080) mg/L
PK are lower than or equal to eference 
values, depending on the reference 
chosen. Conclusion: good PK profile. 
2013, II, $ 76
darunavir + ritonavir C/S, MD, darunavir/ritonavir 600/100 
mg BID
18 healthy volunteers included, 6 
completed
AUC
0-12h 
0.71 (0.38-1.33)
C
max 
0.67 (0.33-1.37)
C
12h
 1.38 (0.16-12.12)
Many dropouts due to adverse events 
(rash).
2008, Merck 77
efavirenz C/S, RAL: SD lactose formulation
Efavirenz: MD 
9 healthy volunteers AUC
0-∞ 
0.64 (0.52-0.80)
C
max 
0.64 (0.41-0.98)
C
12h
 0.79 (0.49-1.28)
Minor induction UGT1A1.
No clinically relevant effect.
2008, Merck 78
etravirine C/S, MD, etravirine 200 mg BID 10 healthy volunteers AUC
0-12h
 0.90 (0.68-1.18)
C
max
 0.89 (0.68-1.15)
C
12h
 0.66 (0.34-1.26)
Possibly induction UGT1A1. The effect 
is likely to be of no clinical importance.
2008, Merck and 
Tibotec
79
maraviroc C/S, fixed sequence, MD, maraviroc 300 
mg BID, range 0.80-1.25.
18 healthy 
volunteers
GMR (95%CI)
AUC
0-12h
 0.633 (0.410-0.976)
C
max 
0.668 (0.371-1.20)
C
12h
 0.724 (0.551-0.952)
No clinically relevant decrease in 
RAL exposure. Mechanism unknown 
but might be related to changes in 
absorption/first-pass metabolism.
2010, Pfizer 80
ritonavir C/S, RAL: SD lactose formulation
Ritonavir: MD
10 healthy 
volunteers
AUC
 
0.84 (0.70-1.01)
C
max 
0.76 (0.55-1.04)
C
12h
 0.99 (0.70-1.40)
No clinically relevant effect. 2008, Merck 78
tenofovir C/S, MD (Study A) 10 healthy volunteers AUC
0-12h 
1.49 (1.15-1.94)
C
max 
1.90 (0.76-4.77)
C
12h
 1.69 (1.21-2.54)
Increase in RAL exposure, mechanism 
unknown. No dose adjustments 
necessary.
2008, Merck 30
tenofovir + lamivudine C/S, MD (Study B) 6 HIV-infected patients received RAL 
400 mg BID
AUC
0-12h 
1.78 (0.86-3.66)
C
max 
1.64 (1.16-2.32)
C
12h
 1.03 (1.21-2.54)
Increase in RAL exposure, mechanism 
unknown. No dose adjustments 
necessary.
2008, Merck 30
tipranavir + ritonavir C/S, MD, tipranavir/ritonavir 500/200 
mg BID
18 healthy 
volunteers
AUC
0-12h 
0.76 (0.49-1.19)
C
max 
0.82 (0.46-1.46)
C
12h
 0.45 (0.31-0.66)
Possible mechanism is UGT1A1 
induction by tipranavir. Despite 
substantial decrease of C
12h
, the 
combination may be administered 
without dose adjustments based on 
phase III efficacy data. 
2009, Merck 81
Calcium channel blockers
amlodipine C/S, MD 17 healthy volunteers AUC
0-12h
 1.39 (0.87-2.29)
C
max 
1.58 (0.84-3.09)
C
12h
 0.78 (0.57-1.04)
No clinically relevant effect. 2014, II, $ 82
156 157
Chapter 9 General discussion
Table 1  Continued.
Co-medication  
per therapeutic group
Design, Single Dose (SD)/ 
Multiple Dose (MD)a
Study population and number  
for PK evaluation
Effect (GMR and 90% CI)b of 
co-medication on raltegravir PK
Mechanism / Conclusion Year,  
sponsor 
Ref.
Drugs for acid related disorders
antacids (Maalox containing 
aluminium, magnesium)
C/S, SD 17 healthy volunteers included, 12 
completed 
AUC 1.08 (0.68-1.73)
C
max 
1.53 (0.9-2.60)
C
12h
 0.33 (0.26-0.42)
Combination of increased gastric pH 
(higher C
max
) and divalent metal ion 
binding (lower C
12h
), no conclusion.
2010, II 27
omeprazole C/S, RAL SD, omeprazol 20 mg QD 14 healthy volunteers AUC
0-12h
 3.12 (2.13-4.56)
C
max 
4.15 (2.82-6.10)
C
12h
 1.46 (1.10-1.93)
Increased bioavailability due to 
increased gastric pH. Based on Phase III 
safety data in HIV-infected patients no 
dose adjustments are necessary. 
2009, Merck 32
famotidine Unknown Unknown AUC ↑ 44 %
C
12u
 ↑ 6 %
C
max
 ↑ 60 %
No dose adjustments required. Merck 11
Lipid modifying agents
atorvastatin 
(Chapter 2)
C/S, MD, atorvastatin 20 mg QD 23 healthy volunteers AUC
0-12h
 1.01 (0.68-1.51)
C
max
 1.14 (0.70-1.86)
C
12h
 0.96 (0.69-1.32)
No effect. 2015, II, $ 83
ezetimibe C/S, MD, ezetimibe 10 mg QD 20 healthy volunteers AUC
0-12h 
1.16 (0.89-1.51)
C
max
 1.13 (0.81-1.58)
C
12h
 1.12 (0.72-1.74)
No significant effect on RAL PK. 2011, II, $ 84
pravastatin C/S, MD, pravastatin 40 mg QD 24 healthy volunteers AUC
0-12h 
1.13 (0.77-1.65)
C
max
 1.31 (0.81-2.13)
C
12h
 0.59 (0.39-0.88)
No clinically relevant effect 2010, II, $ 85
Other
Ginkgo biloba 
(Chapter 5)
C/S, RAL SD, Ginkgo biloba MD 18 healthy volunteers AUC
0-12h 
1.24 (0.97-1.58)
C
max
 1.44 (1.03-2.02)
No clinically relevant effect. 2012, II, $ 86
a Raltegravir dosage is 400 mg as a single dose or 400 mg twice daily (multiple dose) to reach steady-state plasma 
concentrations. If applicable, alternative dosages are mentioned in the table.
b Unless otherwise indicated. 
Abbreviations and symbols: AUC, area under the plasma concentration-time curve; BID, twice daily; C/S, crossover or 
sequential design; C
max
, maximum plasma concentration; C
12h
, plasma concentration 12 hours after intake of raltegravir; 
CI, confidence interval; GM, geometric mean; GMR, geometric mean ratio; II, Investigator-Initiated Research, $ Financial 
support by Merck; SD, single dose; MD, multiple dose; PK, pharmacokinetics; RAL, raltegravir; TID, three times daily; 
QD, once daily.
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Table 1 shows that, apart from a few exceptions, all drug-drug interactions were conducted 
with healthy volunteers by means of a crossover or sequential design. The average number 
of subjects that are included in the pharmacokinetic analysis is 16 subjects, with a 
minimum of 6 subjects and a maximum of 24 subjects. The sample size should be based 
on the intrasubject variability in the exposure to raltegravir and the effect that is considered 
to be clinically relevant. Therefore it is remarkable that in trials that are so similar in design, 
and research question, there is a 4-fold difference in the number of included subjects. 
The effect of therapeutic agents on the main pharmacokinetic parameters of raltegravir 
is in the majority of the trials presented as the GMR with 90% confidence intervals. 
Information on the sample size calculation and which clinical equivalence intervals were 
chosen is often missing in the published data. 
Summary of results
The main findings of our pharmacokinetic drug interaction studies in healthy volunteers 
in which we evaluated the effect of atorvastatin (Chapter 2, AVIATOR study), citalopram 
(Chapter 3, RECITAL study), boceprevir (Chapter 4, OPAL study) and Ginkgo Biloba 
(Chapter 5, GINGER study) on the pharmacokinetics of raltegravir are summarized in 
Figure 2. The GMR and 90% confidence interval is given of the main pharmacokinetic 
parameters of raltegravir with concomitant use versus the intake of raltegravir alone. 
The main pharmacokinetic parameter to evaluate with respect to pharmacokinetic 
drug-drug interactions is the exposure to raltegravir expressed as the area under the 
plasma concentration-time curve (AUC). Another important pharmacokinetic parameter 
is the maximum plasma concentration (C
max
). From a clinical perspective it is also important to 
know whether the trough plasma concentration (C
12h
) is influenced by the coadministered 
drug, as C
12h
 is currently seen as the most important parameter to evaluate with regard to 
virological efficacy.
The AUC of raltegravir is not significantly influenced by atorvastatin or boceprevir. The 
same applies to the other pharmacokinetic parameters of raltegravir when combined 
with atorvastatin or boceprevir. In combination with citalopram or Ginkgo biloba we 
observed, respectively a 23% decrease, and 24% increase in raltegravir exposure (AUC). 
This change in exposure is primarily caused by a change in the peak plasma concentrations 
(36% decrease with citalopram, and 44% increase with Ginkgo biloba) because the t
1/2
 of 
raltegravir did not change significantly. This would suggest that citalopram and Ginkgo 
biloba might change the oral bioavailability of raltegravir rather than influence its glucu-
ronidation.
Characterization of potential drug transporters involved in the transcellular transport of 
raltegravir has shown that raltegravir is a substrate of permeability glycoprotein (P-gp).8,9 
Active efflux mechanisms, such as P-gp, are responsible for transporting a broad range of 
compounds out of the intestinal epithelial cells back into the intestinal lumen and play an 
important role in oral drug absorption. An interesting hypothesis, which is discussed in 
more detail in Chapter 5, is that Ginkgo biloba may increase the oral bioavailability and 
subsequent C
max
 values by inhibition of P-gp. However, this hypothesis does not explain 
the decrease in C
max
 of raltegravir combined with citalopram, as in vitro research showed 
that citalopram might be a weak P-gp inhibitor and therefore is more likely to increase 
oral bioavailability instead of decrease.10 Perhaps a more plausible explanation for the 
difference we found in the C
max
 and AUC of raltegravir alone versus raltegravir with 
citalopram or Ginkgo biloba within subjects, is that this is a result of normal intrasubject 
variability in raltegravir pharmacokinetics instead of an effect caused by an interacting 
agent. This is supported by our findings that the mean change (increase with Ginkgo 
biloba, decrease with citalopram) we observed in raltegravir C
max
 was not a uniform effect in 
Figure 2  The effect of respectively atorvastatin, citalopram, boceprevir, and Ginkgo 
biloba on the pharmacokinetic parameters of raltegravir in healthy volunteers.
Abbreviations: AUC, area under the curve; CI, confidence interval; C
max
, maximum plasma concentration; C
12h
, 
plasma concentration 12 h after intake; GMR, Geometric Mean Ratio; t
1/2
, apparent elimination half-life.
a t
1/2
 could not be determined in all subjects, the number of included subjects are: AVIATOR n=17; RECITAL n=16; 
OPAL n=10; GINGER n=16.
+ Ginkgo biloba
GINGER (n=18)
+ boceprevir
OPAL (n=22)
+ citalopram
RECITAL (n=22)
+ atorvastatin
AVIATOR (n=23) AUC0-12h  1.01 (0.68-1.51)
Cmax 1.14 (0.70-1.86)
C12h  0.96 (0.69-1.32)
t1/2 0.97 (0.77-1.21)
AUC0-12h  0.77 (0.50-1.19)
Cmax  0.64 (0.38-1.09)
C12h  1.03 (0.71-1.50)
t1/2 1.09 (0.94-1.28)
AUC0-12h  1.04 (0.88-1.22)
Cmax  1.11 (0.91-1.36)
t1/2 0.93 (0.73-1.17)
AUC0-12h  1.24 (0.97-1.58)
Cmax 1.44 (1.03-2.02)
t1/2 0.98 (0.74-1.30)
Raltegravir GMR (90% CI)
0.0 0.5 0.8 1.0 1.25 1.5 2.0 2.5
160 161
Chapter 9 General discussion
all subjects. In approximately one third of the included subjects an opposite effect was seen. 
Individual changes in C
max
 and AUC were characterized by large differences in the magnitude 
of the effect as well as the direction of the effect. This is reflected by the large 90% 
confidence intervals displayed in Figure 2 and also graphically in Figure 2 in Chapter 3 and 5. 
An important consideration when interpreting these results is whether the changes in 
pharmacokinetic parameters are clinically relevant. The magnitude of the observed effect 
on the C
max
 and the AUC of raltegravir is not regarded to be of clinical importance. Similar 
effects on the pharmacokinetics of raltegravir are described with drug-interacting agents 
in the product information leaflet without special recommendations to adjust the dosage 
of raltegravir.11 Raltegravir C
12h
, which is an important parameter from a clinical perspective, 
did not change with concomitant use of citalopram. Overall, we concluded that 
atorvastatin, citalopram, boceprevir and Ginkgo biloba do not have a clinically relevant 
effect on the pharmacokinetics of raltegravir.
The AVIATOR and RECITAL study (Chapter 2 and 3) were designed as two-way pharmaco-
kinetic drug-drug interaction studies, meaning that also the potential effect of raltegravir 
on respectively atorvastatin, and citalopram was investigated. Although the OPAL study 
(Chapter 4) was not designed to evaluate boceprevir plasma concentrations with and 
without raltegravir use by intrasubject comparison, we did compare the boceprevir 
plasma concentrations when coadministered with raltegravir with historical reference 
values of boceprevir in plasma. In all three studies we found no effect of raltegravir on the 
pharmacokinetics of atorvastatin, citalopram and boceprevir, including their metabolites. 
Pharmacokinetic variability
The pharmacokinetic profile of raltegravir is characterized by extensive variability, which 
was observed in our studies as well.12-15 In fact, the variability in raltegravir pharmacokinetics 
has been a recurrent point of discussion, not only in the controlled settings of our trials 
but also in the application of TDM of raltegravir in the clinical setting. A distinction can be 
made between the variability that occurs within subjects or patients (intrasubject variability) 
and the variability between subjects or patients (intersubject variability). Intrasubject 
variability is defined as the variation that is seen when a measurement (for example 
sampling of a pharmacokinetic sample or curve) is repeated a number of times under the 
same conditions. The source of intrasubject variability could be multifold, but one 
important source is biological variability in absorption, distribution, metabolism and 
clearance. Intersubject variability is caused by a combination of genetic, demographic, 
physiological and environmental factors. It should be pointed out that in practice when 
measuring the variability between subjects under the same experimental conditions this 
always includes a certain amount of intrasubject variability (for example due to biological 
variation in clearance). Therefore intersubject variability in studies usually refers to the total 
(intersubject) variability. The intrasubject variability in the pharmacokinetics of a particular 
drug is generally much smaller compared with the total intersubject variability.
The drug-drug interaction studies and the pharmacokinetic study of raltegravir in 
pregnant HIV-infected women presented in this thesis have a similar crossover or 
sequential design in which each subject serves as its own control. This approach allows us 
to compare the effect of the reference and the test treatment or test situation within a 
subject (intrasubject comparison) which minimizes the potential contribution of genetic 
differences and the variability between subjects. Of course, in order to evaluate the true 
influence of the drug-drug interaction or pregnancy on the pharmacokinetics of 
raltegravir, other factors that might hamper the study results will be controlled or avoided 
as much as possible by carefully choosing the in- and exclusion criteria and specify 
standard procedures. 
The schematic examples in Figure 3 A, B and C illustrate the change in the exposure (AUC) 
of a particular drug with the reference versus the test treatment and how to interpret 
these results with respect to the variability. The variability between subjects does not 
have a negative impact on the outcome as the change in exposure is evaluated by 
intrasubject comparison. In examples A and B the exposure is not influenced (A) or 
consistently increased (B) by the interacting agent. The GMR of the test AUC versus 
reference AUC will be (close to) 1.0 in all subjects in example A and above 1 in example B 
with narrow or normal confidence intervals. This is not the case for example C, which 
Figure 3  Individual changes (n=3) in exposure (AUC, y-axis) to the investigational drug 
when administered with an interacting agent (test treatment; Test) or alone (reference 
treatment; Ref): A, no drug interaction; B, increased exposure with test treatment; C, no 
uniform effect of test treatment.
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shows large variability, as the potential interacting agent increased the AUC in some 
subjects and decreased the AUC in other subjects. Example C could represent the pharma-
cokinetics of a drug with extensive intrasubject variability, unless a plausible explanation 
can be given for the observed changes in some individuals (for instance vomiting). In that 
case it might be difficult to distinguish a potential effect of an interacting agent, especially 
when the effect is relatively small, from the variation in AUC due to intrasubject variability. 
In example C the GMR could be either 1.0 or below/above 1.0 with large confidence 
intervals given the variation in the individual ratios. The advantage of within subject 
comparison in crossover or sequential studies is diminished when investigating the 
pharma cokinetics of a highly variable drug, such as raltegravir. We have encountered this 
problem in our pharmacokinetic studies with raltegravir in which we used a within-subject 
comparison. The Figures are displayed in Chapter 2, 3, 5 and 6, and show that the 
individual changes in exposure to raltegravir with and without concomitant medication 
or postpartum versus third trimester pregnancy look similar to Figure 3C. The mean 
change in the AUC
0-12h 
of raltegravir when coadministered with citalopram and Ginkgo 
biloba (Chapter 3 and 5) could (partly) be attributed to this intrasubject variability and 
at least gives some uncertainty in the interpretation of the results. 
To give some insight in the variability in the pharmacokinetics of raltegravir as observed 
in our drug-drug interaction studies, a summary of the pharmacokinetic parameters of 
raltegravir when administered without concomitant medication, are given in Table 2 and 3. 
Table 2 presents the steady-state pharmacokinetic parameters of the AVIATOR study 
(Chapter 2), and RECITAL study (Chapter 3), as well as the pooled data of both studies 
(n=46). The pharmacokinetic data from the OPAL study (Chapter 4), and GINGER study 
(Chapter 5) after a single dose of 400 mg raltegravir is presented in Table 3, including 
the pooled data (n=42). 
The geometric mean AUC
0-12h 
in the AVIATOR study is lower than the observed value in the 
RECITAL study (respectively 4.13 mg·h/L versus 6.82 mg·h/L). This is somewhat surprising 
as the study procedures are similar with respect to the number of healthy volunteers, the 
intake of raltegravir on an empty stomach, the standardization of breakfast and lunch, the 
steady-state conditions, and the collection and handling of pharmacokinetic sampling. 
The most likely explanation for the difference in exposure is the variability, which is 
supported by the fact that the width of the confidence intervals around the geometric 
mean is large. This example illustrates well that it is difficult to speak of a ‘true’ reference 
value in the context of comparing raltegravir plasma concentrations collected for research 
purposes or regular patient care to historical control values. When interpreting raltegravir 
pharmacokinetic values it is important to always take into account the variability and the 
width of the confidence interval. 
The OPAL and GINGER study are similar in design and the raltegravir dosage used, except 
for the conditions around the intake of raltegravir. In the OPAL study raltegravir was taken 
with breakfast as opposed to the fasted state in the GINGER study. It is known that food 
influences the pharmacokinetics of raltegravir and increases pharmacokinetic variability 
relative to fasting.16,17 The effect of food explains (at least partly) the differences in pharma-
cokinetics in both studies and could be an argument against pooling of the data. 
Table 2   Raltegravir steady-state pharmacokinetic parameters and pooled data  
of raltegravir administered alone as 400 mg twice daily in the AVIATOR and 
RECITAL study.
Pharmacokinetic
parameter
AVIATOR (n=23) RECITAL (n=23) Pooled (n=46)
GM (95% CI) CV(%) GM (95% CI) CV(%) GM (95% CI) CV(%)
AUC
0-12h
 (mg·h/L) 4.13 (2.91-5.87) 97 6.82 (4.64-10.0) 110 5.31 (4.09-6.90) 108
C
max
 (mg/L) 1.29 (0.83-1.99) 132 2.45 (1.60-3.76) 128 1.78 (1.31-2.42) 139
C
12h
 (mg/L) 0.052 (0.035-0.077) 114 0.054 (0.037-0.080) 110 0.053 (0.041-0.069) 110
t
max 
(h)a 1.6 (0-12) 119 2.0 (0.5-12) 95 2.0 (0-12) 105
t
1/2
 (h)b 3.28 (2.64-4.09) 48 2.65 (2.28-3.09) 33 2.94 (2.58-3.35) 42
Abbreviations: AUC, area under the curve; CI, confidence interval; C
max
, maximum plasma concentration; C
12h
, plasma 
concentration 12 h after intake; CV, geometric coefficient of variation; GM, Geometric Mean; t
1/2
, apparent elimination 
half-life; t
max
, time to reach C
max
.
a For t
max
, median (min-max) is reported. 
b t
1/2
 could not be determined in all subjects, the number of included subjects are: AVIATOR 19 subjects; RECITAL 20 
subjects; pooled data 39 subjects.
Table 3   Raltegravir pharmacokinetic parameters and pooled data of raltegravir 
 administered as 400 mg single dose in the OPAL and GINGER study.
Pharmacokinetic
parameter
OPAL (n=24) GINGER (n=18) Pooled (n=42)
GM (95% CI) CV (%) GM (95% CI) CV(%) GM (95% CI) CV(%)
AUC
0-12h 
(mg·h/L) 4.04 (3.09-5.28) 70 5.93 (4.21-8.34) 77 4.74 (3.85-5.84) 75
C
max
 (mg/L) 0.93 (0.70-1.23) 75 2.08 (1.39-3.12) 96 1.30 (1.00-1.68) 99
C
12h 
(mg/L) 0.093 (0.047-0.186) 368 0.036 (0.022-0.058) 121 0.062 (0.039-0.097 268
t
max
 (h)a 4.0 (1.0-12.00) 96 2.0 (0.5-12) 105 3.0 (0.5-12) 83
t
1/2
 (h)b 1.80 (1.31-2.47) 55 3.17 (2.61-3.86) 29 2.52 (2.12-2.99) 48
Abbreviations: AUC, area under the curve; CI, confidence interval; C
max
, maximum plasma concentration; C
12h
, plasma 
concentration 12 h after intake; CV, geometric coefficient of variation; GM, Geometric Mean; t
1/2
, apparent elimination 
half-life; t
max
, time to reach C
max
.
a For t
max
, median (min-max) is reported. 
b t
1/2
 could not be determined in all subjects, the number of included subjects are: OPAL 13 subjects; GINGER 16 
subjects; pooled data 29 subjects.
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To describe the amount of variability in the geometric mean, the geometric coefficient of 
variation in percentage (CV%) is reported in Table 2 and 3. Because the CV% has no unit of 
measurement such as the standard deviation, it is often used to compare the variability. 
However one should pay attention to which CV% is reported. For example, the geometric 
mean CV of the pooled data of AUC
0-12h 
in Table 2 is 108%, whereas the arithmetic mean 
CV for AUC
0-12h 
is 81% (not shown in Table 2), which is considerably lower. Unlike the 
arithmetic CV which is dependent on the arithmetic mean, the geometric CV is calculated 
differently. The CV% of the AUC
0-12h 
and the C
max
 in the multiple-dose studies (respectively 
108% and 139%, pooled data Table 2) is higher than the variability observed in the 
single-dose studies (75% and 99%, pooled data Table 3). The variability in C
max
 is larger 
than in AUC
0-12h
. This
 
is logical as the AUC is based on multiple sampling points and the 
C
max
 is a single plasma sample which could have been taken before or after the true 
absorption peak concentration. 
In phase III studies in HIV-infected patients the coefficient of variation (geometric CV %) of 
the inter- and intrasubject variability in C
12h 
levels obtained by sparse sampling was 
respectively, 211% and 122%, as reported by Merck.15,18 The CV% of the intersubject 
variability was approximately two-fold higher than observed in our multiple-dose 
drug-drug interaction studies in healthy volunteers (Table 2). The higher CV% can be 
explained by the nature of phase III clinical trials in HIV-infected patients and the method 
of sparse pharmacokinetic sampling. Compared with the controlled setting of a study in 
healthy volunteers, phase III clinical trials are associated with considerably more factors 
that could contribute to the variability in the pharmacokinetics between subjects. Fortuna 
et al described an arithmetic mean CV% of raltegravir C
trough
 in the clinical setting between 
100% and 125% for the total intersubject variability, and between 80 and 86% for the 
intrasubject variability.14 The CV% was dependent on the degree of adherence to the 
protocol with a marginally lower CV% in the fully adherent subgroup. Overall, the authors 
conclude that the intrasubject variability was about 30% lower than the total intersubject 
variability.14 
This is not consistent with the findings of Siccardi et al who described the inter- and 
intrapatient variability of raltegravir trough plasma levels (C
trough
) in the clinical setting in 86 
HIV-infected patients (type of CV% not reported). The intrasubject variability was higher 
than the intersubject variability.13 In their study the median intrasubject CV% was 128% 
(64-265%) in 13 patients with 3 or more C
trough
 samples available per patient, and 245% in 7 
patients with ≥ 10 C
trough
 samples available per patient. The observed intersubject CV% 
was 110%, which is similar to the results of Fortuna et al, and the CV% of the pooled data 
(n=46) in our multiple-dose drug interaction studies (Table 2). 
Although even the amount of variability in raltegravir pharmacokinetics varies between 
studies, one can conclude that the total intersubject variability is very large with a CV% of 
approximately 100% or more. Unfortunately there is some conflicting data on the CV% of 
the intrasubject variability. We did not collect repeated pharmacokinetic measurements 
per subject for the purpose of calculating the intrasubject variability. If we assume that the 
intrasubject variability of raltegravir is approximately one-third lower than the intersubject 
variability, it is considerably higher than the lower threshold of 30% that is being used to 
identify highly variable drugs.7 
Variability and influencing factors
To better understand the pharmacokinetics of raltegravir it is important to discuss which 
potential sources might contribute to the high pharmacokinetic variability.15 The variability 
in raltegravir pharmacokinetics in our studies and research described in this thesis could 
be due to a combination of the following factors which will be discussed into more detail 
in this section:
·	 pharmacogenetics
·	 drug-drug interactions
·	 pH dependent solubility and formulation 
·	 the effect of food
Pharmacogenetics 
As raltegravir is primarily metabolized by UGT1A1, the hepatic UGT1A1 expression levels 
may alter the metabolism of raltegravir. Approximately 7-19% of the Caucasian population 
is homozygous for UGT1A1*28 which is associated with a decreased UGT1A1 expression.19 
Individuals with a decreased UGT1A1 expression caused by UGT1A1*28 polymorphism 
(e.g. subjects with Gilbert’s syndrome) were compared with individuals with wild-type 
UGT1A1 (UGT1A1*1/*1) who have a normal UGT1A1 activity.20 Subjects with a decreased 
UGT1A1 expression have moderately elevated plasma levels of raltegravir (GMR (90% CI); 
1.41 (0.96-2.09) for AUC). This increase in plasma levels is not considered to be of clinical 
importance.20 However, there is quite some variability in the phenotypic expression of 
individuals who are homozygous for UGT1A1*28 making a correlation between UGT1A1 
genotype and UGT1A1 activity less strong. 
The UGT1A1*28 did not exert any relevant effect on raltegravir C
trough
 values in a study by 
Siccardi et al investigating the variability of raltegravir in the clinical setting.13 In the drug 
interaction studies with raltegravir and atorvastatin, citalopram, and boceprevir, we 
performed UGT1A1*28 genotyping in all included subjects (n=72) (Chapter 2, 3 and 4, 
data not presented). The individuals found to be homozygous for UGT1A1*28 (n=3; 4%), 
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were not excluded from pharmacokinetic analysis. The percentage of subjects 
homozygous for UGT1A1*28 was lower as would be expected in a predominant Caucasian 
study population. Based on our screening evaluation and in- and exclusion criteria we 
have excluded two subjects with total and direct bilirubin levels above the upper limit of 
normal (respectively >17 and >5 µmol/L). These individuals could have been homozygous 
for UGT1A1*28 because they are known to have episodes of mild hyperbilirubinemia.20
Genetic variances between subjects were considered to be of minor importance in our 
drug interaction studies because we have used a crossover design instead of a parallel 
group design. However, in case there would have been a clear effect of the interacting 
agent on UGT1A1, it would have been interesting to know if any of the subjects were 
homozygous for UGT1A1*28. The degree of inhibition or induction of UGT1A1 by an 
interacting agent will probably be dependent on the UGT1A1 activity a priori. 
In our drug interaction studies we were not able to observe any differences in pharmaco-
kinetics depending on UGT1A1*28 polymorphism because of the small number of 
subjects homozygous for UGT1A1*28. Nonetheless it is likely that UGT1A1 polymorphism 
has contributed to some extent to the intersubject variability observed in our studies. 
Genotyping of UGT1A1 is not recommend in HIV-infected patients on treatment with 
raltegravir because it is not an important determinant for raltegravir pharmacokinetics 
and has no clinically relevant consequences. Therefore UGT1A1 genotyping was not 
performed in the patients described in Chapter 6, 7 and 8 of this thesis. 
Raltegravir is a substrate of P-gp which plays an important role in oral drug absorption.8,9 
The expression and transport activities of P-gp may differ between individuals due to 
genetic variation in the highly polymorphic ABCB1 gene.21,22 Therefore, the extent of 
P-gp-mediated efflux of raltegravir may vary accordingly between subjects and contribute 
to the intersubject variability in raltegravir pharmacokinetics.
Drug-drug interactions
It is needless to say that concomitant use of raltegravir with an interacting agent, such as 
an UGT1A1 inhibitor or inducer, is going to influence the metabolism and the pharmaco-
kinetics of raltegravir. Although drug-drug interactions are among the most frequently 
reported contributing factors when interpreting pharmacokinetic data in clinical trials and 
its variability between HIV-infected patients, it is a contributing factor that is easily avoided 
in drug-drug interaction trials in healthy volunteers. In our drug-drug interaction studies 
in healthy volunteers the intake of other therapeutic agents other than the study 
medication was prohibited during the whole conduct of the study including two weeks 
prior to the start of the study. This included herbal medicines, multivitamins and other 
dietary supplements. This is a common study procedure and one of the main advantages 
of conducting these type of studies in healthy volunteers. 
However, in our study investigating the pharmacokinetics, efficacy and safety of raltegravir 
in HIV-infected pregnant women (Chapter 6), there were no restrictions on the use of 
concomitant HIV and nonHIV medication which could influence raltegravir exposure. 
Although it was not part of our objective and presentation of the study results in Chapter 6, 
it would be interesting to know whether the use of interacting agents has contributed to 
the variability in raltegravir pharmacokinetics in this study population. The HIV-infected 
pregnant women (n=22) can be divided in three subgroups according to the occurrence 
of drug-drug interactions and their effect on raltegravir exposure: neutral (no effect, n=15), 
favourable (increased exposure, n=4), and deleterious (decreased exposure, n=3). The 
respective interacting agents used were ritonavir boosted atazanavir (n=3) and ranitidine 
(n=1) in the favorable subgroup, and calcium carbonate (n=2) and magnesium (n=1) 
supplement in the deleterious subgroup.23-29 One patient used both ritonavir-boosted 
atazanavir and magnesium and was assigned to the neutral subgroup. We did not include 
the potential influence of tenofovir, which was used by the majority of the included 
HIV-infected patients, on the pharmacokinetics of raltegravir. The mechanism by which 
tenofovir might increase raltegravir exposure (although only investigated in a small 
population) is unknown and not considered clinically relevant.30 To illustrate the variability 
in raltegravir exposure (AUC
0-12h
) per subgroup and change in the third trimester of 
pregnancy versus postpartum a scatter-dot plot was made (Figure 4).
Figure 4  Individual and geometric mean exposure (AUC
0-12h
) to raltegravir in HIV-infected 
women per drug-drug interaction subgroup in the third trimester compared with post- 
partum.
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The geometric mean AUC is higher in the favorable subgroup en lower in the deleterious 
subgroup compared with the neutral subgroup (Table 4). However due to the large 
variability in AUC
0-12h 
within each subgroup this difference is not significant. An important 
limitation of presenting the data like this, is the limited number of patients in the subgroup 
favorable and deleterious ( 2 to 4 subjects). Another limitation worth mentioning is that 
the patients were assigned to a certain subgroup in a rather straightforward way. We were 
not able to take into account for example the timing of the intake of the interacting agents 
on the day of pharmacokinetic assessment.
Nonetheless, we can conclude that drug-drug interactions have contributed to the 
variation seen between the HIV-infected women but the relative contribution is unknown. 
More importantly the mean exposure is lower in third trimester compared to postpartum 
in all subgroups resulting in a ratio < 1.0 of the exposure in third trimester versus 
postpartum. All potential drug-interacting agents were used during both pharmacokinetic 
assessments, limiting its influence on the comparison between the exposure in the third 
trimester versus postpartum. These data however do suggest that HIV-infected women 
during the third trimester could be more at risk for suboptimal exposure when interacting 
agents (such as magnesium) are used that could potentially further decrease raltegravir 
exposure. 
pH-dependent solubility and formulation
Among the numerous plasma concentration-time profiles of raltegravir collected in our 
studies we have encountered a number of unusual pharmacokinetic profiles that lacked a 
sharp absorption peak or had a delayed (up to 12 hours after intake) sometimes blunted 
absorption peak which was not seen in the second pharmacokinetic profiles of these 
subjects, nor related to a certain treatment period. Incidental poor or altered absorption 
of raltegravir in this extent is reported by others as well and evidently contributes to 
the high variability between and within subjects.12 Although these were infrequent 
occurrences of an extreme delayed or altered absorption profile, this experience has led 
to our hypothesis that variation in the extent of absorption of raltegravir may be one of 
the key factors that contributes to the high variability in raltegravir pharmacokinetics. 
The extent of absorption from the gastrointestinal tract can be influenced by the 
dissolution rate of the tablet as well as the solubility and permeability of the drug. 
Important physiological factors that influence absorption are gastrointestinal pH and 
transit time in the gastrointestinal tract.31 Both factors are capable of causing intrasubject 
variability in pharmacokinetics in vivo.28 It is known that the pharmacokinetics of raltegravir 
is affected by acid-reducing agents such as omeprazole and famotidine because 
raltegravir solubility (and as a result its oral bioavailability) is improved at higher gastroin-
testinal pH.11,32 High-fat food has been shown to increase raltegravir exposure as well, 
which may be attributable to improved solubility, but could as well be a result of longer 
transit time and hence more time for absorption.17,28 Raltegravir pharmacokinetic profiles 
occasionally contain multiple peaks. It has been suggested that raltegravir is able to 
undergo enterohepatic recirculation via conversion of raltegravir glucuronide metabolite 
back to the parent form in the intestine which could lead to reabsorption. However, a 
study in healthy volunteers using radiolabelled raltegravir could not confirm this 
theory.28,33,34 Magnesium and other divalent ion metals negatively influence raltegravir 
absorption by binding to raltegravir and reducing its permeability.27,29 
Moss et al developed a population-based in vitro-in vivo extrapolation model (IVEVE) to 
investigate the effects of gastrointestinal pH on raltegravir pharmacokinetics.28 IVEVE is 
the process of using in vitro physiochemical, permeability, and metabolic parameters to 
predict in vivo drug characteristics using pharmacokinetic simulation modelling. In 
simulated subjects, increased gastrointestinal pH and transit time in the small intestin 
were both associated with improved raltegravir exposure (increased AUC, C
max
 and C
12h
). 
Whereas the presence of magnesium in the lumen significantly decreases raltegravir AUC, 
C
max
 and C
12h
. Furthermore the model demonstrates preferential absorption of raltegravir 
from particular sections of the gastrointestinal tract due to local pH differences. This 
together with tablet disintegration rate, which has been shown to increase in higher pH 
solutions in vitro, may help explain variability and unusual raltegravir pharmacokinetic 
profiles. The used model has its limitations and its predictability can be improved for 
example by including the impact of drug transporters. 
The solubility and permeability of a drug is determined by physicochemical characteris-
tics, such as pKa and aqueous/lipid solubility. The biopharmaceutics classification system 
(BCS) has four categories depending on its aqueous solubility and intestinal permeability: 
Table 4   Geometric mean AUC
0-12h 
of raltegravir in HIV-infected pregnant women in  
the third trimester of pregnancy compared with postpartum for all patients 
and per drug-drug interaction subgroup.
Group 3rd trimester raltegravir
AUC0-12h (mg·h/L)
postpartum raltegravir
AUC0-12h (mg·h/L)
n GM (95% CI) n GM (95% CI)
All patients 21 5.00 (3.56-7.01) 18 7.11 (4.91-10.3)
Neutral 14 4.76 (3.05-7.43) 13 7.04 (4.36-11.4)
Favorable 4 7.96 (2.28-27.9) 2 12.9
Deleterious 3 3.37 (1.66-6.86) 3 4.99 (1.37-18.2)
Abbreviations: AUC, area under the curve; CI, confidence interval; GM, Geometric Mean.
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1, high solubility-high permeability drugs; 2, low solubility-high permeability drugs; 
3, high solubility-low permeability drugs; and 4, low solubility-low permeability drugs.35 
Raltegravir poloxamer tablets 400 mg are categorized as BCS 4 which means that 
raltegravir as an active pharmaceutical ingredient in this formulation is poorly soluble and 
poorly permeable.36 Raltegravir ethylcellulose chewable tablet, which is one of the pediatric 
formulations (Chapter 8) is categorized as BCS 2: low solubility-high permeability drugs.36 
Theoretically, it is expected that the influence of the formulation on pharmacokinetics will 
be largest for drugs with low solubility.31 The formulation of the 400 mg tablet is standard 
and based on a matrix of microcrystalline cellulose, lactose monohydrate, calcium 
phosphate dibasic, hypromellose and poloxamer 407. The excipients were selected to 
provide a tablet that would erode rather than disintegrate.11 Poloxamer enhances 
solubilisation of poorly water-soluble drugs. Both pediatric formulations (raltegravir 
chewable tablet and granules for suspension) exhibited lower variability than the adult 
tablet and give a different pharmacokinetic profile compared to the poloxamer tablets. 
The pediatric formulations are not bioequivalent to the adult tablets.37,38 This shows that a 
different formulation of raltegravir may positively improve the variability in drug absorption.
Cattaneo et al investigated whether the observed wide inter- and intrapatient distribution 
of raltegravir plasma concentrations is related to the release of the drug from its 
pharmaceutical formulation.39 HIV-infected patients receiving raltegravir by chewing the 
poloxamer tablet showed higher drug absorption and reduced pharmacokinetic 
variability compared with patients swallowing the intact tablet. The authors conclude 
that this difference in absorption and variability is related to tablet disintegration and drug 
absorption. Improving the pharmaceutical formulation could improve raltegravir pharma-
cokinetics. However, new conflicting data on the pharmacokinetics chewed versus 
swallowing of raltegravir (n=1) suggest otherwise.40 
The possibility that the large intrasubject variability in raltegravir pharmacokinetics may 
be related to the pharmaceutical formulation and to poor solubility and permeability is an 
interesting hypothesis that deserves further investigation. In a recent publication by Merck 
the discovery of the compound MK-8970 is described. This is an optimized acetal 
carbonate prodrug of raltegravir with enhanced colonic absorption and suitable 
physiochemical properties to support the development of a special formulation for 
once-daily dosing.41
One of the physiological changes that can occur during pregnancy and could theoretically 
alter raltegravir drug absorption is an increase in gastric pH, as well as a reduction in 
 gastrointestinal motility. However there is little data documenting that any of these 
changes significantly alter drug absorption in general.42 Raltegravir solubility and oral 
absorption is improved at higher gastrointestinal pH. Therefore the absorption and 
exposure of raltegravir may be increased during pregnancy. We did not observe this as an 
overall effect in our study in HIV-infected pregnant women as we measured a mean 
decrease in exposure instead of an increase (Chapter 6). Nonetheless, because gastro-
intestinal pH is one of the factors that contributes to the variability in raltegravir pharma-
cokinetics in nonpregnant HIV-infected patients, it is likely to have contributed to the 
variability seen within our pregnant population as well. 
The effect of food
Although it is recommended in the product label that raltegravir can be taken with or 
without food, it is known that food influences the pharmacokinetics of raltegravir and 
increases pharmacokinetic variability relative to fasting.16,17 In particular the variability in 
C
12h
 is increased with reported CV% up to 4-fold higher when taken with a meal compared 
with the fasted state.17 The fat content of meals is believed to create variability in absorption 
of raltegravir with a higher time to reach the maximum plasma concentration. Nonetheless, 
it is difficult to make solid recommendations regarding dosing with a specific type of food 
as different meal types seems to have varying effects on the pharmacokinetics of 
raltegravir. It is not known whether this effect is related to the content of the meal, or the 
change in transit time or gastric pH, or a combination of these factors. Because none of 
these effects appear to be clinically relevant, raltegravir can be taken without regard to 
food in the clinical setting, which is more convenient in daily practice and generally 
improves adherence. However when evaluating and interpreting raltegravir pharmacoki-
netic data for research purposes, it is important to take into account the effect of food.
To minimize the variability in pharmacokinetics caused by food, raltegravir was taken on 
an empty stomach on the pharmacokinetic sampling days in our drug-drug interaction 
trials. Due to practical reasons an exception was made for the study with boceprevir 
(OPAL, Chapter 4) as boceprevir is to be taken with food to increase its absorption and 
oral bioavailability.43 In Table 3 is shown that the absorption peak occurs later (t
max
 is 
4 hours) in the subjects from the OPAL study who took raltegravir as a single dose with 
breakfast compared with the subjects in the GINGER study who took raltegravir on an 
empty stomach (t
max
 is 2 hours). The geometric mean C
12h
 level in the OPAL study was 
higher compared with the C
12h
 in the GINGER study with a considerable higher CV%: 0.093 
mg/L and 368% in OPAL, 0.036 mg/L and 121% in GINGER. 
In these crossover pharmacokinetic studies with raltegravir the standardization of the 
breakfast is far more important than the actual content of the breakfast. Standardization 
implies that all the subjects must eat the same type of breakfast at exactly the same time 
during or after intake of the study medication on each pharmacokinetic sampling day. 
However the variability in absorption profile in healthy subjects under the same 
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standardized feeding conditions (as illustrated in Table 2), indicates that factors other than 
food intake are equally or even more important contributors to the pharmacokinetic 
variability.
Pharmacokinetics/pharmacodynamics
The patient’s exposure to drug is a crucial determinant of the drug’s actions, and therefore 
its efficacy and safety. Knowledge on the relationship between pharmacokinetics and 
pharmacodynamics (PK/PD relationship) is important to be able to interpret (changes in) 
the pharmacokinetics of raltegravir in terms of clinical relevance. 
Raltegravir in vitro antiretroviral activity, defined as a 95% inhibitory concentration (IC
95
) is 
33 nM (= 0.015 mg/L) in the presence of 50% human serum. A proof of concept 10-day 
placebo-controlled monotherapy study (protocol 004, part I) plus dose-finding study was 
performed in a small group of treatment-naive patients using 100 mg (n=7), 200 mg (n=7), 
400 mg (n=6), or 600 mg (n=8) raltegravir twice daily or placebo (n=7).44 The results 
showed superior virological response rates in all raltegravir treatment arms compared 
with placebo, regardless of the raltegravir dosage used and the fact that more patients in 
the lower dose groups (100 and 200 mg) had minimum plasma concentrations below the 
IC
95 
compared with the higher dose groups (400 and 600 mg). This observation was 
important in the discussion whether C
12h
 was the most likely pharmacokinetic driver to 
predict viral response as seen with other antiretroviral agents. The exposure of the lower 
limit of clinical experience with 100 mg twice daily was approximately 60% lower (GMR of 
0.4) than the C
12h
 observed in the recommended dose of 400 mg twice daily. Because they 
considered 100 mg twice daily an efficacious dose a decrease in plasma exposure of up 
to 60% was considered unlikely to affect efficacy. Note that this assumption was based 
on very small subsets of subjects (6 to 8) which is not uncommon for proof-of-concept 
studies. Given the high variability in raltegravir pharmacokinetics these conclusions had 
to be interpreted with extreme caution.15,18
In the PK/PD analysis of two phase III studies in treatment-experienced patients with 
48-week efficacy data, the geometric mean of all sparse raltegravir plasma concentrations 
(C
all
) for a given subject regardless of the time of collection showed a weak but consistent 
significant positive correlation with efficacy measurements.45 This association was less 
with C
min
 (the lowest measured plasma concentration) and not observed with C
12h
 
(geometric mean of raltegravir plasma concentrations collected 11-13 hours post dose). 
Baseline HIV RNA load and the presence of other active antiretroviral agents in the regimen 
were the most important predictors for antiretroviral response. The interpretation of C
all
 is 
not clear but is probably best defined as the overall exposure within the dose interval (0 
to12 hours).34 This was supported by the results of an in vitro hollow-fiber model showing 
that raltegravir AUC was best linked with virological response.46 These data has lead to the 
hypothesis that in contrast with other antiretroviral agents not raltegravir C
12h
 is the phar-
macokinetic parameter best related to the efficacy but the overall exposure to raltegravir 
(AUC
0-12h
), although a threshold for AUC was not determined.45 
The pharmacokinetic parameter AUC is compared with C
12h 
a very impractical parameter 
to monitor in HIV-infected patients in the clinical setting because it requires 12-hour 
multiple blood sampling. To limit patient burden and practical issues an alternative limited 
sampling strategy was developed by our research group in which an abbreviated AUC 
from 0 to 3 hours (AUC
0-3h
) is calculated and extrapolated to AUC
0-12h
.47
 
A similar model and 
strategy for raltegravir is well described by Cattaneo et al.48 We used this limited plasma 
sampling method to estimate the exposure to raltegravir in HIV-infected patients with 
advanced stage non-Hodgkin lymphoma as described in Chapter 7. Its value for TDM 
purposes of raltegravir will be discussed in the section on TDM. 
Raltegravir was well tolerated with no reported dose-related toxicity and no acute safety 
findings related to peak plasma concentrations. For many drugs the overall exposure 
(AUC) and C
max 
are the pharmacokinetic parameters most likely to be associated with 
toxicity. When Merck applied raltegravir as new drug, the upper bound of broad clinical 
experience was used to define the highest value of AUC that was achieved without being 
associated with an increased risk of clinically relevant changes in safety and tolerability. 
The highest value of AUC achieved in phase II studies was in patients (n=51) taking 600 mg 
twice daily in combination with atazanavir and/or tenofovir leading to approximately a 
2-fold increase in AUC compared to the registered 400 mg twice daily dosing. These data 
supported that a two-fold increase in exposure is not likely to be clinically relevant.15,18 
When raltegravir was introduced to the market, the results from the PK/PD analyses of 
phase III studies, as well as the lack of a clear PK/PD relationship in the phase II dose-ranging 
studies as described above, suggested that C
12h
 might not be related to the clinical 
outcome. The lack of an observed relationship between C
12h
 and efficacy had to be 
interpreted with caution because it could have been due to high intrapatient variability 
leading to a poor prediction of the true exposure. Another explanation could be the high 
potency of the approved dosage regimen of raltegravir 400 mg twice daily. The C
12h 
levels 
in the approved dosage might already be well above the IC
95 
and on top of the C
12h
-viro-
logical success curve. These issues were addressed by the European Medicines Agency 
(EMA) and the Food and Drug Administration (FDA) in the assessment reports with the 
recommendation to further explore the importance of raltegravir exposure to virological 
outcome measurements post-approval.15,49
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It wasn’t until the pharmacokinetic data of the QDMRK study were published in 2012 that 
the trough level is considered the most important parameter to evaluate with respect to 
raltegravir’s virological efficacy.50 Although no clear relationship between pharmacokinetic 
parameters and the efficacy of raltegravir could be established for the registered twice 
daily dose regimen, failure to achieve an HIV RNA load <50 copies/mL appeared 
predominantly at high baseline HIV RNA load and was associated with lower values of 
trough levels in the 800 mg once-daily arm with a suggested threshold of 0.020 mg/L 
which is just above the IC
95 
(0.015 mg/L).50 
The variability in raltegravir pharmacokinetics has complicated the search for the best 
pharmacokinetic driver for clinical response. And even today the PK/PD relationship of 
raltegravir is not fully elucidated. Generally one can conclude that the therapeutic range 
of raltegravir when dosed twice daily is considered to be large. The initial assumption that 
up to a two-fold increase and up to a 60% decrease in exposure (AUC) of raltegravir was 
not likely to be clinically relevant might have been a bit premature. Nonetheless, these 
have remained roughly the extreme boundaries of clinical relevance although the focus 
in the interpretation lies predominantly on a potential decrease in AUC and C
12h
 and its 
potential effect on virological efficacy instead of a concern for safety issues with an 
increase in exposure. This is also seen in the interpretation of the drug-drug interactions 
with raltegravir in the overview in Table 1 with a shift towards a focus on C
12h
 in the more 
recent studies. 
Therapeutic drug monitoring
General and practical aspects
Therapeutic drug monitoring (TDM) of antiretroviral therapy in HIV infection by measuring 
plasma concentrations of antiretroviral agents may be used as a means to optimize and 
individualize antiretroviral treatment response.51-55 Especially certain patient groups who 
are at increased risk for pharmacokinetic variability resulting in potential low or elevated 
plasma concentrations could benefit from TDM. 
TDM may also be a useful tool to manage drug-drug interactions of antiretroviral agents 
as well as monitor adherence issues, both of which are important issues for optimal 
treatment response.
The following criteria are generally used to evaluate the value of routine TDM to optimize 
treatment response56:
·	 correlation between drug concentration and clinical response
· correlation between drug concentration and toxicity
· the drug must have a narrow therapeutic index
· there is large interpatient variation in pharmacokinetics
· low intrapatient variation at steady-state concentrations
· the effect of the drug must be difficult to assess clinically
· dose adjustment is possible in the case of a too low or high drug concentration
·	 an accurate bioanalytical assay to analyse drug concentrations
The product labelling of raltegravir and treatment guidelines do not recommend to 
perform routine TDM of raltegravir. When using the criteria to evaluate the value of TDM 
of raltegravir, one can conclude that raltegravir is indeed not an ideal candidate for TDM. 
Because of high intrasubject variability, TDM might not be considered useful in the general 
HIV-infected population on a raltegravir-based regimen as significant changes in 
raltegravir plasma concentrations among different sampling times may not reflect, for 
example, poor adherence or changes in pharmacokinetics due to drug-drug interactions. 
The absence of a clear relationship between pharmacokinetic parameters and the efficacy 
of raltegravir in the standard 400 mg twice daily regimen has further complicated the use 
of TDM. However, the QDMRK study revealed in 2012 a greater risk of treatment failure 
observed with a once-daily raltegravir regimen compared with a twice-daily regimen. This 
suggests that drug exposure remains a critical determinant of the efficacy of raltegravir.50 
Although a robust threshold for virological efficacy could not be found, patients with 
raltegravir C
12h 
levels <0.020 mg/L might be more at risk for treatment failure. Nowadays, 
when interpreting the plasma concentrations of raltegravir for TDM purposes the 0.020 
mg/L threshold is being used. No association between exposure to raltegravir and toxicity 
has been found when used in the recommended dosage. Therefore the main reason to 
perform TDM of raltegravir is when there is a concern for suboptimal plasma exposure. 
In that case we advise to collect a trough sample which is ideally taken just before the next 
dose but should be taken at least 8 hours post dose. 
Due to practical reasons blood sampling for raltegravir TDM is often performed before the 
morning dose. In our experience with the pharmacokinetic drug-drug interaction studies 
with raltegravir, we have observed that the mean predose plasma concentration in the 
morning is higher than the C
12h
 level taken in the evening 12 hours after intake. This 
difference (2- to 5-fold), first reported by Neely et al, would suggest a circadian rhythm to 
raltegravir pharmacokinetics and is most likely explained by a difference in absorption 
profiles due to the intake of raltegravir with or without a (high-fat) meal in the morning 
versus the evening.24,57 When interpreting C
trough
 levels for TDM we take into account the 
0.020 mg/L threshold regardless of the sampling time. However, it is important to realize 
that the reference mean C
trough
 values obtained from the literature might vary because of 
differences in the time of collection of the blood samples (morning versus evening) and 
whether that particular dose was taken with or without food.
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Special patient populations
Despite the fact that use of TDM is not believed to be useful in the general HIV-infected 
population, here a few examples are given when TDM can be of value in special patient 
populations in clinical practice.
In pregnant HIV-infected women, in whom physiological changes may lead to altered 
pharmacokinetics, it is difficult to predict whether this might lead to suboptimal drug 
exposure and the need for dose adjustment. The variability in pharmacokinetics as a result 
of pregnancy support the use of TDM in this special patient population.58 However the 
research we have performed on the pharmacokinetics, efficacy, and safety of raltegravir in 
pregnant HIV-infected women (Chapter 6) is reassuring with respect to the changes in 
exposure to raltegravir in the third trimester. We have concluded that dose adjustment is 
not necessary during pregnancy which also argues against routine TDM of raltegravir. 
However, we did illustrate that additional factors, such as the use of interacting agents, 
may contribute to a further decrease and potentially suboptimal exposure to raltegravir 
during the third trimester. In these individual pregnant HIV-infected patients who are 
more at risk for suboptimal drug exposure, TDM of raltegravir could be of value. 
In Chapter 7 a small case series is presented of three HIV-infected patients with 
non-Hodgkin lymphoma at risk for drug-drug interactions and impaired absorption of 
raltegravir, in whom we performed TDM by means of a limited sampling strategy. Pharma-
cokinetic sampling was performed at steady-state conditions from predose up to 3 hours 
after intake of raltegravir 400 mg on an empty stomach. The calculated abbreviated 
AUC
0-3h
 was subsequently extrapolated to AUC
0-12h
 which is the pharmacokinetic parameter 
that best represents the overall absorption and systemic exposure to raltegravir. 
The results suggest that chemotherapy-induced intestinal mucositis may influence the 
absorption and total exposure to raltegravir. Although in our case it did not seem to have 
clinically relevant consequences.
 
We have encountered delayed absorption (no absorption peak <3 hours after intake of 
raltegravir) which, given the limited sampling time, probably has led to an underestimation 
of the true exposure when extrapolated to 12 hours. Unfortunately it is not possible to 
distinguish whether this is due to intake with breakfast (as opposed to fasted), normal 
variability in drug absorption or indeed impaired absorption due to severe diarrhoea. 
Although this strategy provides more insight into the pharmacokinetics of raltegravir than 
a single trough level, the patient burden and costs probably do not outweigh the benefits 
in most patients.
HIV treatment of children, especially in young children, often lags behind that of adults 
with limited availability of age-appropriate formulations suitable for a wide dosage range. 
Even if a pediatric formulation is available, developmental changes occurring with age 
could alter the pharmacokinetics of antiretroviral agents in children with large interindi-
vidual variation in pharmacokinetics as a result. 51,59-61 In Chapter 8 we described the 
successful application of TDM in a 4-year-old HIV-infected patient who used raltegravir 
chewable tablets conform prescription guidelines and repeatedly had trough levels 
below the IC
95
 of raltegravir (0.015 mg/L). To ensure adequate raltegravir trough levels the 
patient switched from a twice-daily dosage to an off-label three-times daily dosage. 
Although this case illustrates the value of TDM to optimize individual raltegravir treatment, 
it does not advocate the application of routine TDM of raltegravir in all pediatric patients. 
First of all, we have reported only one case and do not know whether our dose adjustment 
has had a relevant effect on the treatment response. Furthermore, the raltegravir drug 
assay is not widely available which limits its application in routine pediatric HIV care. In 
fact, TDM of antiretroviral agents is probably nowhere as accessible as currently in the 
Netherlands. Nonetheless, we do believe that TDM (if available) is a useful tool in the 
pediatric HIV-infected population to monitor raltegravir exposure. 
Conclusions and closing remarks
The best strategy for long-term control of HIV infection is the use of combinations of 
potent antiretroviral agents from different drug classes that target different steps of the 
viral life cycle. The accelerated approval of raltegravir in 2007 by the FDA and EMA was 
highly anticipated as it introduced us to the first of a new class of antiretroviral agents 
called the HIV-1 integrase inhibitors. From 2007 and onwards the knowledge of the clinical 
pharmacology of raltegravir has greatly improved. The research in this thesis has 
contributed to that knowledge and to a better understanding of its drug interaction 
potential and the pharmacokinetics of raltegravir in (special) HIV-infected patients.
Despite the extensive pharmacokinetic research that has been done with raltegravir, the 
variability in the pharmacokinetics has never been truly unravelled. The large intra- and 
intersubject variability in raltegravir pharmacokinetics has complicated the investigation 
to establish a dose-response relationship and the development of a population PK model. 
It also contributed to difficulties in assessing the relevance of pharmacokinetic data 
obtained by sparse sampling at single or minimal times. 
The lack of knowledge on the PK/PD relationship of raltegravir in the drug development 
phase, as well as post-approval, has clearly made the prediction of the pharmacokinetics 
in dose-finding studies and the interpretation in terms of response and clinical relevance 
more difficult. The disappointing results of the QDMRK study, which evaluated 800 mg 
raltegravir once daily, might have been prevented if the pharmacokinetics of raltegravir 
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would have been better predicted and interpreted. We believe that the pharmaceutical 
formulation of raltegravir poloxamer tablets and its poor solubility and permeability is an 
important contributor to the inter- and intrasubject variability in raltegravir pharmaco-
kinetics. The development of a pharmaceutical formulation with raltegravir with a more 
predictable absorption profile should have deserved more attention in the biopharma-
ceutical stage of drug development. The question is whether this would have severely 
delayed the development of raltegravir as a new compound. From a clinical perspective, 
raltegravir has been and still is a very potent and safe antiretroviral drug despite its variable 
and unpredictable absorption.
Effective study design in early drug development that incorporates both pharmacokinetics 
and pharmacodynamic properties can help to elucidate the PK/PD relationship and better 
understand the mechanism of drug action and pharmacokinetic characteristics of the 
compound for further improvement. Optimal use of PK/PD modelling relies on the 
continuous integration of new relevant data throughout the different stages of drug 
development and enables crucial decisions to be reached earlier. 62,63  This has led to a new 
strategy within drug development that has a more PK/PD-guided approach. An important 
condition would be the development of a pharmaceutical formulation that delivers 
predictable and consistent pharmacokinetic profiles.
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Summary
Summary
Infection with human immunodeficiency virus (HIV) is one of the world’s most significant 
public health challenges. Currently, 35 million people are living with HIV worldwide and 
the HIV population is still growing. HIV destroys and impairs the function of immune cells 
in the body. The most advanced stage of HIV infection is Acquired Immunodeficiency 
Syndrome (AIDS). AIDS is one of the top causes of infectious disease-related mortality 
worldwide.
During the past 30 years there has been a remarkable progress in the treatment of HIV 
infection. Antiretroviral therapy prevents HIV from multiplying and reduces the level of 
HIV in the body. Suppressing and controlling viral replication protects the immune system, 
prevents HIV infection from advancing to AIDS, and reduces the risk of HIV transmission. 
The best strategy for long-term control of HIV infection is the use of combinations of 
potent antiretroviral agents from different drug classes that target different steps of the 
viral life cycle. HIV treatment nowadays consists of at least three antiretroviral agents from 
two different drug classes. 
Raltegravir was the first of a new class of antiretroviral agents called HIV integrase inhibitors. 
Immediately after the accelerated approval of raltegravir in 2007 it played an important 
role in HIV management. Initially raltegravir was licensed in combination with other 
antiretroviral agents for treatment-experienced patients with evidence of HIV replication 
despite ongoing antiretroviral therapy. The good safety profile and its potent and rapid 
antiretroviral activity has quickly extended the use of raltegravir to include first-line 
treatment of HIV-infected patients. Raltegravir is to be administered orally in a dosage of 
400 mg twice daily.
Clinical pharmacology is the scientific discipline that studies the relationship between 
drugs and humans in order to improve the efficacy and safety of drugs in patients. 
It includes two closely associated pharmacological principles: pharmacokinetics and 
pharmacodynamics. Pharmacokinetics is what the body does to the drug. The pharmaco-
kinetic characteristics of a drug comprises the absorption, distribution, metabolism, and 
elimination of the drug. Pharmacodynamics is what the drug does to the body, in other 
words the drug’s actions in terms of efficacy and toxicity/safety. The relationship between 
pharmacokinetics and pharmacodynamics is important because the patient’s exposure 
to the drug is a crucial determinant of the drug’s actions. 
It is widely acknowledged that better understanding of the clinical pharmacology of 
antiretroviral drugs is essential for their safe and effective use in HIV-infected patients. 
HIV-infected patients take at least three antiretroviral agents but may also take a variety of 
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medication for other medical illnesses. This significantly enhances the risk of drug-drug 
interactions. Drug-drug interactions occur when a drug interacts, or interferes, with 
another drug. This can alter the pharmacokinetics of one or both of the drugs, and 
the way they act in the body. Drug-drug interactions, but also other factors that could 
change the pharmacokinetics of antiretroviral agents in patients, are an important cause 
for suboptimal drug exposure or increased drug levels. This could potentially lead to 
treatment failure or toxicity problems in HIV-infected patients. 
Pharmacokinetic research of raltegravir is performed by measuring the plasma concentration 
of the drug in time under certain circumstances or in certain patient populations. The plasma 
concentration of antiretroviral agents can also be measured to optimize and individualize 
antiretroviral treatment as part of regular HIV patient care. This is called therapeutic drug 
monitoring (TDM). Especially patients who are at risk for potential low or elevated plasma 
concentrations could benefit from TDM. 
The main pharmacokinetic parameter to evaluate in pharmacokinetic studies is the 
exposure to raltegravir expressed as the area under the plasma concentration versus time 
curve (AUC). From a clinical perspective it is also important to know the trough level of 
raltegravir as this is currently the most important pharmacokinetic parameter of raltegravir 
to evaluate with regard to virological efficacy. The trough level can be measured by taking 
a blood sample just prior to the next dose, in other words 12 hours after the last dose.
The general aim of this thesis was to study the clinical pharmacology of the HIV integrase 
inhibitor raltegravir to optimize its safe and effective use in HIV-infected patients in clinical 
practice. The first part of this thesis focuses on pharmacokinetic drug-drug interactions 
between raltegravir and other frequently used concomitant medication. The pharmacoki-
netics of raltegravir in pregnant HIV-infected women and the application of TDM of 
raltegravir in special patient populations were addressed in the second part of this thesis.
Part 1: Drug-drug interactions
HIV-infected patients are at increased risk of cardiovascular disease. Dyslipidemia is highly 
prevalent among patients with HIV infection and contributes to this increased 
cardiovascular risk. Statins are frequently being used as lipid-lowering therapy in this 
patient population by reducing plasma low-density lipoprotein (LDL) cholesterol levels. 
The concomitant use of statins and certain antiretroviral agents have led to clinically 
relevant pharmacokinetic drug-drug interactions with potentially severe toxicity as a 
result. Chapter 2 describes the results of a pharmacokinetic drug-drug interaction study 
between raltegravir and atorvastatin in 24 healthy volunteers. The study was designed to 
investigate the effect of raltegravir 400 mg twice daily on the pharmacokinetics of 
atorvastatin 20 mg once daily and vice versa by intrasubject comparison. Geometric mean 
ratios (GMRs) of the test treatment (combination raltegravir + atorvastatin) versus the 
reference treatment (raltegravir or atorvastatin alone) and 90% confidence intervals (CI) 
were calculated for the AUC. The GMR (90% CI) was 1.01 (0.68-1.51) for raltegravir AUC
0-12h
. 
In other words the mean exposure to raltegravir was similar regardless of concomitant 
atorvastatin use, suggesting that atorvastatin 20 mg has no clinically relevant effect on the 
pharmacokinetics of raltegravir. However, the large confidence intervals indicate that 
there was quite some variability between subjects. The GMR (90%CI) was 1.00 (0.90-1.11) 
for atorvastatin AUC
0-24h
. Fasting lipid profiles were obtained to assess the short-term 
lipid-lowering effect of atorvastatin when combined with raltegravir versus the use of 
atorvastatin alone. Raltegravir does not influence the pharmacokinetics of atorvastatin 
and has no effect on its short-term lipid-lowering effect. We have concluded that the 
combination of raltegravir and atorvastatin can be used without dose adjustments.
Another drug treatment that is frequently being used within the HIV population is 
antidepressive therapy. Depression is the most common mental health disorder among 
HIV-patients with a lifetime prevalence that is approximately 2-fold higher than among 
HIV-uninfected individuals. Depression is associated with an increased risk of treatment 
failure and viral resistance of antiretroviral agents due to adherence problems. Therefore 
treating depression with antidepressant therapy is important to improve health outcomes 
in those living with HIV. Chapter 3 evaluates the two-way pharmacokinetic drug-drug 
interaction and tolerability of concomitant administration of citalopram, a selective 
serotonin reuptake inhibitor (SSRI) for the treatment of depression, and raltegravir in 24 
healthy volunteers. Citalopram was given in a dosage of 20 mg once daily and raltegravir 
in a regular dosage of 400 mg twice daily. Raltegravir does not influence the pharmacoki-
netics of citalopram and its main metabolite desmethylcitalopram. The GMR (90% CI) was 
1.00 (0.98-1.03) for citalopram AUC
0-24h 
and 0.99 (0.88-1.12) for desmethylcitalopram AUC
0-24h
. 
The citalopram metabolite-to-parent ratio, which is a measure for metabolic activity, did 
not appear to be affected by concomitant raltegravir use. The GMR of raltegravir AUC
0-12h
 
was 0.77 (0.50-1.19). The 23% decrease in raltegravir exposure (AUC) in combination with 
citalopram is not considered to be clinically important. Raltegravir C
12h
 did not change 
with concomitant use of citalopram with a GMR (90% CI) of 1.03 (0.71-1.50). This study 
shows that in HIV-infected patients with depression citalopram and raltegravir can be 
used without dose adjustment.
Of the 35 million people living with HIV worldwide, approximately 4 to 5 million are 
co-infected with hepatitis C virus (HCV). As a result many HIV-infected patients need to be 
treated for their HCV infection as well. Boceprevir was introduced in 2011 as a newly 
developed NS3 serine protease inhibitor for the treatment of chronic HCV genotype 1 
infection. Unfortunately several drug combinations with boceprevir and commonly used 
antiretroviral agents for the treatment of HIV should be avoided or used with great caution 
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due to pharmacokinetic interactions. In order to recommend raltegravir as a preferred 
agent for combined HIV/HCV treatment with boceprevir, we performed a pharmacokinetic 
drug-drug interaction study between raltegravir and boceprevir (800 mg three times 
daily) in healthy volunteers as presented in Chapter 4. The GMR (90%CI) of raltegravir 
AUC
0-12h
 for raltegravir with boceprevir versus raltegravir alone was 1.04 (0.88-1.22). 
Boceprevir plasma concentrations when coadministered with raltegravir were comparable 
with historical reference values of boceprevir in plasma. Due to the absence of a clinically 
significant drug-drug interaction, raltegravir can be recommended for combined HIV/
HCV treatment including boceprevir.
Besides conventional medication, approximately 60% of the HIV-infected patients use 
alternative medicines. A popular herbal product used worldwide by HIV-infected patients 
is Ginkgo biloba extract. Ginkgo biloba is used for its claimed beneficial effects on 
concentration, memory and depressive disorders. Ginkgo biloba may influence the 
P-glycoprotein membrane transporter and UDP-glucuronosyltransferase (UGT) liver enzymes 
that play a role in the farmacokinetics of raltegravir. However, these studies show conflicting 
results and were mainly performed in vitro. We performed a herb-drug pharmaco kinetic 
interaction study between Ginkgo biloba and raltegravir in healthy volunteers (Chapter 5). 
GMRs (90% CI) of the exposure (AUC)
 
and maximum plasma concentration (C
max
) of 
raltegravir with Ginkgo biloba versus raltegravir alone were, respectively, 1.21 (0.93-1.58) 
and 1.44 (1.03-2.02). Ginkgo biloba did not reduce the exposure to raltegravir. The potential 
increase in C
max
 of raltegravir is probably of minor importance given the large variability of 
raltegravir pharmacokinetics between subjects and its reported safety profile. There is no 
need to discourage the use of Ginkgo biloba in HIV-infected patients who take raltegravir.
Part 2: Pharmacokinetics in special patient populations
In Chapter 6 we evaluated the effect of pregnancy on the pharmacokinetics of raltegravir 
and its safety, and efficacy in HIV-infected pregnant women. This study was performed 
within the European PANNA research network. HIV can be transmitted from the HIV- 
infected woman to her child during pregnancy, childbirth, or breastfeeding. Mother- 
to-child transmission of HIV is the most common route of HIV-infection among infants 
and children. To reduce the risk of HIV transmission to the (unborn) child it is important 
that the mother takes antiretroviral agents to reduce the amount of HIV particles in her 
body (HIV load). 
Pregnancy may influence the pharmacokinetic profile of antiretroviral agents and lead to 
decreased drug exposure. Suboptimal drug exposure can result in treatment failure and an 
increased risk of HIV transmission to the child. Antiretroviral regimens including raltegravir 
were initially only recommended during pregnancy in special circumstances because 
information on the pharmacokinetics and the safety of raltegravir in pregnancy was limited. 
We included 22 HIV-infected pregnant women on a raltegravir-based regimen in 10 
different European hospitals. Pharmacokinetic assessment was performed in the third 
trimester of pregnancy and repeated approximately 4-6 weeks postpartum which we 
considered to be the normal nonpregnant reference situation. Our findings show an 
average decrease of 29% in the exposure (AUC) to raltegravir during the third trimester of 
pregnancy compared with postpartum. A similar effect of pregnancy on trough levels 
was observed leading to an average decrease of 36%. Approaching delivery 86% of the 
patients had an undetectable HIV load (<50 copies/mL). None of the children were 
HIV-infected and no birth defects were reported. In nine patients we were able to take 
blood samples together with umbilical cord blood samples after delivery. The ratio of the 
amount of raltegravir in the cord blood in relation to the mother blood gives information 
on the placental transfer of raltegravir. The median ratio was 1.21 (interquartile range 
1.02-2.17) meaning that raltegravir readily crosses the placenta. 
Raltegravir was well tolerated during pregnancy. Exposure to raltegravir was highly variable. 
The observed mean decrease in exposure is not considered to be of clinical importance. 
Our results support the use of raltegravir in standard dosages in HIV-infected pregnant 
women for HIV treatment and prevention of mother-to-child HIV transmission. The results of 
our study have been incorporated into the international guideline of the American Department 
of Health and Human Services (DHHS) for the use of antiretroviral drugs in pregnant 
HIV-infected patients. In the latest update of this guideline in August 2015 raltegravir has 
been promoted to one of the preferred agents for initial therapy during pregnancy. 
The optimal antiretroviral treatment for HIV-infected patients with cancer and use of 
chemotherapy is complicated because of drug-drug interactions and overlapping toxicity. 
Although raltegravir is increasingly being recommended and used in clinical practice in 
HIV-infected patients with cancer, surprisingly little is known on the pharmacokinetics of 
raltegravir in this setting. In Chapter 7 we describe a short case series of three HIV-infected 
patients with advanced stage non-Hodgkin lymphoma who used chemotherapy in 
combination with a raltegravir-based antiretroviral regimen. We used a limited blood 
sampling strategy to estimate the total exposure (AUC
0-12h
)
 
to raltegravir. The estimated 
total exposure to raltegravir in these patients was on average lower compared to 
population reference values. However the extent of this reduction was not considered to 
be of clinical importance. Raltegravir trough plasma concentrations, which is the most 
important parameter with respect to virological efficacy, was adequate (>0.020 mg/L) in 
all three patients when using the standard dosage of 400 mg raltegravir twice daily. Severe 
diarrhoea caused by intestinal chemotherapy-induced mucositis may negatively influence 
the extent of absorption of raltegravir. In one patient we observed a decrease in absorption 
of raltegravir compared to baseline levels after developing severe diarrhea. In these 
circumstances TDM could be used to monitor the treatment of raltegravir.
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Raltegravir is the first HIV integrase inhibitor approved by the US Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for treatment of HIV 
infection in the pediatric population. Raltegravir is available as film-coated tablet (400 mg 
raltegravir) and recently also in two special formulations suitable for infants and young 
children who are unable to swallow whole tablets; chewable tablets (25 and 100 mg) and 
granules which are administered as oral suspension (20 mg/mL). There is little experience 
in the use of raltegravir in children and the knowledge of the pharmacokinetics of 
raltegravir in particularly young children is still limited. The pediatric HIV population is at 
risk for variability in antiretroviral drug exposure due a number of developmental changes 
in children that could alter the pharmacokinetics of drugs. To optimize antiretroviral 
treatment in this special patient population TDM could be a useful tool. In this context, we 
describe in Chapter 8 our experience with dose optimization of raltegravir chewable 
tablets in a 4-year-old HIV-infected patient based on TDM of raltegravir. Despite following 
the approved weight-based dose recommendations for raltegravir chewable tablets, we 
repeatedly measured very low raltegravir trough levels (<0.015 mg/L). The patient switched 
from a twice daily dose regimen to an off-label three times daily regimen. By shortening 
the dose interval we could successfully increase the raltegravir trough levels in this young 
patient to acceptable values. At the age of 7 he was able to switch back to a normal twice 
daily dosage of raltegravir chewable tablets. 
In Chapter 8 we reviewed the available literature and information on the pharmacokinetics 
of raltegravir in children which has resulted in the approved dose recommendations for 
the use of raltegravir in children ≥4 week to <18 years. The lowest mean raltegravir trough 
level compared to other age groups and reference values in adults was found in a small 
cohort of children from ≥2 to <6 years who used the chewable tablets. We are concerned 
that some individual young patients who use chewable tablets might experience 
suboptimal trough levels in clinical practice as illustrated by our case. This could especially 
be problematic in children who have a high HIV load before starting a raltegravir-based 
regimen. In these patients TDM could be a useful tool to monitor and if necessary adjust 
the raltegravir dose regimen.
General discussion
The best strategy for long-term control of HIV infection is the use of combinations of 
potent antiretroviral agents that target different steps of the viral life cycle. The accelerated 
approval of raltegravir in 2007 by the FDA and EMA was highly anticipated as it introduced 
us to the first of a new class of antiretroviral agents called the HIV integrase inhibitors. 
Since raltegravir was introduced to the market the knowledge about the clinical 
pharmacology of raltegravir has greatly improved. The research in this thesis has 
contributed to that knowledge and to a better understanding of its drug interaction 
potential and the pharmacokinetics of raltegravir in (special) HIV-infected patients. In the 
general discussion the results of this thesis are discussed focussing on the following 
main topics: pharmacokinetic drug-drug interaction studies, the variability in the pharmaco-
kinetics of raltegravir and potential influencing factors, the relationship between the 
 pharmacokinetics and pharmacodynamics of raltegravir, and the role of TDM in clinical 
practice. 
Despite the extensive pharmacokinetic research that has been done with raltegravir, the 
variability in the pharmacokinetics has never been truly unravelled. This has complicated 
the investigation to establish a clear dose-response relationship and the development of 
a population pharmacokinetic model. We believe that the pharmaceutical formulation of 
raltegravir poloxamer tablets and its poor solubility and permeability is an important 
contributor to the inter- and intrasubject variability in raltegravir pharmacokinetics. 
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Infectie met het humaan immunodeficiëntie virus (hiv) is één van de grootste uitdagingen 
voor de wereldgezondheid. Momenteel zijn er 35 miljoen mensen wereldwijd geïnfecteerd 
met hiv en dit aantal groeit nog steeds. Hiv vernietigt en schaadt de functie van immuun- 
cellen in het lichaam. Het meest vergevorderde stadium van hiv-infectie is acquired 
 immunodeficiency syndrome (aids). Aids behoort tot de belangrijkste oorzaken van 
infectieuze ziektegerelateerde sterfte wereldwijd. 
De afgelopen 30 jaar is er een enorme vooruitgang geboekt bij de behandeling van hiv. 
Antiretrovirale therapie voorkomt dat hiv zich vermenigvuldigt waardoor het aantal 
hiv-deeltjes in het lichaam vermindert. Het onderdrukken van deze virale replicatie 
beschermt het immuunsysteem, voorkomt de progressie naar aids en vermindert de kans 
op overdracht van hiv. De beste strategie voor langdurige onderdrukking van hiv is het 
combineren van meerdere hiv-remmers die op verschillende wijze aangrijpen op de 
levenscyclus van het virus. Tegenwoordig bestaat de behandeling voor hiv uit een 
combinatie van drie hiv-remmers uit twee verschillende geneesmiddelgroepen. 
Raltegravir is de eerste hiv-remmer van een nieuwe groep geneesmiddelen genaamd 
 integraseremmers. Direct nadat raltegravir versneld werd goedgekeurd door de registratie-
autoriteiten eind 2007, nam raltegravir een belangrijke positie in binnen de behandeling 
van hiv. Aanvankelijk was raltegravir geregistreerd voor de behandeling van hiv bij 
volwassen patiënten bij wie hiv, ondanks uitgebreide behandeling, niet onder controle 
was. Omdat raltegravir een snelle en krachtige hiv-remmer bleek te zijn met een gunstig 
bijwerkingenprofiel, werd de toepassing van raltegravir vervolgens uitgebreid naar een 
eerstelijns behandeling. Raltegravir tabletten worden oraal ingenomen in een dosering 
van tweemaal daags 400 mg.
Klinische farmacologie is de wetenschappelijke discipline die de relatie tussen genees- 
middelen en mensen bestudeert om de werkzaamheid en veiligheid van geneesmiddelen 
bij patiënten te verbeteren. Het omvat twee aan elkaar gerelateerde farmacologische 
principes: farmacokinetiek en farmacodynamiek. Farmacokinetiek kan worden gedefinieerd 
als wat het lichaam doet met het geneesmiddel. De farmacokinetische eigenschappen 
van een geneesmiddel omvatten de absorptie, distributie, metabolisme en eliminatie 
van het geneesmiddel. Farmacodynamiek kan worden gezien als wat het geneesmiddel 
doet met het lichaam, dat wil zeggen het effect van het geneesmiddel in termen van 
werkzaamheid, toxiciteit en veiligheid. De relatie tussen farmacokinetiek en farmaco-
dynamiek is belangrijk omdat de blootstelling aan een geneesmiddel in het lichaam (farmaco-
ki netiek) een bepalende factor is voor het effect van het geneesmiddel (farmacodynamiek). 
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Het is algemeen geaccepteerd dat kennis van de klinische farmacologie van antiretrovirale 
geneesmiddelen essentieel is voor een veilig en effectief gebruik van deze middelen 
bij hiv-geïnfecteerde patiënten. Hiv-patiënten gebruiken minimaal drie verschillende 
hiv-remmers maar moeten vaak ook geneesmiddelen gebruiken voor andere aan- 
doeningen. Dit vergroot aanzienlijk de kans op geneesmiddelinteracties. Geneesmiddel-
interacties treden op wanneer een geneesmiddel een wisselwerking heeft, of interfereert 
met een ander geneesmiddel. Dit kan invloed hebben op de farmacokinetiek van één of 
beide geneesmiddelen en het effect van het geneesmiddel. Interacties met genees- 
middelen, maar ook andere factoren die van invloed zijn op de farmacokinetiek van 
hiv-remmers zijn een belangrijke oorzaak van suboptimale blootstelling aan deze 
geneesmiddelen of verhoogde bloedspiegels van deze middelen. Dit kan vervolgens 
leiden tot het falen van de therapie of problemen met bijwerkingen bij hiv-patiënten. 
Door op verschillende tijdstippen na inname van raltegravir en onder verschillende 
omstandigheden de concentratie van raltegravir in het bloedplasma te meten kun je 
meer te weten komen over de farmacokinetiek. De concentratie van raltegravir in het 
bloed kan ook worden gemeten in het kader van reguliere patiëntenzorg met als doel om 
de hiv-behandeling te optimaliseren van de betreffende patiënt. Het op deze wijze 
monitoren van de therapie wordt ‘therapeutic drug monitoring’ (TDM) genoemd. Vooral 
patiënten met een verhoogd risico op te lage of juist verhoogde bloedspiegels kunnen 
baat hebben bij TDM. 
De belangrijkste parameter in het onderzoek naar de farmacokinetiek van raltegravir is de 
blootstelling aan raltegravir. De blootstelling wordt berekend door het oppervlak onder 
de plasmaconcentratie versus tijd curve te berekenen en wordt uitgedrukt als ‘area under 
the curve’ (AUC). Vanuit een klinisch perspectief is het ook belangrijk om de dalspiegel van 
raltegravir te weten aangezien dit de belangrijkste parameter blijkt te zijn in relatie tot de 
effectiviteit. De dalspiegel kan worden gemeten door het nemen van een bloedmonster 
net voor de volgende inname, dat wil zeggen 12 uur na de laatste inname.
Het belangrijkste doel van dit proefschrift is het bestuderen van de klinische farmacologie 
van de hiv integraseremmer raltegravir om de effectiviteit en de veiligheid van dit middel 
te verbeteren bij hiv-patiënten in de klinische praktijk. Het eerste deel van dit proefschrift 
beschrijft een viertal onderzoeken naar geneesmiddelinteracties tussen raltegravir en 
andere veelgebruikte geneesmiddelen. Het tweede deel van dit proefschrift gaat over de 
farmacokinetiek van raltegravir bij zwangere hiv-geïnfecteerde vrouwen en de toepassing 
van TDM van raltegravir bij speciale patiëntengroepen.
Deel 1: Geneesmiddelinteracties
Hiv-geïnfecteerde patiënten hebben een verhoogd risico op het krijgen van hart- en 
vaatziekten. Dyslipidemie, oftewel een verstoorde vetstofwisseling, komt veel voor bij 
hiv-patiënten en draagt in belangrijke mate bij aan dit verhoogde risico. Daarom gebruiken 
veel hiv-patienten lipidenverlagende geneesmiddelen zoals de groep geneesmiddelen 
genaamd statines. Statines verlagen het plasma low-density lipoprotein (LDL) cholesterol 
en kunnen de kans op hart- en vaatziekten verminderen. Er zijn echter klinisch relevante 
farmacokinetische interacties beschreven tussen statines en bepaalde hiv-remmers met 
ernstige bijwerkingen als gevolg. Hoofdstuk 2 beschrijft de resultaten van ons onderzoek 
naar de wisselwerking tussen raltegravir en atorvastatine in 24 gezonde proefpersonen. 
We hebben het effect onderzocht van het gebruik van tweemaal daags 400 mg raltegravir 
op de farmacokinetiek van atorvastatine in een dosering van 20 mg eenmaal daags en 
andersom. Voor iedere deelnemer werden de plasmaconcentraties van de geneesmiddelen 
tijdens de test behandeling (combinatie raltegravir + atorvastatine) vergeleken met de 
waarden van de referentie behandeling (raltegravir of atorvastatine alleen). Het gemiddelde 
van deze verhouding en de spreiding hierin wordt weergegeven als Geometric Mean 
Ratio (GMR) met een 90% betrouwbaarheidsinterval (BI). De GMR (90% BI) was 1,01 
(0,68-1,51) voor raltegravir AUC
0-12h
. Dit betekent dat de gemiddelde blootstelling aan 
raltegravir niet werd beïnvloed door het gelijktijdig gebruik van atorvastatine. Het ruime 
betrouwbaarheidsinterval geeft weer dat er veel variatie is tussen de waarden binnen 
onze onderzoekspopulatie. De GMR (90% BI) was 1,00 (0,90-1,11) voor atorvastatine 
AUC
0-24h
. We hebben tevens het lipidenprofiel gemeten van de deelnemers om te kijken of 
het lipidenverlagende effect van atorvastatine beïnvloed wordt door het gebruik van 
raltegravir. Dit bleek niet het geval te zijn. We concluderen dat de combinatie atorvastatine 
en raltegravir veilig gebruikt kan worden zonder dosisaanpassing.
Andere veel gebruikte geneesmiddelen bij hiv-positieve patiënten zijn geneesmiddelen 
tegen depressieve klachten. Depressie is namelijk de meest voorkomende psychische 
aandoening bij hiv-patiënten en komt ongeveer twee keer vaker voor dan bij mensen 
zonder hiv. Depressie wordt geassocieerd met een verhoogd risico op het falen van de 
hiv-behandeling en het ontwikkelen van resistentie tegen het virus omdat de hiv-remmers 
niet regelmatig genoeg worden ingenomen. Dit maakt dat een goede behandeling met 
antidepressiva de algehele gezondheidssituatie van mensen met hiv en een depressie 
sterk kan verbeteren. In hoofdstuk 3 is het onderzoek beschreven naar de farmacokineti-
sche interactie en de veiligheid van het gelijktijdige gebruik van citalopram, een selectieve 
serotonine heropname inhibitor (SSRI) voor de behandeling van depressie, en raltegravir 
bij 24 gezonde proefpersonen. Citalopram werd gegeven in een dosering van eenmaal 
daags 20 mg en raltegravir in een dosering van tweemaal daags 400 mg. Raltegravir 
beïnvloedt niet de farmacokinetiek van citalopram en zijn belangrijkste metaboliet 
desmethylcitalopram. De GMR (90% BI) was 1,00 (0,98-1,03) voor citalopram AUC
0-24h
 en 
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0,99 (0,88-1,12) voor desmethylcitalopram AUC
0-24h
. De gemiddelde verhouding tussen de 
metaboliet desmethylcitalopram ten opzichte van de moederstof citalopram is een maat 
voor de metabole activiteit en deze bleek niet te worden beïnvloed door raltegravir. De 
GMR (90% BI) was 0,77 (0,50-1,19) voor raltegravir AUC
0-12h
. De gemiddelde daling van 23% 
in de blootstelling (AUC) aan raltegravir in combinatie met citalopram is klinisch niet 
relevant. De dalspiegel van raltegravir veranderde niet bij gelijktijdig gebruik van 
citalopram met een GMR (90% BI) van 1,03 (0,71-1,50). Dit onderzoek laat zien dat bij 
hiv-patiënten met een depressie gelijktijdig de geneesmiddelen raltegravir en citalopram 
gebruikt kunnen worden zonder dosisaanpassing. 
Van de 35 miljoen mensen met hiv wereldwijd zijn ongeveer 4 tot 5 miljoen mensen ook 
geïnfecteerd met het hepatitis C virus (HCV). In de praktijk komt het dus regelmatig voor 
dat hiv-patiënten zowel hiv-remmers moeten gebruiken als antivirale geneesmiddelen 
tegen chronische HCV. In 2011 werd het direct werkende antivirale geneesmiddel 
boceprevir op de markt gebracht voor de behandeling van HCV. Helaas laat boceprevir 
zich niet goed combineren met verschillende hiv-remmers vanwege farmacokinetische 
interacties. Om bij een gecombineerde behandeling van hiv en HCV raltegravir te kunnen 
aanbevelen met boceprevir, hebben we een onderzoek uitgevoerd naar de wisselwerking 
tussen raltegravir en boceprevir (inname van driemaal daags 800 mg) in gezonde 
proefpersonen (hoofdstuk 4). De GMR (90% BI) van raltegravir AUC
0-12h 
voor raltegravir 
met boceprevir versus raltegravir alleen was 1,04 (0,88-1,22). De gemeten plasmaconcen-
traties van boceprevir in combinatie met raltegravir waren vergelijkbaar met referentie-
waarden van boceprevir in bloedplasma. We concluderen dat er geen farmacokinetische 
geneesmiddelinteractie is tussen raltegravir en boceprevir. Raltegravir is een goede keuze 
om te gebruiken als hiv-remmer wanneer patiënten tevens behandeld worden met 
boceprevir vanwege een chronische HCV infectie. 
Naast reguliere medicatie gebruikt ongeveer 60% van de hiv-patiënten ook alternatieve 
medicatie. Een populair kruidenpreparaat dat wereldwijd door hiv-positieve patiënten 
wordt gebruikt is Ginkgo biloba extract. Ginkgo biloba wordt gebruikt omdat het gunstige 
effecten zou hebben op het concentratievermogen, het geheugen en depressiviteit. Uit 
een aantal onderzoeken blijkt dat Ginkgo biloba mogelijk de membraantransporter en 
leverenzymen beïnvloedt die een rol spelen bij de opname en afbraak van raltegravir. 
Maar de resultaten uit deze voornamelijk in vitro onderzoeken zijn tegenstrijdig en er zijn 
geen of nauwelijks onderzoeken gedaan naar dit effect in mensen. In hoofdstuk 5 
onderzochten we het effect van het gebruik van Ginkgo biloba extract gedurende 2 
weken op de farmacokinetiek van een eenmalige dosering van 400 mg raltegravir bij 18 
gezonde proefpersonen. De GMR (90% BI) van de blootstelling (AUC) en de maximale 
plasmaconcentratie van raltegravir met Ginkgo biloba versus raltegravir alleen waren 
 respectievelijk 1,21 (0,93-1,58) en 1,44 (1,03-2,02). Ginkgo biloba zorgt in ieder geval niet 
voor een te lage blootstelling aan raltegravir. De gemiddelde toename van de maximale 
plasmaconcentratie van raltegravir is klinisch niet relevant gezien de grote variabiliteit in 
de gemeten waarden en het goede veiligheidsprofiel van raltegravir. Het gebruik van 
Ginkgo biloba hoeft niet te worden ontraden bij hiv-patiënten die raltegravir gebruiken.
Deel 2: Farmacokinetiek bij speciale patiëntengroepen
In hoofdstuk 6 wordt het effect van de zwangerschap op de farmacokinetiek van 
raltegravir en de veiligheid en werkzaamheid bij hiv-geïnfecteerde zwangere vrouwen 
beschreven. Dit onderzoek is tot stand gekomen door het Europese PANNA onderzoeks-
netwerk. Een hiv-geïnfecteerde vrouw kan hiv overdragen aan haar kind tijdens de 
zwangerschap, bevalling of borstvoeding. Moeder-op-kind overdracht van hiv is verreweg 
de meest voorkomende oorzaak van hiv-infectie bij kinderen. Om het risico van overdracht 
van hiv aan het (ongeboren) kind te verminderen is het belangrijk dat de moeder 
hiv-remmers gebruikt om het aantal virusdeeltjes in haar lichaam te verminderen. 
De fysiologische veranderingen tijdens de zwangerschap kunnen van invloed zijn op de 
farmacokinetiek van antiretrovirale middelen met als mogelijk gevolg een verminderde 
blootstelling aan het geneesmiddel. Suboptimale blootstelling kan vervolgens leiden tot 
therapiefalen en een verhoogd risico van moeder-op-kind transmissie van hiv. Omdat er 
weinig bekend was over de farmacokinetiek en veiligheid van raltegravir tijdens de 
zwangerschap werd in de richtlijnen het gebruik van raltegravir tijdens de zwangerschap 
aanvankelijk alleen aanbevolen onder speciale omstandigheden. 
We hebben 22 hiv-geïnfecteerde zwangere vrouwen geïncludeerd die raltegravir 
gebruikten in 10 verschillende Europese ziekenhuizen. De hoeveelheid raltegravir in het 
bloed werd gemeten in het derde trimester van de zwangerschap en dit werd herhaald 
ongeveer 4-6 weken na de bevalling wat we beschouwden als de normale niet-zwangere 
situatie. Onze resultaten laten zien dat de bloostelling (AUC) aan raltegravir in het derde 
trimester van de zwangerschap gemiddeld 29% lager is dan de blootstelling aan raltegravir 
na de bevalling. We zagen een vergelijkbare daling van gemiddeld 36% in de dalspiegels 
van raltegravir tijdens de zwangerschap. Vlak voor de bevalling had 86% van de patiënten 
een niet detecteerbare virale lading (<50 kopieën/ml). De kinderen waren allemaal 
hiv-negatief en er zijn geen geboorteafwijkingen gerapporteerd. Bij negen patiënten 
konden we direct na de bevalling zowel bloed afnemen bij de moeder als uit de 
navelstreng. De verhouding van de hoeveelheid raltegravir in het navelstrengbloed ten 
opzichte van het bloed van de moeder geeft informatie over de placentapassage van 
raltegravir. De gemiddelde (mediane) verhouding was 1,21 wat betekent dat raltegravir 
gemakkelijk de placenta passeert. 
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Raltegravir werd goed verdragen tijdens de zwangerschap. Wel viel op dat de blootstelling 
aan raltegravir zeer variabel was. De waargenomen gemiddelde daling van de blootstelling 
wordt niet als klinisch relevant beschouwd. Onze gegevens ondersteunen het gebruik 
van raltegravir in standaard doseringen bij hiv-geïnfecteerde zwangere vrouwen voor de 
behandeling van hiv en de preventie van moeder-op-kind transmissie. De resultaten van 
ons onderzoek zijn opgenomen in de internationale richtlijn van de Amerikaanse 
Department of Health and Human Services (DHHS) die gaat over het gebruik van anti-
retrovirale geneesmiddelen bij zwangere hiv-geïnfecteerde patiënten. In de versie van 
augustus 2015 is de plaatsbepaling van raltegravir tijdens de zwangerschap gewijzigd 
naar één van de voorkeursmiddelen voor de behandeling van hiv tijdens de zwangerschap.
De optimale antiretrovirale behandeling voor hiv-geïnfecteerde patiënten met kanker en 
het gebruik van chemotherapie is ingewikkeld vanwege geneesmiddelinteracties en 
overlappende toxiciteit. Hoewel raltegravir steeds vaker wordt aanbevolen in de klinische 
praktijk bij hiv-geïnfecteerde patiënten met kanker, is er verrassend weinig bekend over 
de farmacokinetiek van raltegravir in deze speciale patiëntengroep. In hoofdstuk 7 
beschrijven we drie hiv-geïnfecteerde patiënten met een vergevorderd stadium van 
non-Hodgkin lymfoom die chemotherapie gebruiken in combinatie met een raltegravir- 
bevattend regime. We namen tot 3 uur na inname van raltegravir meerdere keren bloed 
af om een schatting te kunnen doen van de totale blootstelling aan raltegravir in 12 uur 
(AUC0-12h). De geschatte totale blootstelling aan raltegravir bij deze patiënten was 
gemiddeld lager dan onze referentiewaarden, maar de mate van deze verminderde 
blootstelling vonden we klinisch niet relevant. De dalspiegels van raltegravir, de belangrijkste 
farmacokinetische parameter met betrekking tot effectiviteit, bleek voldoende te zijn 
(>0,020 mg/L) bij alle drie de patiënten bij gebruik van de standaard dosering. Wel zagen 
we bij één patiënt een verminderde absorptiecurve van raltegravir na het volgen van een 
chemokuur ten opzichte van de referentiecurve voor het starten van deze hoge dosis 
chemotherapie. Deze patiënt had last gekregen van ernstige diarree en braken wat een 
bijwerking is van hoge doseringen chemotherapie. In deze situaties kan TDM ingezet 
worden om bijvoorbeeld een hogere dosis raltegravir voor te schrijven als de blootstelling 
te laag wordt. 
Hiv-positieve kinderen zijn bij uitstek een patiëntengroep waarbij het monitoren van 
bloedspiegels van antiretrovirale middelen zinvol kan zijn omdat er veel variatie is in de 
farmacokinetiek vanwege de lichamelijke ontwikkeling die ze doormaken. Voor de 
behandeling van hiv bij kinderen is het bovendien belangrijk dat er geschikte kinder-
formuleringen zijn van hiv-remmers die gebruikt kunnen worden voor een breed 
 doseringsgebied. Raltegravir is de eerste integraseremmer die is goedgekeurd door de 
registratieautoriteiten in de Verenigde Staten en Europa voor de behandeling van hiv 
infectie bij kinderen. Raltegravir is verkrijgbaar als tablet en sinds kort ook in twee speciale 
vormen (formuleringen) die geschikt zijn voor zuigelingen en jonge kinderen die niet in 
staat zijn om hele tabletten te slikken; kauwtabletten (25 en 100 mg) en kleine korreltjes 
die kunnen worden opgelost in een vloeistof. Het gebruik en de ervaring met betrekking 
tot de farmacokinetiek van raltegravir bij met name jonge kinderen is nog heel beperkt. In 
deze context, beschrijven we in hoofdstuk 8 onze ervaring met dosisoptimalisatie van 
raltegravir kauwtabletten bij een 4-jarige hiv-positieve patiënt op basis van TDM van 
raltegravir. Bij deze patiënt werden bij herhaling zeer lage raltegravir dalspiegels gemeten 
(<0,015 mg/L). Door raltegravir vaker te geven op een dag, namelijk 3 keer per dag in 
plaats van 2 keer per dag, konden we met succes de raltegravir dalspiegels verhogen tot 
acceptabele waarden. Toen de patiënt 7 jaar oud was is hij succesvol terug gegaan naar 
een normale dosering van tweemaal daags raltegravir kauwtabletten. 
In hoofdstuk 8 worden tevens de onderzoeken over de farmacokinetiek van raltegravir 
bij kinderen besproken die aan de basis liggen van de doseringsadviezen van raltegravir 
bij kinderen vanaf 4 weken tot 18 jaar oud. Opvallend was dat de laagste raltegravir 
plasma concentraties werden gemeten in het cohort van kinderen vanaf 2 tot 6 jaar die de 
kauwtabletten gebruiken. Wij zijn bezorgd dat sommige jonge patiënten die raltegravir 
kauwtabletten gebruiken in de praktijk suboptimale dalspiegels hebben zoals beschreven 
in onze casus. Bij jonge hiv-patiënten kan het daarom zinvol zijn om bij gebruik van 
raltegravir kauwtabletten de bloedspiegels van raltegravir te meten en indien nodig de 
dosering aan te passen.
Algemene discussie
De beste strategie voor het langdurig onderdrukken van hiv is het combineren van krachtige 
antiretrovirale middelen met verschillende werkingsmechanismen. Raltegravir werd eind 
2007 door de registratieautoriteiten versneld goedgekeurd omdat er op dat moment 
grote behoefte was aan nieuwe hiv-remmers. Raltegravir was het eerste geneesmiddel 
van een nieuwe klasse van antiretrovirale middelen, namelijk de integraseremmers. 
Sinds raltegravir in gebruik is genomen zijn we veel meer te weten gekomen over de 
klinische farmacologie van raltegravir. Het onderzoek in dit proefschrift heeft hier aan 
bijgedragen, met name op het gebied van geneesmiddelinteracties en de farmacokine-
tiek van raltegravir in bijzondere (groepen) hiv-geïnfecteerde patiënten. In de algemene 
discussie van dit proefschrift worden de resultaten besproken met een focus op de 
volgende hoofdthema’s: farmacokinetisch interactieonderzoek met raltegravir, de 
variabiliteit in de farmacokinetiek van raltegravir en de mogelijke factoren die hierin een 
rol spelen, de relatie tussen de farmacokinetiek en farmacodynamiek van raltegravir, en de 
rol van TDM in de klinische praktijk.
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Ondanks al het onderzoek dat is gedaan naar de farmacokinetiek van raltegravir, is de 
zo kenmerkende variabiliteit in de farmacokinetiek nooit echt goed opgehelderd. Deze 
variabiliteit heeft er ook voor gezorgd dat het aanvankelijk moeilijk was om een duidelijke 
relatie te vinden tussen de concentratie van raltegravir in het bloed (farmacokinetiek) en 
het effect (farmacodynamiek). Wij denken dat een groot deel van de variabiliteit in de 
farmacokinetiek van raltegravir veroorzaakt wordt door de farmaceutische formulering 
van de raltegravir tabletten en de slechte oplosbaarheid en permeabiliteit. 
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Met heel veel plezier heb ik de afgelopen jaren aan mijn promotieonderzoek gewerkt. Een 
promotietraject zou je kunnen vergelijken met een mooie reis, een soort ontdekkingsreis. 
Onbevangen ging ik eind 2010 het avontuur tegemoet. Op onderzoek uit…. 
 Met veel ervaring rijker en een paar illusies armer heb ik mijn eindbestemming 
bereikt. Dat heb ik gelukkig niet alleen gedaan. Laat ik daarom beginnen met een 
algemeen maar oprecht ‘Bedankt!’ voor iedereen die een bijdrage heeft geleverd aan dit 
proefschrift. Want of het nu de hulp was bij het meten en analyseren, of de interesse en 
steun van collega’s, vrienden en familie…ik heb het allemaal zeer gewaardeerd. Toch wil 
ik graag een aantal mensen in het bijzonder noemen.
Allereerst wil ik de patiënten en gezonde proefpersonen bedanken die hebben deelgenomen 
aan de onderzoeken. Dit alles was nooit mogelijk geweest zonder jullie bijdrage en 
vertrouwen. 
Prof. dr. Burger, beste David, bedankt voor de kans om onderzoek te gaan doen bij jouw 
onderzoeksgroep. Het is een vakgroep om trots op te zijn en dat is voor een groot deel 
jouw verdienste. Als je een promotietraject vergelijkt met een mooie reis dan was jij mijn 
reisleider. De inhoud van dit proefschrift (onze eindbestemming) lag van te voren niet vast 
maar dat we er zouden komen was zeker. David, enorm veel dank voor de fijne (en relaxte) 
manier waarop je mij begeleid hebt. Ik heb veel van je geleerd.
Angela Colbers kan ik dan het beste omschrijven als assistent reisleider en tevens 
reisgenoot. Lieve Angela, ik ben heel blij met jou als paranimf aan mijn zijde. Je bent mijn 
grote steun en toeverlaat geweest bij al mijn onderzoek. Het is heel fijn samenwerken met 
jou en ik kijk met veel plezier terug op onze gezamenlijke congresbezoeken en gezellige 
uitstapjes. Aan mijn andere zijde staat mijn paranimf Bregje Ruijs-Witjes. Lieve Bregje, van 
collega ziekenhuisapotheker in opleiding in het Erasmus MC werd je al snel een hele 
goede vriendin. Bedankt hiervoor en voor je interesse en steun. Ik vind het bijzonder dat 
we dit moment samen kunnen delen.
De leden van de manuscriptcommissie, prof. dr. André van der Ven, prof. dr. Peter Reiss 
en dr. Matthijs van Luin, wil ik hartelijk bedanken voor het bestuderen en het positief 
beoordelen van dit proefschrift. Matthijs, wat leuk dat jij deze rol hebt vervuld. 
Remco de Jong, afdelingshoofd van de Apotheek van het Radboudumc, wil ik bedanken 
voor het mogelijk maken van dit promotietraject binnen de afdeling.
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Ik heb veel tijd doorgebracht op het Clinical Research Centre Nijmegen (CRCN) van het 
Radboudumc waar de interactieonderzoeken zijn uitgevoerd. Alle (oud-)medewerkers 
van het CRCN wil ik bedanken. In het bijzonder bedank ik Christel, Joyce, Wendy, Jackie, 
Adrianne, Simone, Inge, Karin, Corina, Marielle, Willeke, Lanny, Anja, Michel, Mike en Luuk 
voor hun hulp bij de uitvoering. Bas Schouwenberg, bedankt voor je inzet en al je 
(medische) input. Op de drukste momenten van het onderzoek konden we gelukkig ook 
een beroep doen op collega artsen, die ik ook hartelijk wil bedanken: Michiel van Beek, 
David Jansen, Femke Besemer, Helle-Brit Fiebrich, Douwe Dekker en Petra Spies.
Ik kan de analisten van het TDM/Research lab niet genoeg bedanken voor het meten van 
de vele bloedspiegels en alles wat daarbij kwam kijken. Khalid, Erik, Marga, Corrien, Noor, 
Kirsten, Martijn, Guus, Michel en Karin (Maastricht), het was fijn samenwerken met jullie.
Anne Poirters heeft als stagiaire Biomedische Wetenschappen fantastisch meegeholpen 
aan het GINGER (Ginkgo biloba) onderzoek, waaronder veel labwerk. Charlotte Langemeijer 
deed dat voor het RECITAL (citalopram) onderzoek. Dames, bedankt.
Ron van Schaik (Erasmus MC) wil ik bedanken voor het farmacogenetisch onderzoek en 
de bijdrage aan het RECITAL onderzoek.
Ik ben heel trots op ons onderzoek naar de farmacokinetiek van raltegravir bij zwangere 
vrouwen dat is voortgekomen uit een groot internationaal samenwerkingsverband met 
Angela als projectmanager. I would like to thank all PANNA investigators (Chapter 6) for 
making a difference in the treatment of HIV-infected pregnant women and the prevention 
of mother-to-child HIV transmission. 
Onderzoek doen kost geld. We zijn dan ook dankbaar voor de financiële steun die we 
hebben gekregen voor onze interactieonderzoeken van de firma Merck in het kader van 
hun Investigator-Initiated Study Program. Het PANNA onderzoek is financieel mogelijk 
gemaakt door NEAT/Penta, Merck, BMS, Janssen Research BV en ViiV Healthcare.
Door het bijwonen van de wekelijkse hiv-patiëntenbespreking heb ik veel geleerd over de 
behandeling van hiv-patiënten. Dat heeft mijn onderzoek medische diepgang en context 
gegeven. Graag wil ik de infectiologen (i.o.) en verpleegkundig consulenten hiv van het 
Radboudumc hiervoor bedanken. Daarnaast heb ik ten behoeve van dit proefschrift 
samengewerkt met een aantal hele goede medisch specialisten en collega’s. Walter van 
der Velden en prof. dr. Nicole Blijlevens (Hematologie), Reinout van Crevel (Infectieziekten) 
en mijn collega Roger Brüggemann bedank ik voor ieders bijdrage aan de korte case 
series over de hiv-patienten met non-Hodgkin lymfoom. Erik van Maarseveen (Klinische 
Farmacie, UMCU) en Sibyl Geelen (Infectieziekten, Wilhelmina Kinderziekenhuis) wil ik 
bedanken voor de fijne en enthousiaste samenwerking bij het hoofdstuk over de farmaco-
kinetiek van raltegravir bij kinderen, waarin een casus is beschreven van een jonge en 
dappere hiv-patiënt. 
Ik heb me vanaf het begin op mijn plek gevoeld binnen de vakgroep. Het is een leuke en 
inspirerende club mensen bij elkaar. Mede door de gezellige sfeer ging ik iedere dag met 
plezier naar de Apotheek. Bedankt allemaal! Mijn kamergenoten zijn me dierbaar vanwege 
het delen van het dagelijks lief en leed: Quirine, Marieke, Klaartje, Diane, Monique, Robert, 
Eline, Jackie en Vincent. Klaartje, ook bedankt voor de energie die je hebt gestopt in het 
OPAL (boceprevir) onderzoek.
Mijn lieve familie en vrienden wil ik bedanken voor hun belangstelling, gezelligheid en 
warmte. Een speciale plek in dit dankwoord verdienen mijn ouders omdat zij mij altijd met 
veel liefde gesteund hebben. Chris, lieve mama, ik vind het heel bijzonder hoe je altijd 
voor ons klaar staat. Ik heb dit proefschrift opgedragen aan mijn vader, Arthur, die er in 
mijn gedachten bij is en zonder twijfel het meest trots is van iedereen.
Ik ben aangekomen op de eindbestemming: het proefschrift ligt voor u! Het was een 
mooie ontdekkingsreis. Gelukkig is de allerfijnste plek op deze wereldbol bij mijn lieve 
Sander en onze meisjes Zoë & Milou. Jullie zijn mijn thuis.
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